Synthesis of betulin derivatives against intracellular pathogens

Sami Alakurtti
Synthesis of betulin derivatives against intracellular pathogens

Sami Alakurtti
VTT Technical Research Centre of Finland
Division of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Helsinki, Finland

ACADEMIC DISSERTATION

Thesis for the degree of Doctor of Philosophy to be presented with the permission of Faculty of Pharmacy of the University of Helsinki for public examination and criticism in Auditorium 1041 at University of Helsinki, Biokeskus 2, Viikinkaari 5, Helsinki, on September 6, 2013 at 12 noon.
Synthesis of betulin derivatives against intracellular pathogens

Betulinijohdannaisten syntetisointi solunsisäisiä patogeenejää vastaan. Sami Alakurtti.

Abstract

Birch (Betula spp.) is utilized in huge quantities in the forest industry throughout the Northern Hemisphere, and low-value side-stream birch bark is burnt for energy. Outer birch bark is rich in (up to 30% dry weight) triterpene betulin, which is readily isolable by solvent extraction. Betulin can be used both in its raw form and as a starting material for more valuable products and fine chemicals.

The increasing drug resistance of numerous microbes and viruses is an issue of global concern, and new inexpensive therapeutic agents are urgently needed. In this study two sets of betulin derivatives were synthesized and screened as antiviral, antileishmanial and antibacterial agents. The first set includes relatively easily synthesizable betulin derivatives, such as esters and various oxidation products. The second set includes novel heterocyclic betulin derivatives, where the triazole ring is fused by the Diels-Alder reaction to the lupane skeleton of betulin.

Alphavirus Semliki Forest virus (SFV) is distributed by mosquitoes and infects avian and mammalian hosts. Some alphaviruses may cause fatal encephalitis in humans, although the number of cases is small. On the other hand, some alphaviruses have caused millions of cases of serious illnesses characterized by fever, rash and painful arthralgia. There is currently no efficient medical treatment against alphaviruses. In the antiviral assay, 18 betulin-derived compounds displayed good activity against SFV with low-micromolar 50% inhibitory concentration values combined with low cytotoxicity. In addition, three assayed potent and representative compounds displayed synergistic effect with modified nucleoside analogue against SFV, and similar good antiviral efficacy against another alphavirus, Sindbis virus.

The neglected tropical disease leishmaniasis is caused by protozoan parasites belonging to the genus Leishmania, and is transmitted to mammalian hosts by sandflies. It is estimated that around 12 million people are currently infected, mostly in developing countries. The most severe form, visceral leishmaniasis, is fatal if not treated. There are currently several drugs marketed for the treatment of leishmaniasis. However, none of these are fully effective against Leishmania, and severe side effects, often requiring hospitalization, are common. In addition, parasite resistance to drugs is a serious growing problem. In the present study, the most potent betulin derivatives displayed low-micromolar 50% growth inhibition values against L. donovani amastigotes. Good inhibition activity was well retained against L. donovani amastigotes growing inside macrophages. However, in some cases betulin derivatives also showed cytotoxicity to host macrophage cell line.
*Chlamydia pneumoniae* is a common Gram-negative human pathogen mainly causing mild respiratory infections, which can lead to pneumonia or bronchitis. There is also strong evidence that associates *C. pneumoniae* with other severe diseases, such as atherosclerotic cardiovascular diseases as well as some neurodegenerative diseases, such as Alzheimer’s disease and multiple sclerosis. *C. pneumoniae* is susceptible to antibiotics that interfere with DNA and protein synthesis. However, its complex life cycle and its chlamydial persistence, which can last for years, as well as, importantly, the lack of specific diagnostic tests for detection of the organism in clinical samples, make the current treatment regimens unsatisfactory. Out of 32 betulin derivatives, five betulin derivatives showed high (>70% growth inhibition) antichlamydial activity against *C. pneumoniae* at 1 µM concentration. The most potent derivative displayed a remarkable 50% inhibition at nanomolar concentration.

**Keywords**

Betulin, betulinic acid, terpene, organic synthesis, derivative, bioactivity, *Semliki Forest virus*, *Leishmania sp.*, *Chlamydia pneumoniae*
Betuliinijohdannaisten syntetisointi solunsisäisiä patogeenejä vastaan


Tiivistelmä


Useiden pieneliöiden ja virusten kasvava lääkeresistenssi on maailmanlaajuinen ongelma, minkä takia on ilmennyt suuri tarve kehittää uusia lääkeaineita niitä vastaan. Tässä väitöskirjatyössä syntetisoitiin kaksi betuliinijohdannaisryhmää ja yhdisteiden tehokkuutta testattiin alfavirusten, Leishmania-suvun alkeleitä ja keuhkoliomyelobakteerin vastaisina yhdisteinä. Ensimmäinen ryhmä sisältää melko helposti valmistettavissa olevia johdannaisia, kuten betuliinin estereitä ja erilaisia hapetustuotteita. Toinen ryhmä sisältää uusia heterosyklisiä betuliinijohdannaisia, joissa triatsoli-rengas on fuusioitu betuliinin lupaanirakenteeseen lihiivetyrankaan.


Leishmaniaasi-tautia aiheuttavat Leishmania-sukuun kuuluva Leishmania donovani, joka on elämisissä tropiikissa. Taudin vakavin muoto on sisäelinleishmaniaasia. Taudin vakavia muotoja on leishmanieläintä, joka on hyotamattomana tappava. Leishmaniaasia vastaan on käytössä useita lääkeaineita, mutta niiden tehokkuudessa ja turvallisuudessa on toimivien varaa. Ne aiheuttavat usein vakavat oireita, ja niiden käyttö edellyttää sairaalahoitoa. Lisäksi lääkeresistenssi on vakava ja kasvava ongelma. Tässä tutkimuksessa lupaamimmat betulinijohdannaiset osoittivat Leishmania donovani vastaisia vaikutuksia mikromolaarisella konsentraatiolla. Johdannaisen estovaikutus pysyi hyvänä myös selvitettäessä niiden vaikutuksia syöjäasulujen sisällä kasvavia L. donovani-alkueläimiä vastaan. Valitet-
tavasti osa betulunjohdannaisista osoitti sytokesisuutta myös itse syöjäsoluja vastaan.


Avainsanat  Betulin, betulinic acid, terpene, organic synthesis, derivative, bioactivity, *Semliki Forest virus*, *Leishmania* sp., *Chlamydia pneumoniae*
Acknowledgements

This work was carried out at the University of Helsinki, Division of Pharmaceutical Chemistry, during 2004–2007 and at VTT Technical Research Centre of Finland within the Process chemistry centre during 2007–2013. Funding was provided by Tekes – the Finnish Funding Agency for Technology and Innovation, the Foundation for Research of Natural Resources in Finland, the European Commission (Grant 227239) and the Academy of Finland (Grant 252308).

I am most thankful to my supervisor, Professor Jari Yli-Kauhaluoma, for his never-ending support, guidance and knowledge in organic chemistry. I am also grateful for your patience and encouragement throughout the many years of our journey into the chemistry of wood extractives.

I thank my co-authors Pia Bergström and Tuomo Heiska at VTT; Dr. Leena Pohjala, Dr. Alexandros Kiriazis, Antti Siiskonen, Dr. Tero Ahola and Dr. Päivi Tammela at the University of Helsinki; Dr. Olli Salin and Professor Pia Vuorela at Åbo Akademi University; Dr. Nina Sacerdoti-Sierra and Professor Charles L. Jaffe at the Hebrew University-Hadassah Medical School, Jerusalem, Israel; as well as Dr. Viola Maass and Dr. Matthias Maass at PMU University Hospital Salzburg, Austria.

Warm thank to my colleagues in several joint projects concerning valorization of betulin and other wood extractives: Minni Pirttimaa, Pauliina Pitkänen, Dr. Dave Thomas, Heimo Kanerva, Yukho Sok-sar, Juha Karttunen, Jukka Tulisalo, Harri Heikkinen, Anja Salakari and Janne Hulkkö at VTT. In addition, warm thanks to ex-colleagues at the Division of Pharmaceutical Chemistry (JYK group), especially to Raisa Haavikko, Dr. Mohanathas Rajaratman, Dr. Sirsi Harju, Dr. Gustav Boije at Gennäs, Dr. Vânia Moreira and Dr. Ingo Aumüller; and finally to the M.Sc. and other undergraduate students who have helped me with the chemistry of wood extractives: Kristian Meinander, Jaana Minkkinen, Niko Salminen, Maija-Liisa Tuononen, Darin Al-Ramahi, Erkki Metsälä and Jukka Pernilä. Special thanks to my mentor Dr. Salme Koskimies for taking me under her wing.

I wish to thank Professor Tapani Vuorinen of Aalto University and Professor Dulcie Mulholland at the University of Surrey, UK, for kindly reviewing this thesis.

Finally, my heartfelt thanks to my family: my parents Matti and Annikki as well as my siblings, Kirsí and Mikko for all the love and support; and lastly, my beloved partner Sari for her patience and encouragement; and my precious daughter Lumi for always brightening my day and bringing a smile to my face.
Academic dissertation

Supervisor  Professor Jari Yli-Kauhaluoma  
Division of Pharmaceutical Chemistry  
Faculty of Pharmacy  
University of Helsinki  
Finland

Reviewers  Professor Tapani Vuorinen  
School of Chemical Technology  
Department of Forest Products Technology  
Aalto University  
Finland

Professor Dulcie Mulholland  
Division of Chemical Sciences  
Department of Chemistry  
University of Surrey  
UK

Opponent  Professor Stefan Willför  
Laboratory of Wood and Paper Chemistry  
Department of Chemical Engineering  
Åbo Akademi University  
Finland

Custos  Professor Jari Yli-Kauhaluoma
List of publications

This thesis is based on the following original publications which are referred to in the text as I–IV. The publications are reproduced with kind permission from the publishers.


* Equal contribution

Related publications, not included in this thesis:


Author’s contributions in the original publications

I The author synthesized and characterized almost all of the betulin derivatives (few derivatives were synthesized by Mrs. P. Bergström, A. Salakari, senior laboratory technician and undergraduate students T. Heiska and E. Metsälä under author’s supervision). The author wrote the manuscript together with Dr. L. Pohjala with the aid of other co-authors. This publication is included as one of the required publications in Dr. L. Pohjala’s academic dissertation as well.

II The author synthesized and characterized almost all of the betulin derivatives (few urazole intermediates were obtained from Dr. A. Kiriazis and few betulin derivatives were synthesized by undergraduate student T. Heiska under author’s supervision). Author wrote the article with the aid of other co-authors.

III The author synthesized and characterized almost all of the betulin derivatives (few derivatives were synthesized by Mrs. P. Bergström, A. Salakari, senior laboratory technician and undergraduate student E. Metsälä under author’s supervision). The author wrote the article with aid of other co-authors.

IV The author synthesized and characterized almost all of the betulin derivatives (few derivatives were synthesized by Mrs. P. Bergström and undergraduate students T. Heiska and E. Metsälä under author’s supervision). The author wrote the manuscript together with Dr. O. Salin with the aid of other co-authors. This publication is included as one of the required publications in Dr. O. Salin’s academic dissertation as well.
Contents

Abstract ........................................................................................................... 3
Tiivistelmä ....................................................................................................... 5
Acknowledgements ......................................................................................... 7
Academic dissertation ..................................................................................... 8
List of publications .......................................................................................... 9
Author’s contributions in the original publications ...................................... 10
Abbreviations ................................................................................................ 13

1. Introduction ............................................................................................. 16
   1.1 Birch bark ......................................................................................... 16
   1.2 Alphaviruses .................................................................................. 16
   1.3 Leishmania spp. ............................................................................. 17
   1.4 Chlamydia pneumoniae ….............................................................. 17
   1.5 Origin of drugs during the last 25 years ........................................ 18

2. Review of the literature ........................................................................... 19
   2.1 Betulin ........................................................................................... 19
       2.1.1 Pharmacological properties of betulin derivatives ................. 19
   2.2 Alphaviruses ................................................................................ 20
       2.2.1 Species, taxonomy and lifecycle ......................................... 20
       2.2.2 Chemotherapy against infections caused by alphaviruses .... 22
   2.3 Leishmania spp. ............................................................................ 28
       2.3.1 Species, taxonomy and lifecycle ......................................... 28
       2.3.2 Leishmania and HIV co-infection .................................... 30
       2.3.3 Chemotherapy against infections caused by Leishmania spp. 30
   2.4 Chlamydia pneumoniae ….............................................................. 46
       2.4.1 Species, taxonomy and life cycle ......................................... 46
       2.4.2 Chlamydial persistence ....................................................... 48
       2.4.3 Chemotherapy against infections caused by C. pneumoniae... 48
3. Aims of the study ........................................................................................................58

4. Experimental ..............................................................................................................59
   4.1 Materials and methods ......................................................................................59
   4.2 Results and discussion .....................................................................................59
      4.2.1 Synthesis of simple betulin derivatives (I, II, IV) ......................... 60
      4.2.2 Synthesis of heterocyclic betulin derivatives (II) ......................... 66
      4.2.3 SAR studies: *Semliki Forest virus* (I) ..................................... 69
      4.2.4 SAR studies: *Leishmania donovani* (II) ................................ 71
      4.2.5 SAR studies: *Leishmania donovani* (III) ................................. 73
      4.2.6 SAR studies: *Chlamydia pneumoniae* (IV) ............................ 75
      4.2.7 Cytotoxicity of betulin compounds (I, II, III, IV) ........................ 76
   4.3 Conclusion ....................................................................................................... 78

References .....................................................................................................................80

Appendices

Publications I–IV

*Publications II and IV of this publication are not included in the PDF version.*
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{13}$C NMR</td>
<td>Carbon-13 nuclear magnetic resonance</td>
</tr>
<tr>
<td>$^1$H NMR</td>
<td>Hydrogen-1 nuclear magnetic resonance</td>
</tr>
<tr>
<td>AB</td>
<td>Aberrant body</td>
</tr>
<tr>
<td>AIDS</td>
<td>Acquired immunodeficiency syndrome</td>
</tr>
<tr>
<td>AT</td>
<td>Adenine, thymine</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>AV</td>
<td>Antiviral effect</td>
</tr>
<tr>
<td>BALB/c</td>
<td>Bagg albino, laboratory-bred, genotype c/c</td>
</tr>
<tr>
<td>BHK</td>
<td>Baby hamster kidney fibroblast cell line</td>
</tr>
<tr>
<td>BPQ</td>
<td>Buparvaquone</td>
</tr>
<tr>
<td>BVM</td>
<td>Bevirimat</td>
</tr>
<tr>
<td>CHIKV</td>
<td>Chikungunya virus</td>
</tr>
<tr>
<td>CL</td>
<td>Cutaneous leishmaniasis</td>
</tr>
<tr>
<td>CTP</td>
<td>Cytidine triphosphate</td>
</tr>
<tr>
<td>CV</td>
<td>Cell viability</td>
</tr>
<tr>
<td>DCC</td>
<td>$N,N'$-Dicyclohexylcarbodiimide</td>
</tr>
<tr>
<td>DEAD</td>
<td>Diethyl acetylenedicarboxylate</td>
</tr>
<tr>
<td>DHP</td>
<td>3,4-Dihydro-2H-pyran</td>
</tr>
<tr>
<td>DMAP</td>
<td>4-(Dimethylamino)pyridine</td>
</tr>
<tr>
<td>DMC</td>
<td>2',6'-dihydroxy-4'-methoxychalcone</td>
</tr>
<tr>
<td>DMSO-$d_6$</td>
<td>Deuterated dimethyl sulfoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
</tbody>
</table>
DSB  Dimethylsuccinyl betulinic acid
EB   Elementary body
EC_{50}  Half maximal effective concentration
ECHO  Enteric cytopathic human orphan virus
ED_{50} 50% effective dose
EEEV  Eastern equine encephalitis virus
FPV  Fowl plague virus
FTIR  Fourier transform infrared spectroscopy
GETV  Getah virus
GI_{50} 50% growth inhibition
HeLa  Cancer cell line taken from Henrietta Lacks
Hep  Human epithelial cervix carcinoma cell line
HIV  Human immunodeficiency virus
HL  Human promyelocytic leukemia cell line
HPLC  High-performance liquid chromatography
HPLC-MS  High-performance liquid chromatography – mass spectrometry
HSV-1  Herpes simplex type 1
Huh-7  Human hepatocellular carcinoma cell line
I  Interaction index
IC_{50} 50% inhibitory concentration
ICTV  International Committee on Taxonomy of Viruses
IMPDH  Inosine-5’-monophosphate dehydrogenase
kDNA  Kinetoplast DNA
LP  Liposome
MB-III  Maesabalide III
MCL  Mucocutaneous leishmaniasis
mCPBA  m-Chloroperbenzoic acid
MIC  Minimum inhibitory concentration
NC  Nucleocapsid
NSV  Neuroadapted Sinbis virus
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\rho$-TSA</td>
<td>$\rho$-Toluenesulfonic acid monohydrate</td>
</tr>
<tr>
<td>PCC</td>
<td>Pyridinium chlorochromate</td>
</tr>
<tr>
<td>Pd/C</td>
<td>Palladium on carbon</td>
</tr>
<tr>
<td>PLA</td>
<td>Polylactic acid</td>
</tr>
<tr>
<td>PPTS</td>
<td>Pyridinium $\rho$-toluenesulfonate</td>
</tr>
<tr>
<td>PS</td>
<td>Phosphatidylserine</td>
</tr>
<tr>
<td>RB</td>
<td>Reticulate body</td>
</tr>
<tr>
<td>RNA</td>
<td>Ribonucleic acid</td>
</tr>
<tr>
<td>SAR</td>
<td>Structure–activity relationships</td>
</tr>
<tr>
<td>SARS</td>
<td>Severe acute respiratory syndrome</td>
</tr>
<tr>
<td>SFV</td>
<td>Semliki Forest virus</td>
</tr>
<tr>
<td>SI</td>
<td>Selectivity index</td>
</tr>
<tr>
<td>SINV</td>
<td>Sindbis virus</td>
</tr>
<tr>
<td>spp</td>
<td>Species</td>
</tr>
<tr>
<td>t-BuOK</td>
<td>Potassium tert-butoxide</td>
</tr>
<tr>
<td>TEA</td>
<td>Triethylamine</td>
</tr>
<tr>
<td>THF</td>
<td>Tetrahydrofuran</td>
</tr>
<tr>
<td>THP</td>
<td>Tetrahydropyran</td>
</tr>
<tr>
<td>THP-1</td>
<td>Human leukaemia monocyte cell line</td>
</tr>
<tr>
<td>TLC</td>
<td>Thin layer chromatography</td>
</tr>
<tr>
<td>TMS</td>
<td>Trimethylsilyl</td>
</tr>
<tr>
<td>tRNA</td>
<td>Transfer RNA</td>
</tr>
<tr>
<td>UV</td>
<td>Ultra violet</td>
</tr>
<tr>
<td>VEEV</td>
<td>Venezuelan equine encephalitis virus</td>
</tr>
<tr>
<td>VL</td>
<td>Visceral leishmaniasis</td>
</tr>
<tr>
<td>WEEV</td>
<td>Western equine encephalitis virus</td>
</tr>
</tbody>
</table>
1. Introduction

1.1 Birch bark

Birch is (*Betula* spp.) widespread throughout the Northern Hemisphere and harvested in huge volumes. Birch bark is produced in considerable quantities as a by-product of the forest industry and its upgrading is almost totally neglected. Currently, this low-value side stream is burnt for combined heat and power production. Birch bark could, however, find more valuable uses, for example as an additive in plastic composite materials. Birch bark consists of brown inner bark ~75% and white outer bark ~25%. The inner bark consists mainly of wood-like material such as lignin, pentosans and hexosans. The outer bark contains, by dry weight, up to 40% fats, fatty acids, resins and triterpenes, in particular betulin, at up to 30%. In addition, the outer bark contains up to 35% suberin. Valorization and upgrading of these compounds by using modern chemical technology opens up entirely new opportunities to produce new speciality chemicals from this low-value biomass stream. It has been estimated theoretically that a pulp mill with an annual production capacity of 200,000 tonnes of birch kraft pulp produces enough bark to produce around 2,500 tonnes of betulin of around 95% purity and 4,000 tonnes of suberin acids per annum. Suberin polyester can be hydrolyzed by base treatment to multifunctional suberin acids, which are potential raw materials for paints, adhesives, lubricants and surface-active agents. New potential applications for betulin or betulin derivatives include pharmaceuticals and cosmetic products as well as agrochemicals.

1.2 Alphaviruses

The *Semliki Forest virus* (SFV) belongs to the alphaviruses, which are small enveloped viruses containing a single-stranded positive-sense RNA genome. Virus belonging to this genus are predominantly arthropod-borne viruses using mosquitoes as vectors and have a very wide geographic distribution, with isolates having been reported from all continents except Antarctica and from many islands. Alphaviruses infect avian and mammalian hosts and are a serious or potential threat to human health. In North and South America some alphaviruses are known to cause fatal encephalitis in humans, although the number of recorded
fatalities is small.\textsuperscript{9} Alphaviruses have, however, caused millions of cases of serious illness characterized by fever, rash and painful arthralgia.\textsuperscript{10} There is currently no efficient pharmacotherapy for alphavirus-borne diseases.

1.3 \textit{Leishmania} \textit{spp.}

Leishmaniasis is a disease caused by protozoan parasites belonging to the genus \textit{Leishmania}. The disease is transmitted by sandflies and is present in all inhabited continents.\textsuperscript{11} It is estimated that around 12 million people are currently infected. More than 350 million people live in risk areas for the disease, and 2 million new cases occur every year, especially in the developing countries. Leishmaniasis has been designated as a neglected tropical disease by the World Health Organization. The most severe form, visceral leishmaniasis, in which parasites invade the liver, spleen and bone marrow, is fatal if not treated.\textsuperscript{12} Current treatment includes pentavalent antimony compounds, pentamidine and amphotericin B.\textsuperscript{13} However, there are risks of severe side effects and all of these current drugs are administered by intravenous injection. Parasite resistance to pentavalent antimony drugs has become a serious problem and is present in approximately 65% of patients with visceral leishmaniasis in India.\textsuperscript{14} New drugs, such as primaquine, allopurinol, imipramine, are being developed, however none of them are fully effective against \textit{Leishmania}.\textsuperscript{12} Recently, orally administrable miltefosine has shown promising antileishmanial activity.\textsuperscript{15}

1.4 \textit{Chlamydia pneumoniae}

\textit{Chlamydia} (\textit{Chlamydophila}) \textit{pneumoniae} is an important Gram-negative human pathogen, mainly causing respiratory infections. It has been proposed that almost all humans will become infected with \textit{C. pneumoniae} during their life.\textsuperscript{16} \textit{C. pneumoniae} frequently causes community-acquired pneumonia in adults and children. Often infections are asymptomatic and frequently of long duration, up to several years. There is also strong evidence that associates \textit{C. pneumoniae} with other severe diseases, such as atherosclerotic cardiovascular diseases,\textsuperscript{17} as well as some neurodegenerative diseases, such as Alzheimer’s disease and multiple sclerosis.\textsuperscript{18} Interestingly, \textit{C. pneumoniae} infection has also been reported in a wide range of animals, including other mammals such as horses and koalas, and frogs and other reptiles.\textsuperscript{19} All chlamydial species are intracellular bacteria that infect and replicate inside a variety of human cells, including epithelial, endothelial, macrophages, and smooth muscle cells.\textsuperscript{20} \textit{C. pneumoniae} is classified as an obligate intracellular pathogen, as it has to infect another cell to reproduce. \textit{C. pneumoniae} is susceptible to antibiotics that interfere with DNA and protein synthesis, including tetracyclines, macrolides, and quinolones.\textsuperscript{16} However, its complex life cycle and its chlamydial persistence, which can last for years, as well as, importantly, the lack of specific diagnostic tests for detection of the organism in clinical samples, make the current treatment regimens unsatisfactory.
1. Introduction

1.5 Origin of drugs during the last 25 years

A total of 1,184 new chemical entities were approved for the market between 1981 and 2006 for treatment of various infective diseases caused by bacterial, fungal, viral and parasitic infections and for the treatment of cancer. The new drugs can be classified according to their source into six major categories and one subcategory (Table 1).

Table 1. Classification of new drugs according to source

<table>
<thead>
<tr>
<th>Category</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>B</td>
<td>Biological; usually large peptide or protein</td>
</tr>
<tr>
<td>N</td>
<td>Natural product</td>
</tr>
<tr>
<td>ND</td>
<td>Derived from a natural product, usually semisynthetic</td>
</tr>
<tr>
<td>S</td>
<td>Totally synthetic</td>
</tr>
<tr>
<td>S*</td>
<td>Made by total synthesis, but the pharmacophore is from a natural product</td>
</tr>
<tr>
<td>V</td>
<td>Vaccine</td>
</tr>
<tr>
<td>Subcategory NM</td>
<td>Natural product mimic</td>
</tr>
</tbody>
</table>

A breakdown of the 1,184 new drugs based on the above categories is illustrated in Figure 1. Only 30% of the drugs are completely synthetic; the rest have their origins in the natural products.

![Figure 1](image.png)

**Figure 1.** New chemical entities during 1981–2006, according to source (N = 1,184) (original from ref. 21).
2. Review of the literature

2.1 Betulin

Betulin, lup-20(29)-ene-3β,28-diol, also known as betulinol, betuline and betulinic alcohol (Figure 2), is a pentacyclic triterpene alcohol with a lupane skeleton. Common structural features of the lupane skeleton are its five-membered ring E and isopropylidene group. Betulin can be isolated (up to 30% dry weight) from the outer birch bark by extraction with high boiling hydrocarbon solvents or with water azeotropes of alcohols.

Betulin can be used as a starting compound for other useful compounds that possess various interesting pharmacological properties. Betulin has three positions in its structure, namely a secondary hydroxy group at position C-3, a primary hydroxy group at position C-28, and an alkene moiety at position C-20, where chemical modifications can be easily performed to yield derivatives for structure–activity relationship (SAR) studies. It is clear from the chemical structure of betulin that most of the derivatives presented in the experimental part of this thesis are lipophilic compounds and thus poorly soluble in water if no organic co-solvent is used. This may have important implications for the interpretation of the results of the bioactivity assays, which have been carried out predominantly in cell cultures. Observed differences in bioactivity between different modified betulin derivatives may be explained, at least partly, by different water/lipid distribution constants between these analogues.

2.1.1 Pharmacological properties of betulin derivatives

Betulin is biologically a relatively inactive compound. However, betulin can be oxidized to pharmacologically more active betulinic acid. Betulinic acid and its derivatives possess a wide spectrum of biological and pharmacological activity. Most notably, betulinic acid and its derivatives have shown activity against human immunodeficiency virus (HIV) as well as cytotoxicity against a variety of tumour cell lines comparable to some clinically used drugs.

A new mechanism of action has been confirmed for some of the most promising anti-HIV derivatives, which makes them potentially useful additives to current anti-HIV therapy. A43D and statine-derived IC9564 act as entry inhibitors...
and block HIV adsorption or membrane fusion. Furthermore, the dimethylsuccinyl derivative of betulin, bevirimat 5 (DSB, BVM), acts as a virus maturation inhibitor. Bevirimat 5 was demonstrated to have dose-dependent anti-HIV potency in phase I and phase II clinical studies. However, mutations in HIV cause resistance to BVM 5, in addition to which some patients have this polymorphism present, resulting in lower BVM 5 anti-HIV efficacy. Development of BVM 5 has thus been recently halted.

Betulinic acid 2 is specifically cytotoxic to several tumour cell lines by directly triggering mitochondrial membrane permeabilization and inducing apoptosis in cells. Moreover, it is non-toxic up to 500 mg/kg body weight in mice. Currently, betulinic acid 2 is undergoing anti-cancer development with assistance from the Rapid Access to Intervention Development Program of the National Cancer Institute.

![Figure 2](image)

**Figure 2.** Betulin 1 and potential anticancer agent betulinic acid 2, as well as potential anti-HIV agents A43D 3, IC9564 4 and bevirimat 5.

### 2.2 Alphaviruses

#### 2.2.1 Species, taxonomy and lifecycle

Currently there are two main schemes used for the classification of viruses: the International Committee on Taxonomy of Viruses (ICTV) system and the Baltimore classification system. A universal system for classifying viruses, and a unified taxonomy, is being established by the International Committee on Taxonomy of Viruses (ICTV). The system makes use of a series of ranked taxons:
2. Review of the literature

Table 2. Taxonomy of Semliki Forest virus.

<table>
<thead>
<tr>
<th>Order (-virales)</th>
<th>Virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family (-viridae)</td>
<td>Togaviridae</td>
</tr>
<tr>
<td>Subfamily (-virinae)</td>
<td>-</td>
</tr>
<tr>
<td>Genus (-virus)</td>
<td>Alphavirus</td>
</tr>
<tr>
<td>Species</td>
<td>Semliki Forest virus</td>
</tr>
</tbody>
</table>

In the ICTV 2012 taxonomy classification, the *Semliki Forest virus* (SFV) (which was used as a target pathogen for betulin inhibition activity in publication I) species is classified under the family *Togaviridae* and the genus *Alphavirus*, which contains a total of 30 viruses, including human pathogens such as *Rubella*, Sindbis and *Chikungunya* viruses (Table 2).  

In the Baltimore classification system, viruses are divided into one of seven groups depending on a combination of their nucleic acid (DNA or RNA), strandedness (single- or double-stranded), sense, and method of replication (Table 3).

Table 3. Virus groups according to the Baltimore classification system.

<table>
<thead>
<tr>
<th>Group</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Double-stranded DNA (dsDNA) viruses</td>
</tr>
<tr>
<td>II</td>
<td>Single-stranded DNA (ssDNA) viruses (+)sense DNA</td>
</tr>
<tr>
<td>III</td>
<td>Double-stranded RNA (dsRNA) viruses</td>
</tr>
<tr>
<td>IV</td>
<td>Single-stranded RNA [(+)ssRNA] viruses (+)sense RNA</td>
</tr>
<tr>
<td>V</td>
<td>Single-stranded RNA [(−)ssRNA] viruses (−)sense RNA</td>
</tr>
<tr>
<td>VI</td>
<td>Single-stranded RNA (ssRNA-RT) viruses (+)sense RNA with replication through a DNA intermediate</td>
</tr>
<tr>
<td>VII</td>
<td>Double-stranded DNA (dsDNA-RT) viruses with replication through a single-stranded RNA intermediate</td>
</tr>
</tbody>
</table>

Alphaviruses have a single-stranded, positive-sense RNA genome and are classified under group IV according to the Baltimore classification. Group IV includes viruses from several ICTV orders: 1. *Nidovirales* including significant pathogens such as *Coronavirus* and *Severe acute respiratory syndrome virus* (SARS); 2. *Picornavirales* including significant pathogens such as Norwalk, Polio, the common cold and Hepatitis A viruses; 3. *Tymovirales*; and unassigned virus families including significant human pathogens such as Yellow fever, West Nile, Hepatitis C and Dengue fever.

Entry of alphavirus into cells is initiated by receptor-binding, followed by endocytosis (Figure 3). Fusion to endosomal membranes transports nucleocapsid (NC) into the cytoplasm, where ribonucleic acid (RNA) is released after disassembly. Genomic RNA is used for transcription of nascent (+)RNA via a (−)RNA template.
and translation of proteins from genomic and subgenomic (26S) RNA. The structural proteins translated from 26S RNA encapsidate nascent genomic RNA before budding from cells, and eventual release.

**Figure 3.** Life cycle of alphavirus (original from ref. 7).

### 2.2.2 Chemotherapy against infections caused by alphaviruses

This section focuses on small-molecule antiviral inhibitors found to be effective against viruses in the genus Alphavirus. The alphaviral species discussed in this section include the *Chikungunya virus* (CHIKV), *Eastern equine encephalitis virus* (EEEV), *Getah virus* (GETV), *Semliki Forest virus* (SFV), *Sindbis virus* (SINV), *Venezuelan equine encephalitis virus* (VEEV) and *Western equine encephalitis virus* (WEEV). As there are only very few reported *in vivo* alphavirus experiments, *in vitro* experiments are also discussed here.

**Nucleoside or nucleotide analogues**

Synthetic nucleoside or nucleotide analogues are prodrugs that are phosphorylated to active triphosphate drugs by viral enzymes and used as normal building blocks for the DNA polymerase-catalyzed replication of viral DNA. However, as a consequence of the modifications in the nucleobase or in the sugar moiety, viral DNA polymerase enzyme is deactivated or DNA chain formation is terminated.

In an early study by Huffman and co-workers, the synthetic nucleoside guanosine analogue ribavirin 6 (Figure 4) was screened against a wide panel of viruses, including SFV. Ribavirin 6 showed broad antiviral activity, with moderate anti-
alphaviral activity and a minimum inhibitory concentration (MIC) value of 131 µM. Ribavirin 6 has since been used as a positive control in several assays.

Nucleotide analogue ribavirin 5'-sulphamate 7 displayed several-fold improved antiviral activity against SFV with an IC₅₀ value of 10 µM. The IC₅₀ value represents the concentration of drug required for 50% inhibition in vitro (50% inhibitory concentration). Ribavirin 6 displayed an IC₅₀ value of <1 mm. In vivo testing with lethally SFV infected mice, ribavirin 5'-sulphamate 7 showed a clear protective effect with survival rates of 92% and 83% when intraperitoneally administered at doses of 20 and 40 mg/kg/day for seven days.

Selenazofurin 8 and tiazofurin were assayed alone or in combination with ribavirin 6 against several viruses, including VEEV. Selenazofurin 8 displayed good activity against VEEV with a 50% effective dose (ED₅₀) value of 0.5 µg/mL, whereas tiazofurin was inactive. Combination of ribavirin and 6 selenazofurin 8 displayed synergistic efficacy with an ED₅₀ value of 0.1 µg/mL.

Nucleoside adenosine-derived neplanocins A 9 and C 10 (Figure 5) displayed broad antiviral activity and significant anti-alphaviral activities against SFV with IC₅₀ values of 4 and 7 µM, respectively.

Five 3'-fluorinated ribonucleosides were synthesized and screened against a panel of viruses, including SFV and SINV. 3'-Fluoro-3'-deoxyadenosine 11 displayed the best activity against several viruses, with IC₅₀ values of 7 µM and 15 µM against SINV and SFV, respectively. General cytotoxic effects were observed at 150 µM concentration.
2. Review of the literature

In a study by de Clercq et al., antiviral activity of racemic cytidine analogue carbodine 12 and 13 (Figure 6) was compared to known antiviral agents such as carbocyclic 3-deazaadenosine (C-c3 Ado) and ribavirin 6. The racemic mixture of carbodine enantiomers 12 and 13 showed broad activity against most of the viral species tested by inhibition of cellular cytidine triphosphate (CTP) synthetase. Especially against SINV, carbodine showed an IC50 value of 3 µM, which was almost 60 times more potent than C-c3 Ado and over 200 times more potent than ribavirin 6. In addition, the carbodine racemate displayed good inhibition against SFV with an IC50 value of 12 µM.

In a study by Julander et al., activity of the D-(-)- and L-(+)-enantiomers of carbodine was determined against VEEV in cell culture and in an in vivo mouse model. (-)-Carbodine 13 showed good inhibition activity with an EC50 value of 0.8 µM, while (+)-carbodine 12 was not active (EC50 > 100 µM). Post-virus exposure treatment with (-)-carbodine 13 was effective in significantly improving disease parameters in mice infected with VEEV when treatment was initiated as late as 4 days post-virus installation, with a mouse survival rate of 90% (placebo 0%).

In another study by De Clercq et al., cyclopentenylcytosine (Ce-Cyd) 14 displayed broad-spectrum antiviral activity against several viruses, including SFV and SINV with IC50 values of 0.4 and 0.2 µg/mL, respectively.

Antiviral activity of eight commercially available compounds was estimated against CHIKV and SFV. When comparing antiviral activities against CHIKV, positive control ribavirin 6 had an EC50 value of 83 µM and a selectivity index (SI) of 24. The two best test compounds, 6-azauridine 15 and sulfated polysaccharide iota-carrageenan, displayed significantly better EC50 values of 0.2 and 3.8 µM and SI values of 204 and >133, respectively. Against SFV, these compounds showed similar activities: 6-azauridine 15 and iota-carrageenan EC50 values of 0.4 and 0.7 µM and SI values of 85 and >714, respectively, while ribavirin 6 showed a moderate EC50 value of 47 µM and an SI value of 109.

![Figure 6. Nucleoside cytidine analogues with antiviral activity against alphavirus.](image)

**Non-nucleoside analogues**

In a study by Pohjala et al., a library of 356 compounds was screened in vitro against CHIKV and SFV. The library consisted of natural compounds (mainly flavonoids, coumarins and other phenolic compounds) as well as clinically approved drugs and their metabolites. Four natural 5,7-dihydroxyflavones, 16–19,
were found to be effective against CHIKV with IC₅₀ values of around 20–70 µM (Figure 7). In the assay against SFV, in addition to the same four flavones (naringenin 18 as the most potent compound with an IC₅₀ value of 2.2 µM, SI 43), several other natural compounds such as a synthetic coumarin derivative, coumarin-30 20, (IC₅₀ value of 0.4 µM, SI 231) was found to be effective.

In addition, several pharmaceutical compounds were found to be effective as SFV entry inhibitors. A phenothiazine core was identified in six out of twelve pharmaceutical compound hits, with antipsychotic prothipendyl 21 and antihistamine methdilazine 22 (Figure 8) showing the best IC₅₀ values of 8 and 11 µM, respectively. The reference compounds 3'-amino-3'-deoxyadenosine 23 and chloroquine 24 showed good activity with IC₅₀ values of 13.4 and 16.2 µM and SI values of 14.9 and 10.7, respectively. Mycophenolic acid 25 was relatively inactive (IC₅₀ = 121 µM).

![Figure 7. Natural compounds or their derivatives with good SFV inhibition activity.](image)
2. Review of the literature

Figure 8. Pharmaceutical and selected reference compounds with good SFV inhibition activity.

In a study by Peng et al., a library of over 50,000 compounds was assayed in a high-throughput screening against WEEV RNA replication. The most promising lead compound, CCG-32091 (Figure 9), displayed an $IC_{50}$ value of 24 µM with low cytotoxicity against BSR-T7/5 cells, which are BHK cells that constitutively express bacteriophage T7 RNA polymerase. Several derivatives of CCG-32091 were synthesized for SAR studies, and in a follow up study the most promising compound, displayed a clear protective effect with a mouse survival rate of 80%, compared to the control group with a survival rate of 20%.

Arbidol, an antiviral drug originally licensed in Russia for treatment of influenza, showed potent CHIKV inhibition activity with an $IC_{50}$ value of 12.2 µM. However, a single amino acid substitution in a mutant CHIKV envelope protein caused resistance to arbidol.

In another HTS study, 61,600 commercial small molecular weight compounds were screened against influenza virus. The most promising lead compound, was further evaluated against a broad spectrum of viruses representing several different families, including alphavirus SINV. Compound showed a broad spectrum of viral inhibition and a degree of inhibition of 2 logs against SINV.

VX-497 is a potent, reversible uncompetitive inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor, which was investigated in a comparison study with ribavirin in terms of their cytotoxicities and their efficacies against a variety of viruses including alphavirus VEEV. VX-497 displayed superior anti-alphaviral activity ($IC_{50} = 19.2$ µM) compared to non-active ribavirin ($IC_{50} > 500$).

The effect of four lysosomotropic weak bases (chloroquine, amantadine, tributylamine and methylamine) and NH$_4$Cl against SFV infection has been studied
in BHK cells. All substances prevent the transfer of the virus nucleocapsid into the cytoplasm by increasing the lysosomal pH from 4–5 to approximately 6, which is above the critical value needed to trigger a low pH-dependent fusion reaction between the membranes of the lysosome and the virus. Antimalarial drug chloroquine displayed the best IC50 value of 50 µM. However, in a double-blind placebo-controlled randomized human trial with chloroquine doses of 600 mg at days 1–3 and 300 mg at days 4–5, no significant difference between the treated and placebo groups could be identified.

![Figure 9. N-heterocyclic compounds possessing anti-alphaviral activity.](image)

Molecular modelling of the hydrophobic binding pocket of SINV capsid protein was used to design 1,4-dioxane-based antiviral agents. Surprisingly, the best target compound according to the model with a three-carbon linker chain connecting two 1,4-dioxane moieties was significantly less active (EC50 = 40 µM) than the synthetic intermediate (EC50 = 1 µM). Both compounds were not cytotoxic in uninfected BHK cells at concentrations of 1 mm.

Seco-pregnane steroid glaucogenin C and its glycosides isolated from Strobilanthes cusia (Nees) Kuntze and Cynanchum paniculatum (Bunge) Kitagawa displayed selective inhibitory activity against several members of the alphavirus genus. The EC50 value of the most potent glaucogenin C derivative, pentasugarglycoside paniculatumoside C, was remarkable. Paniculatumoside C showed EC50 values of 1.5, 1 and 2 nM against SINV, GETV and EEEV, respectively. In addition, it proved effective in reducing the mortality rate (18%, 54%, and 100%) of SINV infected mice when administered at a dose of 5, 50, or 100 mg/kg body weight before inoculation. However, when paniculatumoside C was administered 1 or 4 h after SINV infection, no mice survived, although delayed mortality was observed.
2. Review of the literature

![Figure 10. 1,4-Dioxane-based compounds 31 and 32, and seco-pregnane-derived compounds 33 and 34.](image)

**Betulin-derived compounds**

Bevirimat 5 (Figure 2), a semisynthetic dimethylsucciinic acid derivative of natural product betulinic acid53, blocks HIV maturation by inhibiting the final stage of HIV Gag protein processing54. It was initially considered as a possible first member of the HIV maturation inhibitors, and it successfully demonstrated potency in phase I and phase II clinical studies.26 However, mutations in HIV cause resistance to BVM 5, in addition to which some patients also have this polymorphism present, resulting in lower anti-HIV efficacy.27 Thus, development of BVM 5 has been currently halted. Bevirimat 5 was found to be inactive against herpes simplex type 1 (HSV-1) and influenza virus.25

The antiviral activity of betulin 1 and betulinic acid 2 and their derivatives have also been studied against influenza A, herpes simplex type 1 (HSV-1), influenza FPV/Rostock and ECHO-6 enterovirus, however their antiviral activities were weak.55,56,57

2.3 **Leishmania spp.**

2.3.1 **Species, taxonomy and lifecycle**

Protozoan parasites belonging to the genus *Leishmania* are transmitted to mammalian hosts by female sandflies of the genera *Phlebotomus* and *Lutzomyia* in the Old and New World, respectively.58 The life cycle of the leishmanial parasite consists of a flagellated promastigote phase in the sandfly gut and a non-flagellated intracellular amastigote phase in mammalian macrophages (Figure 11).59 After a blood meal from the infected host, amastigotes are released from the macrophages into the sandfly gut; these then transform through a multiplying non-infectious procyclic promastigote phase to infectious metacyclic promastigotes and migrate to the pharyngeal valve of the sandfly.60 The metacyclic promastigotes are transmitted during feeding to the mammalian host, where the promastigotes successfully
infect and invade the host macrophages. Inside the macrophages, the parasites transform into amastigotes and start to multiply. The amastigotes are released into the blood stream from the infected macrophages to infect new macrophages, which are finally transferred during feeding back to the vector sandfly.

In taxonomy, the species *Leishmania donovani* (used as a target microbe for betulin inhibition activities in publications II and III), is classified under the subkingdom Protozoa, order Kinetoplastida, family Trypanosomatidae, genus *Leishmania*, subgenus *Leishmania* and complex *L. donovani* (Table 4). Other complexes under the subgenus *Leishmania* are *L. tropica*, *L. major*, *L. aethiopica* and *L. mexicana*. In addition, the genus *Leishmania* also contains the subgenus *Viannia*, which includes the complexes *L. braziliensis*, *L. guyanensis*, *L. naiffi* and *L. lainsoni*. These complexes include a total of 30 species, of which 20 are infectious to humans.61,62

**Table 4. Taxonomy of *L. donovani*.**

<table>
<thead>
<tr>
<th>Subkingdom</th>
<th>Protozoa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Order</td>
<td>Kinetoplastida</td>
</tr>
<tr>
<td>Family</td>
<td>Trypanosomatidae</td>
</tr>
<tr>
<td>Genus</td>
<td>Leishmania</td>
</tr>
<tr>
<td>Subgenus</td>
<td>Leishmania</td>
</tr>
<tr>
<td>Complex</td>
<td><em>L. donovani</em></td>
</tr>
<tr>
<td>Species</td>
<td><em>L. donovani</em></td>
</tr>
</tbody>
</table>
Leishmaniasis is a disease caused by leishmania parasites and it has been divided into three major clinical manifestations:12

1) Cutaneous leishmaniasis (CL): produces skin lesions.
2) Mucocutaneous leishmaniasis (MCL): ulcerates oro-naso-pharyngeal region.
3) Visceral leishmaniasis (VL): devastates internal organs, especially liver, spleen and bone marrow and the untreated disease is usually fatal.

2.3.2 Leishmania and HIV co-infection

Interaction between leishmaniasis (VL) and HIV has been well established, making VL-HIV co-infection a serious worldwide concern.63 HIV-infected people are particularly vulnerable to VL infection and the risk of developing active VL is increased dramatically. VL accelerates HIV replication and progression to AIDS. In areas endemic for VL, many people have asymptomatic infection and patients should be considered as potential reservoirs of infection. In addition, all antileishmanial therapies are less effective with HIV-positive patients and the risk of treatment failure or relapse of VL is increased. There is a high mortality rate due to concurrent illness, complications, and drug toxicity. VL-HIV co-infection decreases host humoral and cellular responses (specific antibodies), which limits the diagnostic value of simple serological tests for co-infected patients.

2.3.3 Chemotherapy against infections caused by Leishmania spp.

This section focuses on small molecule antileishmanial drugs currently in use as well as on compounds in clinical or preclinical trials, and experimental inhibitors found promising in in vivo activity in mouse trials. The results of preclinical human trials are collected in Table 5.

Vaccines

The ideal antileishmanial treatment would be an effective vaccine. The Leishmania parasite has a relatively uncomplicated life cycle and patients that recover from infection have resistance to subsequent infection. This indicates that a successful vaccine could be produced. For example, vaccines comprising killed parasites, subunits such as parasite proteins, DNA, poly-protein, and peptides derived from leishmanial antigens have shown promising results on animal models. However, these vaccines have been disappointing when tested in field trials and currently there is no effective vaccine available.54,65
Currently approved drugs

The first-line drugs for treatment of leishmaniasis include pentavalent antimony compounds such as stibogluconate (Pentostam®) 35 and meglumine antimonate (Glucantime®) 36 (Figure 12), 66 which have been in use for over 70 years. However, there are several drawbacks with these drugs. As pentavalent antimony drugs are highly water soluble, they are not absorbed through the lipophilic intestinal barrier and must be administered by intravenous injection. 67 In addition, drugs have severe toxic side effects, such as cardiotoxicity and hepatotoxicity, and their use requires clinical supervision or hospitalization. Moreover, resistance to antimony-based drugs is increasing, for example in India. 68 Although antimonials have been used for decades for the treatment of leishmaniasis, their mode of action is not fully known. Pentavalent antimony compounds are accumulated to promastigotes and amastigotes and, in the most accepted model for the mechanism of action, Sb(V) acts as a prodrug and is reduced to the more biologically active and toxic Sb(III). 69 There is evidence that Sb(III) inhibits trypanothione reductase and glutathione reductase 70 or induces apoptosis 71 of the parasite.

![Figure 12. Traditional antimony-based drugs stibogluconate 35 and meglumine antimonate 36 used for treatment of leishmaniasis.](image)

The second-line drugs for treatment of leishmaniasis include aromatic diamine pentamidine 37 and amphotericin B 38 (Figure 13). Pentamidine 37 binds to the adenine and thymine (AT) sequences of leishmanial kinetoplast DNA, leading to mitochondrial destruction and parasite death. 72 Pentamidine 37 has severe toxic side effects leading to renal toxicity 73 and cardiotoxicity 74, in addition to which resistance to pentamidine 37 has developed. 75 The polyene macrolide compound amphotericin B 38 increases parasite membrane permeability by acting with membrane sterols. 76 This leads to release of cellular components, mainly potassium, thus killing the parasite. Using relatively expensive lipid-based formulations of the drug, 77 the occurrence of severe side effects, such as nephrotoxicity, is reduced. 78
2. Review of the literature

![Chemical structure of paromomycin](image1)

**Figure 13.** Second-line drugs, pentamidine 37 and amphotericin B 38, used for treatment of leishmaniasis.

The aminoglycoside antibiotic paromomycin 39 (Figure 14) was approved in 2006 for treatment of leishmaniasis in India. Paromomycin administered intramuscularly for 21 days showed an initial cure rate of 96% of patients and a definitive cure rate of 92% after 6 months.\(^7^9\) It has a reasonable safety profile with only a minimal proportion of patients suffering possible side effects such as ototoxicity.\(^8^0\) However, the drug must be administered by injection. Paromomycin 39 affects mitochondrial activity\(^8^1\) and ribosomes.\(^8^2\)

8-Aminoquinoline sitamaquine 40\(^8^3\) has been approved for treatment of leishmaniasis in India. This orally administered drug has shown good cure rates of up to 87%, and side effects seem to be relatively mild, such as vomiting, dyspepsia and methemoglobinemia.\(^8^4\) The drug induces collapse of mitochondrial membrane potential\(^8^5\) as well as alkalization of acidocalcisomes, specific organelles present only in parasites.\(^8^6\)

Alkylphosphocholine miltefosine 41\(^8^7\) was the first approved orally administered antileishmanial drug on the market. Miltefosine has displayed an initial cure rate of up to 97% and a final cure rate of 82% after 6 months.\(^8^8\) It has a generally safe toxicology profile, the main side effects being related to toxicity to the gastrointestinal tract. However, due to possible teratogenic effects of miltefosine 41,\(^8^9\) it is not suitable for treatment of pregnant women. Suggested targets for miltefosine 41 include inhibition of glycosomal acyltransferase,\(^9^0\) mitochondrial enzyme cytochrome c oxidase\(^9^1\) and effects on lipid metabolism.\(^9^2\)
2. Review of the literature

Figure 14. New drugs for treatment of leishmanial infections.

Lead compounds in clinical and preclinical trials

In this section antileishmanial agents showing promising in vivo inhibition activities in human clinical or preclinical studies are presented. Some of the following lead compounds are currently in further development.

Antifungal heterocyclic imidazole and 1,2,4-triazole-derived compounds have been tested in several clinical trials for the treatment of leishmaniasis. The effectiveness of itraconazole, ketoconazole and fluconazole (Figure 15) in in vivo human studies are promising but still inconclusive. The performance of itraconazole (400 mg dosage for a minimum of 3 months) was studied in an uncontrolled study with 13 Ecuadorian patients with mucocutaneous leishmaniasis. All 13 subjects responded to itraconazole during the first month of treatment, but by 12 months after treatment complete resolution of mucocutaneous leishmaniasis lesions was observed in only three (23%) patients. No adverse effects of treatment were reported.

The efficacy of ketoconazole (600 mg/day for 28 days) was compared to reference drug pentostam (20 mg antimony/kg for 20 days) against Panamanian cutaneous leishmaniasis due to L. braziliensis panamensis. Ketoconazole clinically cured 16 out of 21 (76%) patients. Side effects were limited to a 27% incidence of mild, reversible hepatocellular enzyme elevation and an asymptomatic, reversible, approximately 70% decrease in serum testosterone in all patients. Pentostam cured 13 of 19 (68%) patients and a placebo group of 11 patients had a 0% cure rate. The authors conclude that oral ketoconazole is comparable in efficacy to this parenteral pentostam regimen and can be recommended as initial treatment for this disease.

Fluconazole (200 mg daily for six weeks) was studied for the treatment of cutaneous leishmaniasis caused by L. major. A total of 106 patients received
2. Review of the literature

fluconazole 44 and 103 patients received a placebo. 79% of patients in the fluconazole 44 group and 34% of the placebo group showed complete recovery during the trial. Side effects were mild, and oral fluconazole 44 thus seems to be a safe and useful treatment for cutaneous leishmaniasis caused by L. major.

![Figure 15. Antifungal heterocyclic imidazole and 1,2,4-triazole drugs displaying antileishmanial activity.](image)

Purine analogue allopurinol 45 (drug used to treat hyperuricaemia, including chronic gout; see Figure 16) has been tested in a clinical trial (20 mg/kg for 15 days) for treatment of American cutaneous leishmaniasis in an area where L. b. panamensis is endemic. Reference treatment with meglumine antimonate 36 (20 mg antimony/kg for 15 days) showed a moderate 36% cure rate, a combination treatment of allopurinol 45 and meglumine antimonate 36 displayed a 74% cure rate, and allopurinol 45 alone showed a good, 80%, cure rate. There were no complete recoveries among the untreated patients. In addition, no major toxic effects were observed. However, in another study contradictory results were observed. A group of 187 patients with cutaneous leishmaniasis caused by L. panamensis (84% of patients) or L. braziliensis (16% of patients) were treated with allopurinol 45 (20 mg/kg of body weight per day for 28 days), a placebo, or meglumine antimonate 36 (20 mg of intramuscular antimony/kg per day for 20 days). After the treatment period, the allopurinol 45 group showed 33%, the placebo group 37% and the meglumine antimonate 36 group 93% cure rates. The authors of that study concluded that allopurinol 45 monotherapy has no effect on Colombian cutaneous disease primarily caused by L. panamensis and therefore is unlikely to be effective against cutaneous leishmaniasis in other endemic regions.

Topical treatment with antiviral drug imiquimod 46 (immune response modifier) in combination with meglumine antimonate 36 has shown very good efficacy against meglumine antimonate 36 resistant cutaneous leishmaniasis. The study
was performed in Peru, where \textit{L. peruviana} is endemic. All of the patients responded well to this combination therapy, and 90% of the patients were found to be cured after a 6-month follow-up period.

The affectivity of the antibiotic/anti-leprosy drug dapsone 47 was studied with 120 patients infected with cutaneous leishmaniasis. Two patient groups were treated with tablets of dapsone 47 (100 mg) or placebo tablets every 12 h for 6 weeks. 82% of the dapsone-treated group were cured. In addition, dapsone 47 is economical, widely available and well-tolerated.

Azalide antibiotic azithromycin 48 has demonstrated very good efficacy (85%) for the treatment of patients infected with cutaneous leishmaniasis caused by \textit{L. (Viannia) braziliensis}. However, unsatisfactory results were obtained from trials conducted against \textit{L. major} in Iran, with only 10% of patients displaying fully cured lesions. A reference group treated with meglumine antimonate 36 showed a better, though still moderate, cure rate of 34%.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{image.png}
\caption{N-heterocyclic drugs 45 and 46 and antibiotics 47 and 48 showing potency as antileishmanial drugs in humans.}
\end{figure}

\begin{table}[h]
\centering
\caption{Antileishmanial cure rates in human preclinical trials.}
\begin{tabular}{|c|c|c|c|}
\hline
\textbf{Compound} & \textbf{Regimen} & \textbf{Species} & \textbf{Cure \%} & \textbf{Ref.} \\
\hline
42 & 400 mg/day/3 months & \textit{L. viannia} \textit{braziliensis} / \textit{L. viannia} & 23 & 93 \\
43 & 600 mg/day/28 days & \textit{L. b. panamensis} & 76 & 94 \\
44 & 200 mg/day/6 weeks & \textit{L. major} & 79 & 95 \\
45 & 20 mg/kg/15 days & \textit{L. b. panamensis} & 80 & 96 \\
45 & 20 mg/kg/28 days & \textit{L. panamensis} & 33 & 97 \\
45 + 36 & 20 mg/kg/15 days + 20 mg antimony/kg/15 days & \textit{L. b. panamensis} & 74 & 96 \\
46 + 36 & topically 250 mg/every other day/20 days + 20 mg antimony/kg/20 days & \textit{L. peruviana} & 90 & 98 \\
47 & 100 mg tablets/every 12 h/6 weeks & \textit{L. major} / \textit{L. tropica} & 82 & 99 \\
48 & 500 mg/3 days, 500 mg/5 days, 500 mg/10 days and 1000 mg/2 days & \textit{L. viannia} \textit{braziliensis} & 85 & 100 \\
48 & 500 mg/day/5 days/month & \textit{L. major} & 10 & 101 \\
\hline
\end{tabular}
\end{table}
2. Review of the literature

<table>
<thead>
<tr>
<th>Controls</th>
<th>Hit compounds in in vivo animal testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>35</td>
<td>L. b. panamensis 68 94</td>
</tr>
<tr>
<td>36</td>
<td>20 mg antimony/kg/20 days</td>
</tr>
<tr>
<td>Placebo</td>
<td>L. b. panamensis 36 96</td>
</tr>
<tr>
<td>35</td>
<td>20 mg antimony/kg/15 days</td>
</tr>
<tr>
<td></td>
<td>L. panamensis 93 97</td>
</tr>
<tr>
<td>36</td>
<td>20 mg of antimony/kg/20 days</td>
</tr>
<tr>
<td></td>
<td>L. major 34 101</td>
</tr>
<tr>
<td>35</td>
<td>60 mg/kg meglumine antimonate/20 days</td>
</tr>
<tr>
<td></td>
<td>L. b. panamensis 0 94</td>
</tr>
<tr>
<td></td>
<td>L. major 34 95</td>
</tr>
<tr>
<td></td>
<td>L. b. panamensis 0 96</td>
</tr>
<tr>
<td></td>
<td>L. panamensis 37 97</td>
</tr>
<tr>
<td></td>
<td>L. major / L. tropica 0 99</td>
</tr>
</tbody>
</table>

In this section, antileishmanial agents showing promising in vivo inhibition activities in animal studies are presented. Some of these early lead compounds are currently in further development.

Investigational triazole antifungal agent posaconazole (SCH 56592) 49 (Figure 17) showed very good in vivo activity with BALB/c mice against cutaneous leishmaniasis due to L. amazonensis infection. At a dose of 60 mg/kg/day posaconazole 49 was superior to amphotericin B 38 at a dose of 1 mg/kg/day. However, activity against visceral leishmaniasis due to L. donovani infection was clearly lower when compared to positive control amphotericin B.

In a mouse model of L. major leishmaniasis, administration of indole-based imidazole antifungal agent 50 led to a clear parasite burden reduction: 99% in the spleen, 79% in the liver and 50% in the cutaneous lesion. Compound 50 decreases ergosterol biosynthesis, leading to membrane fungal cell alterations. In addition, 50 induces a parasite burden-correlated decrease in interleukine-4 production both in the splenocyte and the popliteal node of the mouse.

Based on in vitro studies of 16 synthetic oximino benzocycloalkyl azoles against L. donovani, five compounds showing best activity profile (SI) were tested further in vivo in a hamster model. Of these derivatives, imidazole 51 showed significant 70% reduction of parasite burden in spleen. However, 51 was still clearly less active than the reference drug miltefosine 41 (96% inhibition) in vivo.

A library of 19 synthetic aryloxy alkyl/aryl alkyl imidazoles displayed very good 94–100% inhibition at 10 µg/mL in vitro against L. donovani promastigotes. In addition, 12 compounds exhibited high inhibition with IC_{50} values in the range of 0.47–4.85 µg/mL against amastigotes (compound 52 had the best IC_{50} activity at 0.47 µg/mL). However, in vivo assays with the most promising four compounds showed only moderate activities with 58–60% inhibition.
Pyrazinamide 53 (Figure 18), which is used in tuberculosis chemotherapy, showed good efficacy in the treatment of *L. major*-infected mice with a 100-fold reduction in parasite burden, when compared to the control. In addition, mechanistic studies suggest that pyrazinamide 53 enhances effective immune responses against the parasite and has an immunostimulatory effect. Treatment was non-toxic and did not affect the growth of the experimental animals.

Two novel arylimidamide class antileishmanial drug candidates, DB745 and DB766 54 showed exceptional activity against intracellular *L. donovani*, *L. amazonensis*, and *L. major* *in vitro*. In vivo orally given, DB766 54 produced a dose-dependent inhibition of liver parasitemia in two efficacy models, *L. donovani*-infected mice and hamsters, (71% and 89%, respectively). A marked reduction in parasitemia in the spleen (79%) and bone marrow (92%) of hamsters was also observed. Furthermore, the compounds were well distributed in the liver and spleen target tissues, showed moderate oral bioavailability (up to 25%), and had a suitable elimination half-life ranging from 1 to 2 days in mice. No toxic side effects to liver or kidney were observed, although mild hepatic cell eosinophilia, hypertrophy, and fatty changes were noted. The results demonstrated that arylimidamides are a promising class of compounds for preclinical development as an orally administered drug.

The conventional dihydropyridine antihypertensive drugs amlodipine 55 and lacidipine 56 inhibited *L. donovani* infection *in vitro* and in mice when administered orally. Amlodipine 55 and lacidipine 56 therapies led to significant reductions in splenic (85% and 75%) and liver (86% and 72%) parasite burdens, when compared to controls. The compounds functioned through dose-dependent inhibition of oxygen consumption, triggering caspase 3-like activation-mediated programmed cell death of the parasites.
2. Review of the literature

A series of 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines were synthesized and screened for \textit{in vitro} and \textit{in vivo} antileishmanial activity against \textit{L. donovani}\textsuperscript{109}. Three compounds, 57, 58 and 59, showed a good selectivity index (SI) \textit{in vitro}, and these were screened for \textit{in vivo} activity in golden hamsters infected with \textit{L. donovani}. The compounds showed decent \textit{in vivo} inhibition of 48–56% at a dose of 50 mg/kg when administered intraperitoneally.

![Chemical structures]

\textbf{Figure 18.} Six-membered nitrogen-containing heterocycles with \textit{in vivo} antileishmanial activity.

A sitamaquine derivative of 8-aminoquinoline (±)NPC1161B 60 (Figure 19) and pure (-)- and (+)-enantiomers were studied \textit{in vivo} with \textit{L. donovani}-infected mice\textsuperscript{110}. All three components (dose 10 mg/kg/day) showed very good and comparable activity to the parent compound sitamaquine, and cleared the parasites after a 5-day course of treatment. (-)-Enantiomer was better tolerated and had an increased therapeutic window when compared to the racemate or (+)-enantiomer of the compound.

Oral administration of natural quinoline-based compound chimanine B 61 (twice a day 50 mg/kg) to mice infected with \textit{L. amazonensis} or \textit{L. venezuelensis} resulted in a decrease in lesion weight by 70% and parasite loads by 95% when compared to the group of untreated mice\textsuperscript{111}. Injections of chimanine B 61 (five injections at four-day intervals) and subcutaneous administration or intralesional injections of reference drug meglumine antimonate 36 displayed similar and very good efficacy. In the follow up study, the efficacy of nine chimanine B derivatives was determined.
Activity was further improved by the hydroxy derivative 62, showing antileishmanial activity up to 90% in in vivo rat models.

A series of synthetic bis-quinolines showed excellent antileishmanial efficacy against *L. donovani* in both in vitro and in vivo studies. Compound 63 exhibited the most significant activity against visceral leishmaniasis in a mouse model without showing any toxic manifestation. Intraperitoneal treatment with compound 63 at 12.5 mg/kg body weight led to significant reduction of parasite burden in spleen (95%) and liver (98%) compared to untreated controls. Ultrastructural studies of treated promastigotes demonstrated membrane blebbing, chromatin condensation and vacuolization in the parasites, and flagellated parasites became round-shaped after treatment.

The quinazoline derivative peganine hydrochloride dihydrate 64 isolated from *Peganum harmala* L. seeds showed only moderate in vitro activity against both extracellular promastigotes as well as intracellular *L. donovani* amastigotes growing inside macrophages. However, the alkaloid 64 administered by oral route exhibited good in vivo activity with 80% reduction of *L. donovani* parasites in hamster spleen at a dose of 100 mg/kg. The reference drug miltefosine 41 resulted in 96% inhibition of parasites at a dose of 40 mg/kg.

The quaternary isoquinoline alkaloid berberine 65 and several of its derivatives were tested for efficacy against *L. donovani* and *L. braziliensis panamensis* in golden hamsters. Tetrahydroberberine 66 was the most potent derivative against *L. donovani* with 50% suppression of parasite burden, but was not as potent as the reference drug meglumine antimonate 36. Only berberine 65 and 8-cyanodihydroberberine 67 showed significant activity (>50% suppression of lesion size) against *L. braziliensis panamensis*.

![Chemical structures](image)

**Figure 19.** Quinoline-derived compounds showing antileishmanial activity in vivo.
2. Review of the literature

Various synthetic rhodacyanine derivatives were studied for their antileishmanial *in vitro* and *in vivo* activities. Among the derivatives, the fluorinated variant SJL-01 (Figure 20) showed an excellent *in vitro* selectivity index of >15,000 and an IC_{50} value of 0.011 μM against *L. donovani*. The fluorinated compound 68 displayed an exceptional 95% inhibition against *L. donovani* parasites in female mice by 1.3 mg/kg intravenous administrations. Preliminary studies showed that no bioavailability was obtained by subcutaneous administration.

*In vitro* and *in vivo* (mice) activities of antiarrhythmic amiodarone 69 and miltefosine 41 were investigated alone or in combination on *L. mexicana*. It was found that whereas both drugs given individually failed to cure lesions, a combination of amiodarone 69 and miltefosine 41 had synergistic effects on the proliferation of intracellular amastigotes growing inside macrophages and led to 90% parasitological cures in a murine model. Amiodarone 69 disrupts intracellular Ca^{2+} homeostasis and inhibits the *de novo* sterol biosynthesis of the parasite.

![Figure 20. Structures of potential antileishmanial compounds rhodacyanine derivatives 68 and 69.](image)

The common flavonoids luteolin 70 and quercetin 71 (Figure 21) were assayed *in vivo* for visceral leishmaniasis against *L. donovani*-infected golden hamsters. Luteolin 70 showed good activity by an over 80% reduction in splenic parasites. Quercetin 71 reduced the splenic parasite load by 90% at four times higher concentration. *In vitro* studies suggested that leishmanicidal activity was related to inhibition of promastigotes DNA synthesis and promotion of topoisomerase II-mediated linearization of kDNA minicircles. Quercetin 71 was almost equally potent to the standard antileishmanial drug sodium stibogluconate 35 in lowering the parasite load in the spleen of *L. donovani*-infected hamsters (reductions 77% and 82%, respectively). Combination therapy with quercetin 71 and stibogluconate 35 showed improved synergistic activity with a 93% reduction of parasites in hamster spleen.

Hydroxynaphthoquinone-based buparvaquone 72 showed moderate antileishmanial activity in *L. donovani* infected mice at very high concentration. Potency of buparvaquone 72 was increased several-fold with the formulation containing buparvaquone 72 (BPQ) and phosphatidylserine (PS) entrapped in liposomes (BPQ–PS–LP). BPQ–PS–LP was evaluated *in vivo* against *L. infantum* (syn. *L. chagasi*) in a murine model and showed promising results.
L. chagasi) infected hamsters. BPO–PS-LP reduced the number of amastigotes by 89% in the spleen and by 67% in the liver, compared to 84% and 99.7%, respectively, with meglumine antimonate. Buparvaquone alone failed to treat the hamsters when compared to the untreated group.

Natural compound 2',6'-dihydroxy-4'-methoxychalcone (DMC) induced only 23% reduction in parasites in L. amazonensis-infected mice. When chalcone was formulated with polylactide to form DMC-PLA nanoparticles, activity was improved to 53% parasite reduction. Moreover, lesion size was reduced by about 60%. Thirty days after the initiation of treatment, the parasite load in the lesions was reduced by 90% and the effect was comparable to equivalent doses of the antileishmanial drug meglumine antimonate. In the follow up study, it was demonstrated that DMC alters the sterol composition of L. amazonensis, suggesting that the target is different from other known sterol inhibitors.

A treatment of hamsters infected with L. donovani with intraperitoneal administration of natural chalcone derivative, licochalcone A, resulted in a 96% reduction of parasite load in the liver and the spleen. Oral administration resulted in 65% and 85% reductions of L. donovani parasite loads in the liver and the spleen, respectively. In a subsequent study by the same authors, activity of the oxygenated chalcones was studied. The best derivative, '35m4ac', showed very good in vivo activity. L. donovani parasite load in hamster liver was reduced by 97% after intraperitoneal administration. The chalcone derivative inhibits parasite respiration and activity of mitochondrial dehydrogenases.

Figure 21. Flavonoids 70 and 71, naphthoquinone 72 and chalcones 73–75 displaying antileishmanial activity in vivo.

The seco-iridoid glycoside amarogentin (Figure 22) was investigated in an in vivo hamster model against visceral leishmaniasis caused by L. donovani. The free form of amarogentin displayed a 34% reduction in parasite load in the spleen. When amarogentin was applied with liposomal or niosomal non-ionic...
2. Review of the literature

Surfactant vesicles, its activity was improved considerably with a parasite load reduction in the spleen of 90% and 69%, respectively.

Argentilactone 77 showed very good in vivo antileishmanial activity when administered to L. amazonensis-infected mice by oral or subcutaneous routes. Argentilactone showed the same efficacy as the reference drug meglumine antimonate 36, reducing parasite load in lesions by 96% and in the spleen by 50%.

![Image of lactone derivatives](Image)

**Figure 22.** Lactone derivatives having antileishmanial activity in vivo.

Four potential anticancer alkyl-lysophospholipids were assayed by oral administration against two strains of L. donovani in a mouse model. The currently approved antileishmanial drug miltefosine 41 displayed the best parasitic reduction in liver (97% and 99% inhibition against strain LV9 and Patna I) at a 30 mg/kg dose. Ilmofosine 78 (Figure 23) displayed good activity with 67% and 92% inhibition. Edelfosine 79 was moderately active. In a study by Cabrera-Serra et al., miltefosine-related derivatives edelfosine 79 and perifosine 80 were orally administered to L. amazonensis-infected mice. The edelfosine-treated mouse group showed 49% and perifosine 80 38% inhibition in footpad lesions. Biopsies obtained from mice treated with edelfosine 79 showed a 19% parasitic burden when compared to the non-treated control. In perifosine-treated mice, the parasitic burden was only 7% when compared to the control. The researchers concluded that perifosine 80 should be studied further in preclinical studies.

In vivo intraperitoneal administration of the osteoporosis bisphosphonate drug pamidronate 81 to mice infected with cutaneous leishmaniasis caused by L. mexicana amazonensis resulted in long-term disappearance of lesions. In another study, pamidronate 81 and related bisphosphonate risedronate 82 were studied against L. donovani. Intravenous administration of pamidronate 81 and risedronate 82 was found to inhibit L. donovani amastigotes parasite burden in mouse liver by 92% and 99%, respectively. However, at high doses of risedronate 82 toxicity was also observed.
2. Review of the literature

Figure 23. Phosphorus-containing antileishmanial compounds.

Hydroxybibenzyl 14-hydroxylunularin 83 (Figure 24) was highly active in an in vitro assay against culture and intracellular forms of *Leishmania* spp., without cytotoxicity to mammalian cells. In addition, 14-hydroxylunularin 83 showed high anti-protozoal activity in *Leishmania* spp.-infected mice by subcutaneous and oral administration routes. Treatment caused the lesion weight to decrease by 96% and the parasite load by 93% with the subcutaneous route, and 90% and 69% with oral administration. The authors of that study suggest that 83 could be chosen as a new candidate in the development of leishmanicidal therapy.

Antiestrogen drug tamoxifen 84, which is used as a chemotherapeutic and chemopreventive agent against breast cancer, showed excellent antileishmanial activity in mice infected with *L. amazonensis* promastigotes. Parasite burden in tamoxifen-treated animal lesions was reduced by 99.7% in treated groups, as compared to untreated animals. In addition, the reduction in parasite burden was sustained for 6 weeks after the end of treatment. Thus, the results support the proposal for further testing of this drug in other models of leishmaniasis.
2. Review of the literature

Natural oleane triterpene saponin maesabalide III 85 (MB-III, PX-6518, Figure 25) demonstrated in vivo activity against *L. donovani* in golden hamsters.\textsuperscript{134} It was concluded that administration of a single dose of MB-III has efficacy comparable to that of a single dose of liposomal amphotericin B 38. However, severe toxicity was observed as several animals died during the experiment series and further development is required. Activity of MB-III 85 was further evaluated in vivo with mice infected with *L. mexicana*, *L. panamensis* or *L. major*.\textsuperscript{135} MB-III 85 completely healed *L. mexicana* and *L. panamensis* lesions, whereas *L. major* lesions were reduced by 50%, thus demonstrating broad-spectrum curative efficacy. In the follow up study, the same authors synthesized several semisynthetic MB-III derivatives to study the structure-activity relationships, but in in vitro studies none of the derivatives showed increased activity compared to 85.\textsuperscript{136}

Monoterpenoid cantharidin 86 is a natural poisonous terpenoid secreted by male blister beetles (*Lytta vesicatoria*). The effect of different doses of cantharidin 86 on *L. major* were investigated both in vitro (promastigote and amastigote viability) and in infected mice (skin lesions) using ointment or soluble cantharidin. Two weeks of topical treatment with 0.1% cantharidin ointment was an effective method for treating cutaneous leishmaniasis in infected mice and skin lesions were totally healed. However, in the follow up study, after two months a relapse of lesions was observed for two mice out of eight.

The widely used antimalarial drug sesquiterpene lactone, which contains an unusual peroxide bridge, artemisinin 87, demonstrated only moderate antileishmanial activity against promastigotes of a wide range of *Leishmania* species, including strains responsible for visceral leishmaniasis (*L. donovani, L. infantum*), cutaneous leishmaniasis (*L. tropica, L. mexicana*) and mucocutaneous leishmaniasis (*L. amazonensis, L. braziliensis*) promastigotes, the IC\textsubscript{50} value being approx. 100 µM.\textsuperscript{137} However, in a mouse model of visceral leishmaniasis, orally administered artemisinin 87 (10 mg/kg and 25 mg/kg body weight) effectively reduced both splenic weight and parasite burden by 83% and 86%, respectively. The reference drug sodium stibogluconate 35 demonstrated a similar significant 85% decrease in parasite burden.

\begin{figure}[h]
\centering
\includegraphics[width=0.5\textwidth]{figure24.png}
\caption{Antileishmanial compounds 14-hydroxylunularin 83 and antiestrogen agent tamoxifen 84.}
\end{figure}
2. Review of the literature

![Figure 25. Terpenes and terpenoids possessing antileishmanial activity in vivo.](image)

**Betulin-derived compounds**

In a study by Sauvain et al., betulinic aldehyde 88 (Figure 26), obtained from Dolichocarpus dentatus (Aubl.) Stand. showed weak in vitro activity against *L. amazonensis* amastigotes with a survival index of 12% at 136 µM and 42% at 68 µM. However, at these doses 88 also showed toxicity against peritoneal macrophages with survival indices of 70% and 80%, respectively. At a concentration of 34 µM, aldehyde 88 was ineffective against *L. amazonensis* as well as nontoxic to macrophages.

In another study, in which a library of natural compounds was screened for antileishmanial activity, betulinic acid 2 was found to be weakly active against *L. major* with an IC$_{50}$ value of 88 µM. It was also noted that in triterpenes having a ursane, oleanane or lupane skeleton, a carboxy substituent was required for antileishmanial activity.

In a study by Chowdhury et al., dihydrobetulinic acid 89 was found to inhibit growth of *L. donovani* promastigotes and amastigotes with an IC$_{50}$ value of 2.6 and 4.1 µM, respectively. It acts by targeting DNA topoisomerase I and II, preventing DNA cleavage and formation of the enzyme-DNA complex, ultimately inducing apoptosis. Leishmanial parasitic burden in golden hamsters was reduced by 92% after 6-week treatment with dihydrobetulinic acid 89 (10 mg/kg body weight). In a subsequent study by the same authors, six betulin and six dihydrobetulin esters were assayed against sodium stibogluconate sensitive and resistant
2. Review of the literature

*L. donovani* strains *in vitro*. Derivatives having small ester groups were active against both *L. donovani* strains. 3,28-Disuccinoylbetulin 90, 3,28-disuccinoyldihydrobetulin 91 and 3,28-diglutaroylbetulin 92 showed the best inhibition activity against amastigote growth inside macrophages, with EC₅₀ values between 6.1 and 10.5 µM. The suggested biochemical mechanism of these betulin esters was similar to dihydrobetulinic acid 89, as they inhibited in a reversible manner the relaxation activity of enzyme type IB topoisomerase of the parasite as well as topoisomerase I–DNA complex formation.

![Figure 26. Betulin derivatives with antileishmanial activity.](image)

2.4 *Chlamydia pneumoniae*

2.4.1 Species, taxonomy and life cycle

The order Chlamydiales comprises four families and 13 species, with the *C. pneumoniae* species belonging to Family I: Chlamydiaceae and Genus I: *Chlamydia* (Table 6). In addition to *C. pneumoniae*, *C. trachomatis* is the only other bacterial species in the order Chlamydiales that infects humans. *C. trachomatis* causes urogenital infections and also trachoma, which causes roughening of the inner eyelids and can lead to blindness. The remaining species are infectious to animals only, including insects, birds and other mammals.
Table 6. Taxonomy of *Chlamydia pneumoniae*.

<table>
<thead>
<tr>
<th>Order</th>
<th>Chlamydiales</th>
</tr>
</thead>
<tbody>
<tr>
<td>Family</td>
<td>Chlamydiaceae</td>
</tr>
<tr>
<td>Genus I</td>
<td>Chlamydia</td>
</tr>
<tr>
<td>Species</td>
<td><em>Chlamydia pneumoniae</em></td>
</tr>
</tbody>
</table>

The chlamydial life cycle consists of two distinct morphological forms: the elementary body (EB) and reticulate body (RB). EB is the metabolically inactive, infective extracellular stage, and RB the metabolically active, replicating, intracellular form.

In the *C. pneumoniae* life cycle (Figure 27):

1) EB attaches to the host cell (yet unknown receptors).
2) Entry of EB to host cell via phagocytosis or receptor-mediated endocytosis.
3) Inside the host cell EB is surrounded by double-membrane inclusion. EB is converted to RB.
4) Inclusion is enlarged and filled with new replicates of RB.
5) RBs are converted back to infectious EBs and exit of the EBs can occur via lysis of the host cell or via extrusion of the EB packed inclusion.

Figure 27. Life cycle of *C. pneumoniae*. A = *C. pneumoniae* elementary body (EB). B = Host cell, usually lung cell.
2. Review of the literature

2.4.2 Chlamydial persistence

Chlamydial persistence can last for years and it is defined as a viable but non-cultivable growth stage inside the infected host cell. In the persistence stage, C. pneumoniae is not metabolically active and not replicating. Persistence is caused by several stress factors that are unfavourable for bacterial growth, such as insufficient nutrients (e.g. amino acids), iron depletion, non-lethal antibiotics, heat and growth in monocytes. In all cases, the developmental cycle is halted and the RBs are not converted back to the infective extracellular EB stage. Instead of the normal round shape of EBs, enlarged aberrant bodies (AB) are formed. This is clinically highly relevant, since a persistent culture cannot be subcultured for diagnostic purposes. However, chlamydial persistence can be detected from chlamydial DNA or marker proteins in the absence of viable Chlamydiae. It has been suggested that C. pneumoniae can persist for many years after initial respiratory infection.

2.4.3 Chemotherapy against infections caused by C. pneumoniae

C. pneumoniae is susceptible to antibiotics that interfere with DNA and protein synthesis, including tetracyclines, macrolides, quinolones and rifamycins. These classes of antibiotics are most widely studied and used for treatment of human infections. However, C. pneumoniae is resistant to some common antibiotic classes, such as trimethoprim, sulphonamides, aminoglycosides and glycopeptides.

Clinical manifestation and treatment

Asymptomatic infection or unrecognized, mildly symptomatic illnesses, such as prolonged cough and mild fever, are very common symptoms of C. pneumoniae infection. Severe systemic infections with C. pneumoniae alone are not common. Even in mild cases, complete recovery is slow, despite appropriate antibiotic therapy, and cough and malaise may persist for many weeks after the acute illness. It has been estimated that 10% of cases of pneumonia and approximately 5% of bronchitis and sinusitis cases in adults have been attributed to this organism. In addition, there is strong evidence that C. pneumoniae is associated with other severe diseases, such as atherosclerotic cardiovascular diseases as well as some neurodegenerative diseases, such as Alzheimer’s disease and multiple sclerosis.

The intracellular location of C. pneumoniae limits and hampers the efficacy of some antibiotics. The antichlamydial agent must penetrate several biological membranes in therapeutic concentrations: the host cell membrane, the inclusion membrane, and, finally, the inner and outer membrane of the Gram-negative bacterium itself. Thus, antimicrobial agents need good intracellular penetration properties to be effective. The following regimen guidelines (Table 7) for adults can be followed in clinical treatment of C. pneumoniae infection. However, some patients may need re-treatment.
Table 7. Current treatment guidelines for the treatment of respiratory infection due to C. pneumoniae.¹⁶

<table>
<thead>
<tr>
<th>Antibiotic class</th>
<th>Drug</th>
<th>Dosing</th>
<th>Regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluoroquinolone</td>
<td>Levofloxacin 101</td>
<td>500 mg once a day</td>
<td>Orally or intravenously 7–14 days</td>
</tr>
<tr>
<td></td>
<td>Moxifloxacin 103</td>
<td>400 mg once a day</td>
<td>Orally 10 days</td>
</tr>
<tr>
<td>Tetracycline</td>
<td>Doxycycline 112</td>
<td>100 mg twice a day</td>
<td>Orally 14–21 days</td>
</tr>
<tr>
<td></td>
<td>Tetracycline 114</td>
<td>250 mg four times a day</td>
<td>Orally 14–21 days</td>
</tr>
<tr>
<td>Macrolide</td>
<td>Azithromycin 115</td>
<td>1.5 g once a day</td>
<td>Orally 5 days</td>
</tr>
<tr>
<td></td>
<td>Clarithromycin 116</td>
<td>500 mg twice a day</td>
<td>Orally 10 days</td>
</tr>
</tbody>
</table>

Fluoroquinolones

Many of the commonly used fluoroquinolone antibiotics show very good in vitro antichlamydial activity with low micromolar MIC values. The fluoroquinolone class of antibiotics share a quinoline ring system with a fluorine atom at C-6. Piperazine or another ring system is attached to C-7. Fluoroquinolones block DNA replication and repair by inhibiting topoisomerase II function.¹⁵³

The chemical structures of fluoroquinolone antibiotics and some experimental fluoroquinolones (and a few quinolones) screened in vitro against C. pneumoniae are presented in Figure 28 and their in vitro MIC values in Table 8. In most of the cases, susceptibility of C. pneumoniae to antibiotics is tested using a HEp-2 cell line or, in some cases, a HeLa 229 cell line, as a host. Several antibiotics, such as garenoxacin 97 (MIC 0.015–0.03 µg/mL), sitafloxacin 107 (MIC 0.031–0.0125 µg/mL) and experimental BMS-284756 94 (MIC 0.015–0.03 µg/mL) show very good in vitro activities (Table 8). The MIC values from different studies are very consistent, and usually only small variations can be seen between HEp-2 or HeLa 229 host cell lines. The current recommendation for human treatment is to use levofloxacin 101 (MIC 0.25–1 µg/mL) or moxifloxacin 103 (MIC 0.06–1 µg/mL) as the first-choice antibiotic of this class.¹⁶
2. Review of the literature

Figure 28. Chemical structures of the fluoroquinolone and quinolone classes of antibiotics with antichlamydial activity.
Table 8. *In vitro* efficacy of fluoroquinolones and some quinolones against *C. pneumoniae*.

<table>
<thead>
<tr>
<th>Quinolone or fluoroquinolone</th>
<th>MIC range µg/mL</th>
<th>Cell line</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>BAY 12-8039 93</td>
<td>0.5–1</td>
<td>HEp-2</td>
<td>104</td>
</tr>
<tr>
<td>BMS-284756 94</td>
<td>0.015–0.03</td>
<td>HEp-2</td>
<td>155</td>
</tr>
<tr>
<td></td>
<td>0.004–0.008</td>
<td>HEp-2</td>
<td>156</td>
</tr>
<tr>
<td>Ciprofloxacin 95</td>
<td>1.0–4.0</td>
<td>HEp-2</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td>0.25–4</td>
<td>HeLa 229, HEp-2</td>
<td>158</td>
</tr>
<tr>
<td>Fleroxacin 96</td>
<td>2–8</td>
<td>HeLa 229, HEp-2</td>
<td>158</td>
</tr>
<tr>
<td>Garenoxacin 97</td>
<td>0.008</td>
<td>HEp-2</td>
<td>159</td>
</tr>
<tr>
<td></td>
<td>0.015–0.03</td>
<td>HEp-2</td>
<td>160</td>
</tr>
<tr>
<td>Gatifloxacin (AM-1155) 98</td>
<td>0.125</td>
<td>HEp-2</td>
<td>159</td>
</tr>
<tr>
<td></td>
<td>0.125–0.25</td>
<td>HEp-2</td>
<td>161</td>
</tr>
<tr>
<td></td>
<td>0.063–0.125</td>
<td>HeLa 229</td>
<td>162</td>
</tr>
<tr>
<td>Gemifloxacin 99</td>
<td>0.125–0.25</td>
<td>HEp-2</td>
<td>163</td>
</tr>
<tr>
<td>Grepafloxacin 100</td>
<td>0.063–0.125</td>
<td>HeLa 229</td>
<td>162</td>
</tr>
<tr>
<td>Levofloxacin 101</td>
<td>0.5–1.0</td>
<td>HEp-2</td>
<td>155</td>
</tr>
<tr>
<td></td>
<td>0.25</td>
<td>HEp-2</td>
<td>159</td>
</tr>
<tr>
<td></td>
<td>0.5</td>
<td>HEp-2</td>
<td>156</td>
</tr>
<tr>
<td>Lomefloxacin 102</td>
<td>2</td>
<td>*</td>
<td>164</td>
</tr>
<tr>
<td>Moxifloxacin 103</td>
<td>0.125–1.0</td>
<td>HEp-2</td>
<td>155</td>
</tr>
<tr>
<td></td>
<td>0.06–0.12</td>
<td>HEp-2</td>
<td>156</td>
</tr>
<tr>
<td></td>
<td>0.063</td>
<td>HEp-2</td>
<td>159</td>
</tr>
<tr>
<td>Norfloxacin 104</td>
<td>16</td>
<td>*</td>
<td>164</td>
</tr>
<tr>
<td>Ofloxacin 105</td>
<td>0.5–2.0</td>
<td>HEp-2</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td>0.5–2.0</td>
<td>HEp-2</td>
<td>165</td>
</tr>
<tr>
<td></td>
<td>0.5–1</td>
<td>HEp-2</td>
<td>156</td>
</tr>
<tr>
<td>L-Ofloxacin</td>
<td>0.125–0.5</td>
<td>HeLa 229, HEp-2</td>
<td>166</td>
</tr>
<tr>
<td>OPC-17116 106</td>
<td>0.25–0.5</td>
<td>HEp-2</td>
<td>155</td>
</tr>
<tr>
<td>Sitafluoxacin (DU-6859a) 107</td>
<td>0.031–0.125</td>
<td>HEp-2</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td>0.031–0.063</td>
<td>HeLa 229</td>
<td>162</td>
</tr>
<tr>
<td>Sparfloxacin 108</td>
<td>0.031–0.125</td>
<td>HEp-2</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td>0.016</td>
<td>HEp-2</td>
<td>159</td>
</tr>
<tr>
<td></td>
<td>0.06–0.25</td>
<td>HEp-2</td>
<td>165</td>
</tr>
<tr>
<td></td>
<td>0.06–0.25</td>
<td>HeLa 229, HEp-2</td>
<td>158</td>
</tr>
<tr>
<td>Temafloxacin 109</td>
<td>0.125–1</td>
<td>HeLa 229, HEp-2</td>
<td>158</td>
</tr>
<tr>
<td>Tosulfloxacin 110</td>
<td>0.063–0.25</td>
<td>HEp-2</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td>0.125</td>
<td>*</td>
<td>164</td>
</tr>
<tr>
<td>Trovafloxacin 111</td>
<td>0.5–1</td>
<td>HEp-2</td>
<td>167</td>
</tr>
</tbody>
</table>

* Cell line not mentioned in publication.
2. Review of the literature

Tetracyclines

The first tetracycline antibiotics, chlortetracycline and oxytetracycline, were discovered in the late 1940s and they are produced by the bacteria *Streptomyces aureofaciens* and *S. rimosus*, respectively. Tetracycline antibiotic molecules consist of four linearly fused rings, to which a variety of functional groups are attached. Tetracyclines inhibit bacterial protein synthesis by preventing the association of aminoacyl-tRNA with the bacterial ribosome.

The chemical structures of tetracycline antibiotics, natural tetracycline 114, and semisynthetic derivatives doxycycline 112 and minocycline 113, screened *in vitro* against *C. pneumoniae*, are presented in Figure 29, and their *in vitro* MIC values using HEp-2 or HeLa 229 host cell lines are given in Table 9. All three compounds display good efficacy (MIC 0.05–0.25 µg/mL) against *C. pneumoniae*. Currently, doxycycline 112 and tetracycline 114 are recommended antibiotics for treatment of chlamydial infection in humans.

![Chemical structures of tetracycline-class antibiotics with antichlamydial activity.](image)

**Figure 29.** Chemical structures of tetracycline-class antibiotics with antichlamydial activity.

<table>
<thead>
<tr>
<th>Tetracycline</th>
<th>MIC range</th>
<th>Cell line</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxycycline 112</td>
<td>0.06–0.25</td>
<td>HEp-2</td>
<td>166</td>
</tr>
<tr>
<td>Minocycline 113</td>
<td>0.0625</td>
<td>HEp-2</td>
<td>170</td>
</tr>
<tr>
<td>Tetracycline 114</td>
<td>0.05–0.1</td>
<td>HeLa 229</td>
<td>171</td>
</tr>
</tbody>
</table>

Macrolides

Macrolide antibiotics are usually used to treat infections caused by Gram-positive bacteria. The macrolide antibiotics have a large, usually 14-, 15-, or 16-membered macrocyclic lactone ring with one or more deoxy sugars attached. Macrolides belong to the polyketide class of natural products, and they act by inhibiting the bacterial protein synthesis machinery, the ribosome.

The chemical structures of macrolide antibiotics and some experimental macrolides screened *in vitro* against *C. pneumoniae* are presented in Figure 30, and their *in vitro* MIC values using a HEp-2 host cell line are given in Table 10.
Azithromycin 115, clarithromycin 116 and erythromycin 118 display very good antichlamydiaal in vitro inhibition activity (MIC 0.004–0.5 µg/mL), whereas dirithromycin and roxithromycin show slightly diminished activities. MIC results from different studies are very consistent. The current recommendation for human treatment is to use azithromycin 115 (MIC 0.06–0.5 µg/mL) or clarithromycin 116 (MIC 0.004–0.063 µg/mL) as the first-choice antibiotic of this class.16

![Chemical structures of macrolide-class antibiotics with antichlamydiaal activity.](image)

**Figure 30.** Chemical structures of macrolide-class antibiotics with antichlamydiaal activity.

<table>
<thead>
<tr>
<th>Macrolide</th>
<th>MIC range</th>
<th>Cell line</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin 115</td>
<td>0.125–0.5</td>
<td>HEp-2</td>
<td>173</td>
</tr>
<tr>
<td></td>
<td>0.06–0.25</td>
<td>HEp-2</td>
<td>166</td>
</tr>
<tr>
<td>Clarithromycin 116</td>
<td>0.016–0.063</td>
<td>HEp-2</td>
<td>173</td>
</tr>
<tr>
<td></td>
<td>0.015–0.06</td>
<td>HEp-2</td>
<td>155</td>
</tr>
<tr>
<td></td>
<td>0.004–0.03</td>
<td>HEp-2</td>
<td>166</td>
</tr>
<tr>
<td>Dirithromycin 117</td>
<td>0.5–4</td>
<td>HEp-2</td>
<td>174</td>
</tr>
<tr>
<td>Erythromycin 118</td>
<td>0.063–0.25</td>
<td>HEp-2</td>
<td>173</td>
</tr>
<tr>
<td></td>
<td>0.016–0.5</td>
<td>HEp-2</td>
<td>174</td>
</tr>
<tr>
<td>Roxithromycin 119</td>
<td>0.0625–2</td>
<td>HEp-2</td>
<td>176</td>
</tr>
</tbody>
</table>

**Table 10.** In vitro efficacy of macrolides against *C. pneumoniae*.
2. Review of the literature

Ketolides

Ketolide antibiotics are broad spectrum 14-membered semi-synthetic derivatives of the macrolide erythromycin A. Main modifications are replacement of the neutral L-cladinose sugar at position C-3 in erythromycin by a 3-ketone carbonyl, and attachment of a cyclic carbamate group in the lactone ring. These structural modifications give ketolides improved pharmacodynamic and pharmacokinetic properties, such as improved acid stability, reduced risk of resistance induction and higher lipophilicity when compared with 14-membered macrolides. Similarly to macrolides, ketolides act by inhibiting the bacterial protein synthesis machinery, the ribosome.

Figure 31 presents the chemical structures of ketolide antibiotics and some experimental ketolides screened in vitro against *C. pneumoniae*, and Table 11 shows their in vitro MIC values using HEp-2 host cells. Cethromycin 120 (MIC 0.008–0.031 µg/mL) and telithromycin 121 (MIC 0.031–0.25 µg/mL) show very good antichlamydial efficacy. However, none of the ketolide antibiotics are included in current treatment recommendations for humans. 16

![Chemical structures of ketolide-class antibiotics with antichlamydial activity.](image-url)
Table 11. In vitro efficacy of ketolides against *C. pneumoniae*.

<table>
<thead>
<tr>
<th>Ketolide</th>
<th>MIC range</th>
<th>Cell line</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cethromycin (ABT-773) 120</td>
<td>0.016–0.031</td>
<td>HEp-2</td>
<td>173</td>
</tr>
<tr>
<td></td>
<td>0.008–0.015</td>
<td>HEp-2</td>
<td>176</td>
</tr>
<tr>
<td>HMR 3647 121</td>
<td>0.031–2</td>
<td>HEp-2</td>
<td>175</td>
</tr>
<tr>
<td>Solithromycin (CEM-101, OP-1068) 122</td>
<td>0.25–1.0</td>
<td>HEp-2</td>
<td>179</td>
</tr>
<tr>
<td>Telithromycin 123</td>
<td>0.031–0.25</td>
<td>HEp-2</td>
<td>173</td>
</tr>
</tbody>
</table>

Rifamycins

The molecular structure of rifamycins consists of an aromatic moiety bridged at nonadjacent positions by an aliphatic chain. The aromatic moiety can be a naphthalene or naphthoquinone ring system, as in rifamycin, or a benzene or benzoquinone ring. The rifamycins were first isolated by Sensi and co-workers in 1959.

The rifamycins display a broad spectrum of antibiotic activity, especially against Gram-positive bacteria. After evaluation of a large number of semisynthetic analogues, rifampicin 126 with excellent oral bioavailability was developed. Rifampicin 126 shows more pronounced activity against Gram-positive bacteria, in particular mycobacteria. In addition, activity against Gram-negative bacteria is improved. The antibacterial action of rifampicin 126 results from its inhibition of DNA-dependent RNA synthesis.

The chemical structures of semisynthetic rifamycin antibiotic derivatives screened in vitro against *C. pneumoniae* are presented in Figure 32, and their in vitro MIC values using a HEp-2 host cell line are given in Table 12. All compounds display excellent efficacy (MIC 0.00125–0.02 µg/mL) against *C. pneumoniae*, however, rifamycins are currently not recommended for antichlamydial antibiotics in humans.
2. Review of the literature

![Chemical structures of rifamycin-class antibiotics with antichlamydial activity.](image)

**Figure 32.** Chemical structures of rifamycin-class antibiotics with antichlamydial activity.

<table>
<thead>
<tr>
<th>Rifamycins</th>
<th>MIC range</th>
<th>Cell line</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABI-1131 124</td>
<td>0.00125–0.0025</td>
<td>HEp-2</td>
<td>183</td>
</tr>
<tr>
<td>Rifalazil (ABI-1648) 125</td>
<td>0.00125–0.0025</td>
<td>HEp-2</td>
<td>183</td>
</tr>
<tr>
<td>Rifampicin 126</td>
<td>0.005</td>
<td>HEp-2</td>
<td>184</td>
</tr>
<tr>
<td>Rifapentin 127</td>
<td>0.04–0.02</td>
<td>HEp-2</td>
<td>185</td>
</tr>
</tbody>
</table>

**Table 12.** *In vitro* efficacy of rifamycins against *C. pneumoniae*.

Natural non-antibiotic-derived compounds

Little research has been conducted on the antichlamydial properties of non-antibiotic natural compounds. In a study by Alvesalo et al., a library of 57 natural phenolic compounds or their derivatives were tested against *C. pneumoniae in vitro* using HL cells. The compounds included flavones, flavonols, flavonones, isoflavonones, coumarins, catechins, phenolic acids, gallates, a stilbene or their semisynthetic derivatives. Active compounds were found in several compound groups, especially in gallates (dodecyl gallate 128, MIC = 18 µM), but also flavones (luteolin 70 MIC = 8.8 µM) and flavonols (myricetin 131, MIC = 29 µM) with no cytotoxicity to host cells (Figure 33).
In a related study, two flavonoids luteolin 70, quercetin 71 and octyl gallate 129 were tested in an in vivo mouse model. Results were contradictory: octyl gallate 129 had no significant effect; quercetin 71 increased both the inflammatory responses and the chlamydial load in the lungs. On the other hand, luteolin 70 suppressed the presence of Chlamydia and inflammation in lung tissue as well as development of C. pneumoniae-specific antibodies.

A tea polyphenol product "Polyphenon 70S", consisting of a mixture of flavan-3-ols, galloatechins and catechins, was found to inhibit C. pneumoniae growth in HL cells completely at 0.8–1.6 mg/mL concentration, depending on the bacterium strain.

Corn mint (Mentha arvensis L.) extract, and its main flavone components, acetin 132, linarin (diglycoside acacetin); and rosmarinic acid were evaluated against C. pneumoniae infection. In vitro both flavones showed roughly 100% inhibition at 100 µM concentration with no toxicity to the HL host cell line, whereas the activity of corn mint extract and rosmarinic acid were lower. Corn mint extract was tested in a mouse model in which the extract was able to reduce the inflammatory parameters related to C. pneumoniae infection and the number of C. pneumoniae genome equivalents at biologically relevant amounts.

The antichlamydial properties of retinoic acid (Vitamin A) 130 have been studied in vitro and in vivo. The in vitro results showed two separate effects of retinoic acid 130: firstly, retinoic acid prevents attachment of the organism to the host endothelial cell surface and, secondly, inhibits growth in both epithelial and endothelial cells. The in vivo results showed that retinoic acid 130 prevents C. pneumoniae-induced foam cell development in a mouse model of atherosclerosis.

Betulinic acid 2 has been found to be inactive against Staphylococcus aureus, Escherichia coli, Bacillus subtilis, Micrococcus luteus, as well as Enterococcus faecalis and Pseudomonas aeruginosa. Generally, betulin derivatives seem to have rather poor antibacterial activity.

![Figure 33. Natural compounds with antichlamydial activity.](image-url)
3. Aims of the study

The aim of this study was to use the triterpene skeleton of an abundant birch bark extractive betulin 1 to synthesize a library of derivatives with various functional groups for bioactivity screening.

More specifically, the aims were:

- to prepare a library of betulin derivatives with diverse functional groups by modifying reactive moieties of the betulin skeleton at 3-OH, 28-OH and isopropenyl group at C22–C29

- to investigate the structure-activity relationships of betulin derivatives against intracellular pathogenic bacteria, protozoan parasites and viruses

- to synthesize a library of novel heterocyclic betulin derivatives with more hydrophilic drug-like properties and optimize their bioactivities against Leishmania donovani.
4. Experimental

4.1 Materials and methods

Commercially available reagents were used without further purification and all solvents were HPLC grade. Anhydrous solvents were purchased from Sigma-Aldrich. All reactions in anhydrous solvents were performed in oven-dried glassware under an inert atmosphere of anhydrous argon or nitrogen. Thin layer chromatography (TLC) was performed on E. Merck Silica Gel 60 aluminium packed plates, with visualization accomplished by UV illumination and staining with 5% H$_2$SO$_4$ in MeOH. The $^1$H NMR spectra were measured on a Varian Mercury-VX 300 MHz or a Chemagnetics CMX 400 MHz spectrometer with chemical shifts reported as parts per million (in CDCl$_3$ at 23 °C, solvent peak at 7.26 ppm as an internal standard or in DMSO-d$_6$ at 23 °C, solvent peak at 2.50 ppm as an internal standard). The $^{13}$C NMR spectra were obtained on a Varian Mercury-VX 75 MHz or a Chemagnetics CMX 100 MHz spectrometer with chemical shifts reported as parts per million (in CDCl$_3$ at 23 °C, solvent peak at 77.0 ppm as an internal standard or in DMSO-d$_6$ at 23 °C, solvent peak at 39.50 ppm as an internal standard). HPLC-MS and elemental analyses were performed to determine the purity of all tested compounds. The purity of all tested compounds was >95%. Mass spectra were measured on a Bruker Daltonik Esquire-HPLC spectrometer, with an XTerra MS RP18 column (4.6 x 30 mm, 2.5 µm) or on a JEOL JMS-AXS505 spectrometer with direct input and electron ionization (EI). Elemental analyses were performed by Robertson Microlit Laboratories, Madison, NJ, USA. Melting points were obtained with a Sanyo Gallenkamp apparatus without correction. Fourier transform infrared (FTIR) spectra were recorded on a Bruker Vertex 70 spectrometer with Pike MiRacle diamond crystal or with a Bruker Equinox 55 spectrometer including IRScope II and diamond anvil.

Biological assays, cell lines and methodology are described in details in the original publications I–IV.

4.2 Results and discussion

The overall objective in the synthesis work was to produce desired test compounds for bioactivity screening. Neither synthesis method development nor optimization
of the reaction conditions was performed and in many cases yields are only mod-
erate, but still sufficient to obtain enough pure material for bioactivity assays.

The first objective was to prepare a library of betulin derivatives with diverse
functional groups by modifying the reactive moieties of the betulin skeleton at 3-
OH, 28-OH and isopropenyl group between C22–C29. Details of the chemical
synthesis procedures and characterization data are presented in Publications I, II
and IV. The chemical structures of all synthesized simple betulin derivatives are
presented in Table 13.

The second objective of the study was to synthesize a library of novel hetero-
cyclic betulin derivatives for bioactivity screening. Details of the chemical synthesis
procedures and characterization data are presented in Publication II. The chemical
structures of all synthesized heterocyclic betulin derivatives are presented in Table 14.

4.2.1 Synthesis of simple betulin derivatives (I, II, IV)

Synthesis of betulin esters and related derivatives (I, II, IV)

Many of the natural terpenes or aromatic acids possess numerous bioactivities in
nature, such as pheromones and semiochemicals in insects. At least 30 hy-
droxy- and polyhydroxybenzoic acids have been reported in the last 10 years to
have biological activities with potential use in pharmaceutical and agricultural
products to improve human health and nutrition. In addition, hydroxycinnamic
acids are a large group of phenolic compounds (e.g. caffeic, \( p \)-coumaric and feru-
ic acids), which have shown antioxidant and anticancer activities. Because both
betulin and its naturally occurring carboxylic acid derivatives have been shown
to possess numerous bioactivities, it was hypothesized that it would be very inter-
esting to try combining these kinds of moieties in a single compound. Thus, sever-
al such carboxylic acids were chosen and esterified with betulin to yield a set of
betulin esters and related derivatives for bioactivity screening [(Figure 34), see
Table 13 for the chemical structures of the compounds]. Some of the
aromatic betulin derivatives were initially designed for cosmetic applications as
possible bioactive agents having UV-activity in a single molecule. These subst-
ances were also included in the bioactivity assays.

Ethyl chrysanthemate was hydrolyzed to produce chrysanthemic acid, which
was subsequently converted with oxalyl chloride to chrysanthemoyl chloride. Finally,
chrysanthemoyl chloride was reacted with to afford a 1:3 mixture of cis and trans
28-O-chrysanthemoylbetulin. The treatment of carvacrol with chloroacetic acid
in an aqueous solution of sodium hydroxide gave carvacryloxyacetic acid, which
was esterified with using titanium(IV) isopropoxide as a catalyst to produce betu-
linyl 28-carboxyethoxycarvacrol. Treatment of with nicotinic acid using
DCC as a coupling reagent gave 28-O-nicotinoylbetulin. Cinnamic acid was
converted to cinnamoyl chloride with thionyl chloride, which was subsequently
esterified with to give 28-O-cinnamoylbetulin. N-Acetylanthranilic acid was
treated with oxalyl chloride to produce N-acetylanthraniloyl chloride, which was
treated immediately with 1 to give 28-O-(N-acetylanthraniloyl)betulin 137. Betulin 1 was treated with t-BuOK followed by addition of methyl bromoacetate to give 28-O-bromoacetylbetulin 138. 3,28-Di-O-levulinoylbetulin 139 was obtained by esterifying of 1 with levulinic acid using PPTS as a catalyst.

Treatment of 1 with DHP produced a diastereomeric mixture of the corresponding tetrahydropyranyl ether 140. The THP-protected betulin was subsequently acetylated to give 141. Removal of the THP group with PPTS produced 3-O-acetylbetulin 142, which was treated with mesyl chloride to give 3-O-acetyl-28-O-mesitylbetulin 143.

Betulin 1 was diacetylated to 144 with excess acetic anhydride, and the resulting diacetylbetulin was converted by acidic (HBr) treatment to 145 with double-bond migration to position C18–C19. The alkene 145 was subsequently epoxidized with 3-chloroperoxybenzoic acid (mCPBA) to yield the intermediate 146.

Finally, 28-O-acetylbetulin 147 was obtained by treating betulin 1 with 1.05 equiv of acetic anhydride. The subsequent oxidation of 147 with PCC afforded 28-O-acetyl-3-oxobetulin 148.

Figure 34. Synthesis of betulin esters and related betulin derivatives. Conditions: (a) (i) ethyl chrysanthemate, NaOH, MeOH-THF (2:1), 80 °C, 4 h, 91%, (ii) chrysanthemoyl chloride, DMAP, py, 40 °C, 48 h, 63%; (b) (i) carvacrol, chloroacetic acid, NaOH, Δ, 3 h, 45%, (ii) carvacryloxyacetic acid, Ti(OPr-i)4, PhMe, Δ, 6 h, 55%; (c) nicotinic acid, DCC, DMAP, CH2Cl2, rt, 23 h, 31%; (d) (i) cinnamic acid, SOCl2, 40 °C, 2 h, 92%, (ii) cinnamoyl chloride, DMAP, pyridine, 40 °C, 22 h, 21%; (e) (i) N-acetylanthranilic acid, (COCl)2, rt, 3 d, 99%, (ii) N-acetylanthraniloyl chloride, DMAP, py, 40 °C, 40 h, 25%; (f) t-BuOK, methyl bromoacetate, THF, 75 °C, 10 min, 15%; (g) levulinic acid, PPTS, PhMe, 175 °C, 24 h, 23%; (h) DHP, PPTS, CH2Cl2, rt, 2 d, 30%; (i) Ac2O, DMAP, py, CH2Cl2, rt, 20 h, 95%; (j) PPTS, EtOH, rt, 14 d, 94%; (k) CH2SO2Cl, TEA, CH2Cl2, 0 °C, 2 h, 99%; (l) Ac2O (6 equiv), DMAP, py, CH2Cl2, rt, 17 h, 97%; (m) HBr, Ac2O, AcOH, PhMe, rt, 21 d, 42%; (n) mCPBA, Na2CO3, CHCl3, rt, 2 h, 65%; (o) Ac2O (1.05 equiv), DMAP, py, CH2Cl2, rt, 22 h, 45%; (p) PCC, CH2Cl2, rt, 24 h, 57%. THF = tetrahydrofuran; DCC = N,N'-dicyclohexylcarbodiimide; DHP = 3,4-dihydropyran; PPTS = pyridinium p-toluenesulfonate; DMAP = 4-(dimethylamino)pyridine; py = pyridine; PCC = pyridinium chlorochromate; mCPBA = 3-chloroperoxybenzoic acid.
4. Experimental

Synthesis of betulin oxidation products (I, IV)

Based on a thorough literature survey,\textsuperscript{6} it was hypothesized that oxidized betulin derivatives may have improved bioactivity when compared to the starting material betulin. Thus, a set of betulin oxidation products was synthesized for bioactivity screening [(Figure 35), see Table 13 for chemical structures of compounds 2, 88 and 149–155].

Oxidation of betulin 1 with Jones reagent (\(\text{CrO}_3/\text{H}_2\text{SO}_4/\text{H}_2\text{O}\)) gave betulonic acid 149, which was subsequently methylated with TMS\textit{CHN}$_2$ to give methyl betulonate 150. The subsequent treatment of 149 with oxalyl chloride gave betulonoyl chloride,\textsuperscript{86} which was immediately reacted with vanillin or L-aspartic acid dimethyl ester to produce vanillyl betulonate 151 and L-aspartyl amide of betulonic acid 152, respectively.

Reduction of betulonic acid 149 with Na\textit{BH}_4 gave betulinic acid 2,\textsuperscript{55} which was subsequently methylated with TMS\textit{CHN}$_2$ to give methyl betulinate 153.\textsuperscript{201} 28-Oxyallobetulone 154 was synthesized by refluxing betulonic acid 149 with \(p\)-TSA.

When betulin 1 was oxidized with excess PCC, betulonic aldehyde 155\textsuperscript{202} was formed. When a smaller molar amount of PCC was used, betulin aldehyde 88 was isolated from a 3:1 mixture of betulonic aldehyde 155 and betulin aldehyde 88.

The synthesis of two additional oxidized betulin derivatives 28-O-acetyl-3-oxobetulin 148 and dihydrobetulonic acid 158 is presented in Figure 34 and Figure 36.

\textbf{Figure 35.} Synthesis of oxidized betulin derivatives. Conditions: (a) \(\text{H}_2\text{CrO}_4\), acetone, 0 °C \(\rightarrow\) rt, 21 h, 44%; (b) TMS\textit{CHN}$_2$, PhMe-MeOH (3:2), rt, 40 min, 66% 152, 89% 153; (c) (i) (COCl)$_2$, CH$_2$Cl$_2$, rt, 22 h, 85%, (ii) vanillin, DMAP, py, 40 °C, 21 h, 20%; (d) L-aspartic acid dimethyl ester hydrochloride, TEA, CH$_2$Cl$_2$, rt, 19 h, 42%; (e) Na\textit{BH}_4, \textit{i}-PrOH, rt, 2.5 h, 82%; (f) \(p\)-TSA, H$_2$O, CH$_2$Cl$_2$, 3 h, 19%; (g) PCC (1.8 equiv), CH$_2$Cl$_2$, rt, 40 min, 18%; (h) PCC (6 equiv), CH$_2$Cl$_2$, rt, 1 h, 82%. TMS = trimethylsilyl; TEA = triethylamine. \(p\)-TSA = \(p\)-toluenesulfonic acid monohydrate.
Synthesis of miscellaneous betulin derivatives (I, IV)

To gain a more comprehensive understanding of the structure-activity relationships (SAR) of different betulin derivatives, a set of miscellaneous betulin derivatives with diverse functional groups were synthesized (Figure 36, Table 13).

Allobetulin 156 was synthesized by refluxing a mixture of betulin 1 and p-TSA in chloroform.\textsuperscript{203}

Dihydrobetulin 157 was obtained by catalytic hydrogenation of 1 in the presence of palladium on carbon as a catalyst. The subsequent oxidation of dihydrobetulin 157 with Jones reagent produced dihydrobetulonic acid 158.

3-Deoxy-2,3-didehydrobetulin 159 was prepared by treating 1 with a mixture of DEAD, PPh\textsubscript{3} and 3,3-dimethylglutarimide.\textsuperscript{204} Subsequent acetylation of 159 gave 3-deoxy-2,3-didehydro-28-O-acetylbetulin 160.

Betulin 1 was oxidized with PCC to a 3:1 mixture of betulonic aldehyde 155 and betulin aldehyde 88,\textsuperscript{202} which was subsequently treated with excess hydroxylamine hydrochloride to produce oximes 161 and 162.\textsuperscript{205} Separate treatment of 161 and 162 with neat acetic anhydride gave the nitriles 163 and 164, respectively.
Figure 36. Synthesis of miscellaneous betulin derivatives. Conditions: (a) p-TSA, H₂O, CHCl₃, Δ, 3 h, 93%; (b) H₂, 5% Pd/C, THF-MeOH (1:2), rt, 22 h, 99%; (c) H₂CrO₄, acetone, rt, 20 h, 31%; (d) DEAD, PPh₃, 3,3-dimethylglutarimide, THF, 0 °C → rt, 24 h, 31%; (e) Ac₂O, DMAP, py, CH₂Cl₂, rt, 22 h, 81%; (f) PCC (1.8 equiv), CH₂Cl₂, rt, 40 min, 88:155 (1:3); (g) NH₂OH·HCl, py-EtOH (1:3), 100 °C, 18 h, 10% 161, 33% 162; (h) Ac₂O, 120 °C, 2 h, 34% 163, 46% 164. DEAD = diethyl azodicarboxylate.
Table 13. Summary and chemical structures of the simple betulin derivatives.

<table>
<thead>
<tr>
<th>Compound</th>
<th>R₁</th>
<th>R₂</th>
<th>R₃</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>OH</td>
<td>CH₃OH</td>
<td>CH₂-C=CH₂</td>
</tr>
<tr>
<td>133</td>
<td>OH</td>
<td></td>
<td>CH₂-C=CH₂</td>
</tr>
<tr>
<td>134</td>
<td>OH</td>
<td></td>
<td>CH₂-C=CH₂</td>
</tr>
<tr>
<td>135</td>
<td>OH</td>
<td></td>
<td>CH₂-C=CH₂</td>
</tr>
<tr>
<td>136</td>
<td>OH</td>
<td></td>
<td>CH₂-C=CH₂</td>
</tr>
<tr>
<td>137</td>
<td>OH</td>
<td></td>
<td>CH₂-C=CH₂</td>
</tr>
<tr>
<td>138</td>
<td>OH</td>
<td></td>
<td>CH₂-C=CH₂</td>
</tr>
<tr>
<td>139</td>
<td>O</td>
<td></td>
<td>CH₂-C=CH₂</td>
</tr>
<tr>
<td>140</td>
<td>OH</td>
<td></td>
<td>CH₂-C=CH₂</td>
</tr>
<tr>
<td>141</td>
<td>OAc</td>
<td></td>
<td>CH₂-C=CH₂</td>
</tr>
<tr>
<td>142</td>
<td>OAc</td>
<td>CH₃OH</td>
<td>CH₂-C=CH₂</td>
</tr>
<tr>
<td>143</td>
<td>OAc</td>
<td>CH₃OMs</td>
<td>CH₂-C=CH₂</td>
</tr>
</tbody>
</table>
### 4. Experimental

<table>
<thead>
<tr>
<th>144</th>
<th>OH</th>
<th>CH₂OAc</th>
<th>CH₂=CH₂</th>
</tr>
</thead>
<tbody>
<tr>
<td>145 (vide supra)</td>
<td>OH</td>
<td>CH₂OAc</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>146 (vide supra)</td>
<td>OH</td>
<td>CH₂OAc</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>147</td>
<td>H</td>
<td>CH₂OAc</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>148</td>
<td>O</td>
<td>CH₂OAc</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>149</td>
<td>O=</td>
<td>CO₂H</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>150</td>
<td>O=</td>
<td>CO₂Me</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>151</td>
<td>O</td>
<td></td>
<td>CH₂=CH₂</td>
</tr>
</tbody>
</table>

![Chemical structure](image)

<table>
<thead>
<tr>
<th>152</th>
<th>O=</th>
<th>CH₂=CH₂</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>2</th>
<th>OH</th>
<th>CO₂H</th>
<th>CH₂=CH₂</th>
</tr>
</thead>
<tbody>
<tr>
<td>153</td>
<td>OH</td>
<td>CO₂Me</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>154 (vide supra)</td>
<td>O=</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>155</td>
<td>O=</td>
<td>CHO</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>88</td>
<td>OH</td>
<td>CHO</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>156 (vide supra)</td>
<td>OH</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>157</td>
<td>OH</td>
<td>CH₂OH</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>158</td>
<td>O=</td>
<td>CO₂H</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>159</td>
<td></td>
<td>CH₂OH</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>160</td>
<td></td>
<td>CH₂OAc</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>161</td>
<td>=NOH</td>
<td>CH=NOH</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>162</td>
<td>OH</td>
<td>CH=NOH</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>163</td>
<td>=NOAc</td>
<td>CN</td>
<td>CH₂=CH₂</td>
</tr>
<tr>
<td>164</td>
<td>OAc</td>
<td>CN</td>
<td>CH₂=CH₂</td>
</tr>
</tbody>
</table>

### 4.2.2 Synthesis of heterocyclic betulin derivatives (II)

It is clear from the chemical structure of betulin 1 that most of the betulin derivatives presented in Table 13 are lipophilic and thus poorly soluble in water. This may have important implications for the interpretation of the results of the bioactivity assays. Observed differences in bioactivity between different modified betulin derivatives may be explained at least partly by different partition coefficients (log P) of these compounds. This prompted us to convert these hydrophobic triterpenoids to more soluble and drug-like compounds by introducing a fused heterocyclic system to the lupane skeleton.

A treatment of 146 (see Figure 34 for synthesis of 146) with pyridine p-toluenesulfonate (PPTS) gave a mixture (4:1) of conjugated dienes, 3,28-di-O-acetyllup-12,18-diene 165a and 3,28-di-O-acetyllup-18,21-diene 165b (Figure 37). Heterocycloadducts 166–188 were synthesized by reaction of a mixture of betulin-derived dienes 165a/165b and urazines 195, which were generated in situ by
oxidation of urazoles 194 with the hypervalent iodine reagent, (diacetoxyiodo)benzene (Figure 38). In addition, reactions of commercially available 4-phenyl- or 4-methyl-1,2,4-triazoline-3,5-dione with a mixture of dienes 165a/165b gave the corresponding heterocycles 178 and 179. The subsequent hydrolysis of heterocycles 178 and 179 with NaOH provided the diols 180 and 181 as the hydrolysis products.

In order to synthesize heterocyclic derivatives with different acyl groups at C3 and C28, the dienes 165a/165b were hydrolyzed with NaOH treatment and the obtained diols 189a/189b were subsequently acylated with various acyl chlorides. The resulting acylated dienes 190a/190b (see Table 14 for acyl R1 groups) were treated with 4-methyl- or 4-phenyl-1,2,4-triazoline-3,5-dione to give the corresponding heterocycles 182–187. In addition, heterocycloaduct 188, with bulky R1 and R2 groups, was synthesized by treating 190a/190b with tert-butyl-substituted in situ-generated urazine 195. In all cases, the only isolable heterocyclic betulin derivatives 166–188 were those obtained from the Diels-Alder reaction between the sterically least hindered diene 165a and urazines 195. The [4+2] cycloaddition reactions between the mixture of dienes 165a/165b and other less reactive dienophiles, such as maleic anhydride, N-phenylmaleimide, diethyl azodicarboxylate and dimethyl acetylenedicarboxylate were unsuccessful.

Figure 37. Synthesis of conjugated betulin dienes 165a/165b and heterocyclic betulin derivatives 166–188. Conditions: (a) PPTS, AC2O, PhMe, reflux, 3 h, 68%; (b) 4-substituted urazole 194, PhI(OAc)2, CH2Cl2, THF, rt, 20 h; (c) 4-methyl- or 4-phenyl-1,2,4-triazoline-3,5-dione, CH2Cl2, THF, rt, 20 h; (d) NaOH, MeOH, THF, rt, 18 h, 189a/189b 85%; (e) R2Cl, DMAP, py, CH2Cl2, 40 °C, 20 h.

The dienophilic urazines 195 and their corresponding urazole precursors 194 were synthesized as follows (Figure 38). Reaction of a stoichiometric amount of ethyl hydrazinocarboxylate 191 and isocyanates 192 yielded carboxysemicarbazides 193. When the substituent R1 of the carboxysemicarbazides 193 was aromatic (see Table 14 for R1 groups, betulin derivatives 166–174), cyclization to the corresponding urazoles 194 was carried out by heating in aqueous KOH solution. Acidification (HCl) of the basic solution afforded urazoles 194. When the substituent R1 was aliphatic (see Table 14 for R1 groups, betulin derivatives 175, 176 and 188),
4. Experimental

the cyclization reaction was carried out by sodium ethoxide in refluxing ethanol. Acidification (HCl) of the basic solution afforded urazoles 194.

\[
\begin{align*}
\text{O} & \quad \bigg\uparrow \quad \text{NH}_2 \\
\text{O} & \quad \bigg\uparrow \quad \text{O} = \text{C} = \text{N} - \text{R}_1
\end{align*}
\]

**Figure 38.** Synthesis of urazines 195. Conditions: (a) PhMe, rt, 2 h to 80 °C, 2 h, 90–99%; (b) (i) 4 M KOH in H\(_2\)O, 70 °C, 90 min, (ii) 37% HCl (see Table 14 for R\(_1\) groups, betulin derivatives 166–174) 37–88%; (c) (i) Na, EtOH, 85 °C, 24 h, (ii) 1.25 M HCl in EtOH (see Table 14 for R\(_1\) groups, betulin derivatives 175, 176 and 188), 94–96%; (d) in situ Phl(OAc)\(_2\), CH\(_2\)Cl\(_2\), THF.

**Table 14.** Summary and chemical structures of heterocyclic betulin derivatives.

<table>
<thead>
<tr>
<th>Compound</th>
<th>R(_1)</th>
<th>R(_2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>166</td>
<td>Bn</td>
<td>Ac</td>
</tr>
<tr>
<td>167</td>
<td>3-MeO-Ph</td>
<td>Ac</td>
</tr>
<tr>
<td>168</td>
<td>4-F-Ph</td>
<td>Ac</td>
</tr>
<tr>
<td>169</td>
<td>3-NO(_2)-Ph</td>
<td>Ac</td>
</tr>
<tr>
<td>170</td>
<td>4-CI-Ph</td>
<td>Ac</td>
</tr>
<tr>
<td>171</td>
<td>4-Ac-Ph</td>
<td>Ac</td>
</tr>
<tr>
<td>172</td>
<td>1-naphthyl</td>
<td>Ac</td>
</tr>
<tr>
<td>173</td>
<td>indan-5-yl</td>
<td>Ac</td>
</tr>
<tr>
<td>174</td>
<td>1,3-dioxol-5-yl</td>
<td>Ac</td>
</tr>
<tr>
<td>175</td>
<td>n-Bu</td>
<td>Ac</td>
</tr>
<tr>
<td>176</td>
<td>Et</td>
<td>Ac</td>
</tr>
<tr>
<td>177</td>
<td>H</td>
<td>Ac</td>
</tr>
<tr>
<td>178</td>
<td>Ph</td>
<td>Ac</td>
</tr>
<tr>
<td>179</td>
<td>Me</td>
<td>Ac</td>
</tr>
<tr>
<td>180</td>
<td>Ph</td>
<td>H</td>
</tr>
<tr>
<td>181</td>
<td>Me</td>
<td>H</td>
</tr>
<tr>
<td>182</td>
<td>Me</td>
<td>COEt</td>
</tr>
<tr>
<td>183</td>
<td>Me</td>
<td>COPr</td>
</tr>
<tr>
<td>184</td>
<td>Me</td>
<td>COi-Pr</td>
</tr>
<tr>
<td>185</td>
<td>Me</td>
<td>COcHex</td>
</tr>
<tr>
<td>186</td>
<td>Me</td>
<td>COPh</td>
</tr>
<tr>
<td>187</td>
<td>Ph</td>
<td>COPh</td>
</tr>
<tr>
<td>188</td>
<td>t-Bu</td>
<td>COcHex</td>
</tr>
</tbody>
</table>
4.2.3 SAR studies: *Semliki Forest virus* (I)

In the primary screen, the inhibition activity of 33 simple betulin derivatives and 18 heterocyclic betulin derivatives was assayed against SFV at 50 µM concentration. In addition, the cytotoxicity of the compounds to a Huh-7 cell line was determined (Figure 39, Figure 40). Based on the results from the primary screen, a total of 18 (marked by * in Figure 39 and Figure 40) promising compounds having good anti-viral activity combined with low cytotoxicity to the Huh-7 cell line were selected for determination of IC\(_{50}\) values (Figure 41).

In the set of simple betulin derivatives, only three derivatives having an unmodified hydroxy group at C3 showed good activity combined with low cytotoxicity. The starting material betulin 1 inhibited SFV replication with an IC\(_{50}\) value of 46 µM, and betulinic acid 2 and 28-O-tetrahydropyranylbetulin 140 displayed improved activity with IC\(_{50}\) values 15 µM and 17 µM, respectively. Five compounds out of seven having an acetyl group at C3 performed well, 3,28-di-O-acetylbetulin 144 having the best SFV inhibition with an IC\(_{50}\) value of 9 µM. Compounds having a carbonyl group at C3 also performed well, with four out of seven compounds showing good performance, of which betulonic acid 149 displayed best activity with an IC\(_{50}\) value of 13 µM. For comparison, a standard SFV inhibitor, ribavirin, has an IC\(_{50}\) value of 95 µM.

![Figure 39. Antiviral effect of simple betulin derivatives against SFV in the primary screen at 50 µM. For chemical structures, see Table 13. Compounds marked (*), yielding <20% (dashed blue line) remaining viral replication (AV) and >80% (dashed red line) cell viability (CV), were selected for determination of IC\(_{50}\) values.](image)

In the subgroup of heterocyclic betulin derivatives, all compounds that displayed good inhibition combined with low cytotoxicity had acetyl R\(_2\) groups at C3 and C28 and a bulky R\(_1\) substituent at N-4, except for compound 183 (IC\(_{50}\) = 30 µM), which had propanoyl groups at C3 and C28 and methyl at N-4 (Figure 40). From the group of betulin derivatives having bulky aromatic R\(_1\) moiety at N-4, benzyl 166...
(IC\textsubscript{50} = 36 µM), phenyl 178 (IC\textsubscript{50} = 20 µM) as well derivatives having an electron-withdrawing group on the aromatic ring, performed well: 3-nitrophenyl 169 (IC\textsubscript{50} = 23 µM) and 3-chlorophenyl 170 (IC\textsubscript{50} = 22 µM) showed good activity.

**Figure 40.** Antiviral effect of heterocyclic betulin derivatives against SFV in the primary screen at 50 µM. For chemical structures of compounds see Table 14. Compounds marked (*), yielding <20% (dashed blue line) remaining viral replication (AV) and >80% (dashed red line) cell viability (CV), were selected for IC\textsubscript{50} determination.

**Figure 41.** IC\textsubscript{50} values of betulin-derived compounds against *Semliki Forest virus* (SFV). Positive control = ribavirin.
It is reported that antiviral inhibition of betulin-derived compounds takes place during the early or late stages of the virus life cycle.\textsuperscript{24,204} On the other hand, it can be speculated that the inhibitory effect of the SFV inhibitor nucleoside analogue 3'-amino-3'-deoxyadenosine (3'-NH$_2$-3'-dAdo) occurs during the replication phase.\textsuperscript{209} Thus, synergism of the three representative and potent betulin derivatives 28-O-tetrahydropyranlybetulin 140, betulinic acid 2 and heterocycloadduct 178 was assayed in combination with (3'-NH$_2$-3'-dAdo). The best synergism was achieved by combination of 5 µM 3'-NH$_2$-3'-dAdo and 2 µM of the heterocycle 178, showing an interaction index (I) value of 0.16.

Finally, the three compounds 28-O-tetrahydropyranlybetulin 140, betulinic acid 2 and heterocycloadduct 178 were assayed against another alphavirus Sindbis (SIN). All three compounds were also effective against SIN, with lower IC$_{50}$ values when compared to SFV, betulinic acid 2 having the best activity at a IC$_{50}$ value of 0.5 µM.

4.2.4 SAR studies: *Leishmania donovani* (II)

Initial antileishmanial activity of heterocyclic compounds 166–181 was screened against *Leishmania donovani* axenic amastigotes at 50 µM on a microplate assay with alamarBlue as previously described.\textsuperscript{210} The screening results of the first batch with derivatives having acetyl R$_2$ groups at C3 and C28 showed that small R$_1$ substituents at the nitrogen atom gave the best antileishmanial activity (Figure 42). Derivatives 176 (R$_1$ = Et; inhibition = 88%), 177 (R$_1$ = H; inhibition = 88%) and 179 (R$_1$ = Me; inhibition = 98%) displayed the best activity at 50 µM.

Therefore, a second batch of heterocyclic betulin derivatives 182–186 was synthesized such that the acyl groups at R$_2$ were altered and the R$_1$ group was kept as methyl. In addition, two cycloadducts 187 and 188 with bulky R$_1$ and R$_2$ groups were synthesized. Also in this case, the screening results showed that small acyl R$_2$ groups at C3 and C28 (182 R$_2$ = Et; inhibition = 93%) were more active than derivatives with bulky acyl groups.
Figure 42. Antileishmanial activity of heterocyclic betulin derivatives against L. donovani axenic amastigotes. Determined at 50 µM concentration of betulin derivative with the exception of compounds 183 and 184, which were used at 15 µM due to their poor solubility. The most potent compounds are marked (*). Pos. control = amphotericin B (1 µM). Neg. control = culture medium and DMSO. See Table 14 for chemical structures.

The most potent derivatives (176, 177, 179 and 182, Figure 42) with a small acyl group at R₂ and small substituent R₁ (Me or Et) at the nitrogen on the initial microplate assay were selected for further investigation: determination of GI₅₀ on axenic amastigotes, cytotoxicity for THP-1 macrophages, and antileishmanial activity against L. donovani amastigotes growing inside macrophages (Figure 43). The methyl derivative 179 had the best GI₅₀ value at 8.9 µM. However, it showed cytotoxicity against macrophage cell line THP-1. Other compounds showed slightly higher but very similar GI₅₀ values and displayed cytotoxicity only at highest 50 µM concentration.

Finally, the compounds were tested for antileishmanial activity against L. donovani amastigotes growing inside macrophages at concentrations that showed less than 40% cytotoxicity to the macrophages. When compared to initial screening with axenic amastigotes at 50 µM, compound 182 showed similar strong activity against L. donovani amastigotes growing inside macrophages. At 25 µM, 176, 177 and 182 still showed good activity and the relatively cytotoxic derivative 179 showed good inhibition even at 12.5 µM concentration.
Figure 43. GI_{50}, cytotoxicity to THP-1 cells as well as antileishmanial activity of 176, 177, 179 and 182 against L. donovani amastigotes growing in THP-1 cells at concentrations showing <40% (dashed line) cytotoxicity to THP-1 cells.

4.2.5 SAR studies: Leishmania donovani (III)

Similarly to Publication II, the antileishmanial activities of simple betulin derivatives at 50 µM were screened using a fluorescent viability microplate assay with L. donovani axenic amastigotes (Figure 44).

Betulin 1 showed moderate antileishmanial activity against L. donovani axenic amastigotes, showing 35% inhibition at 50 µM in a microplate assay. Acetylation, esterification or etherification of the hydroxy groups at C3 or C28 in most cases retained antileishmanial activity. Only 28-O-(N-acetylanthraniloyl)betulin 137 and 28-O-bromoacetyletbetulin 138 showed improved leishmanicidal activity, compared with 1.

Oxidized betulin derivatives seem to have similar or increased antileishmanial activity when compared to 1. Furthermore, 28-O-Acetyl-3-oxobetulin 148, methyl betulonate 150, betulonic aldehyde 155 and betulinic acid 2 all showed moderate 40% inhibition at 50 µM. L-Aspartyl amide of betulonic acid 152, betulin aldehyde 88 and dihydrobetulonic acid 158 displayed improved antileishmanial growth inhibition between 64–72%, and betulonic acid 149 had remarkable antileishmanial activity with 98% inhibition at 50 µM.

In addition, oxime derivatives 161 and 162 and the betulin derivative 164 SAL-II-141 with a nitrile group at C28 showed increased inhibition (63–73%) at 50 µM.
4. Experimental

Figure 44. Antileishmanial activity of simple betulin derivatives at 50 µM against *L. donovani* axenic amastigotes. The most potent compounds are marked (*). Pos. control = amphotericin B (1 µM). Neg. control = culture medium and DMSO. See Table 13 for chemical structures.

The most potent betulin derivatives (138, 149, 152, 158 and 161) from initial screening were selected for further investigation: GI$_{50}$ values, cytotoxicity to macrophage THP-1 cell line, as well as activity against *L. donovani* growing inside macrophages were determined (Figure 45).

Betulonic acid 149 showed the best GI$_{50}$ value of 14.6 µM. However, it also showed cytotoxicity against the THP-1 cell line at all test concentrations. The L-aspartyl amide derivative 152 displayed good GI$_{50}$ values of 21.2 µM with no cytotoxicity to the THP-1 cell line. The oxime derivative 161 also displayed good GI$_{50}$ values of 22.8 µM, but also increased general cytotoxicity. 28-O-bromoacetylbetulin 138 had a moderate GI$_{50}$ value of 34.9 µM with no toxicity to the THP-1 cells. Dihydrobetulonic acid 158 had a moderate GI$_{50}$ value (56.0 µM), but also increased general toxicity. Compounds 138 and 152 were moderately active (inhibition >50%) against *L. donovani* amastigotes growing in THP-1 cells at 50 µM. At 12.5 µM concentration, only oxime derivative 161 showed moderate inhibition, whereas the rest of the compounds were relatively inactive.
4. Experimental

Figure 45. GI<sub>50</sub>, cytotoxicity to THP-1 cells, and antileishmanial activity of 138, 149, 152, 158 and 161 against L. donovani amastigotes growing in THP-1 cells at concentrations showing <40% (dashed line) cytotoxicity to THP-1 cells.

4.2.6 SAR studies: Chlamydia pneumoniae (IV)

A total of 32 betulin derivatives, including 5 heterocyclic adducts (compounds 176, 178, 182, 185 and 187), were screened for activity against Chlamydia pneumoniae at 1 µM concentration (Figure 46). In addition, the cytotoxicity of the compounds was screened at 1 and 8 µM concentration against HL cells (only the results of the 8 µM assay are presented in Figure 46). Five derivatives, methyl betulonate 150, dihydrobetulonic acid 158, betulin-3,28-dioxime 161, betulin-28-oxime 162 and 3-acetoxy-mebetulinyl-28-nitrile 164 showed high (>70% growth inhibition) antichlamydial activity. These five compounds were selected for dose–response experiments to determine MIC concentrations. Only compound 161 was able to completely eradicate C. pneumoniae from the HL cells, having a MIC value of 1 µM. Furthermore, a 50% inhibition activity of betulin-3,28-dioxime 161 was achieved with a nanomolar concentration of 290 nM or 125 nM depending on the assay method. For comparison, one of the most potent antichlamydial compounds known, rifampicin 126, displayed a MIC value of 12 nM.

Chlamydia stimulates the production of host cytosolic phospholipase A<sub>2</sub> (cPLA<sub>2</sub>). Preventing this enzyme from functioning is known to cause inhibition of chlamydial growth. Thus, the effect of ten betulin derivatives was assayed against the PLA<sub>2</sub> enzyme of HL cells. Betulin 1 showed PLA<sub>2</sub> inhibition of 62.5% at 0.5% (w/v) concentration. The potent antichlamydial derivatives betulin-3,28-dioxime 161 and betulin-28-oxime 162 displayed the highest PLA<sub>2</sub> inhibition of 75% at
0.5% (w/v) concentration. Despite good PLA₂ inhibition activity of compounds 161 and 162, no clear correlation was observed between antichlamydial activity and PLA₂ inhibition of the betulin derivatives.

Figure 46. Antichlamydial activity of betulin derivatives at 1 μM against *Chlamydia pneumoniae* and host cell viability at 8 μM. The most potent compounds are marked (*). See Table 13 and Table 14 for chemical structures.

4.2.7 Cytotoxicity of betulin compounds (I, II, III, IV)

The cytotoxic effects of the test compounds to cell viability were evaluated with two methods using three cell lines (Figure 47, Figure 48). The methods included an ATP assay using HL and Huh-7 cell lines, and an alamarBlue assay using an THP-1 cell line. In general, betulin compounds were well tolerated by the test cell lines at a concentration of 8 μM or 50 μM. However, in some cases there were clear differences between the cell line tolerances to certain betulin derivatives. For example, 138 was found to be toxic to the Huh-7 cell line, but nontoxic to the other two cell lines tested. Conversely, betulonic acid 149 and dihydrobetulonic acid 158 were nontoxic to the Huh-7 cell line, but relatively toxic to HL and THP-1 cells. These kinds of toxicity differences should be taken into an account when testing cytotoxicity, and several cell lines should be used to exclude possible false non-toxic compounds.

The cytotoxicity of the heterocyclic betulin derivatives was also relatively low (Figure 48). However, in this case, not all derivatives were tested extensively with all three cell lines. Unfortunately, the most active heterocyclic betulin derivatives against *Leishmania donovani*, i.e. 48 and 50, were also significantly toxic to the THP-1 cell line.
Figure 47. Cytotoxicity of simple betulin derivatives to HL cells (8 µM), Huh-7 cells (50 µM) and THP-1 cells (50 µM). Bars represent cell viability after treatment with the test compound. Compounds marked (*) were not assayed with HL cells and compounds marked (') were not assayed with Huh-7 cells. Toxicity to THP-1 cells was assayed only with compounds marked (*).

Figure 48. Cytotoxicity of heterocyclic betulin derivatives to HL cells (8 µM), Huh-7 cells (50 µM) and THP-1 cells (50 µM). Bars represent cell viability after treatment with the test compound. Toxicity to HL cells was assayed only with compounds marked (*) and toxicity to THP-1 cells tested only with compounds marked (*). Compounds marked (') were not tested with Huh-7 cells.
4. Experimental

4.3 Conclusion

New inexpensive therapeutic agents are urgently needed due to increasing drug resistance of disease agents and to ensure the availability of needed drugs in the developing countries. In this study, two sets of betulin derivatives were synthesized and screened for their antiviral, antileishmanial and antibacterial activities.

The first set of 34 compounds included relatively easily synthesizable betulin derivatives, such as esters, various oxidation products (e.g. carboxylic acids, ketones and aldehydes); and miscellaneous betulin derivatives such as oximes and nitriles or compounds where hydroxyl group of ring A was cleaved or double bond in betulin isopropenyl group was hydrogenated.

The second set of 23 compounds consisted of novel heterocyclic betulin derivatives in which the triazole ring is fused by the Diels-Alder reaction to the lupane skeleton of betulin. First, mixture of conjugated dienes 3,28-di-O-acetyllupa-12,18-diene 165a and 3,28-di-O-acetyllupa-18,21-diene 165b was prepared in four steps. Formed mixture was reacted with urazines, which were generated in situ by oxidation of urazoles with the hypervalent iodine reagent, (diacetoxyiodo)benzene. Diversity of heterocyclic betulin derivatives was increased by using different urazole intermediates (which were synthesized in two steps starting from ethyl hydrazinecarboxylate and various isocyanates) and different ester groups at 3-OH and 28-OH in the betulin skeleton.

In the antiviral assays against SFV, betulin acetyl esters performed well; for example 28-O-tetrahydropyranylbetulin 140 and 3,28-di-O-acetylbetulin 144 displayed IC_{50} values of 17 µM and 9 µM, respectively. Additionally, oxidation products betulinic acid 2 and betulonic acid 149 displayed good activity, with IC_{50} values of 13 µM and 15 µM, respectively. In the subgroup of heterocyclic betulin derivatives, compounds having acetyl R_2 groups at C3 and C28 and an aromatic group R_1 at N-4 displayed generally good activity. Derivative 178 (IC_{50} = 20 µM) with a phenyl at R_1, as well as derivatives having an electron-withdrawing group on the aromatic ring performed well.

In the antileishmanial studies, L-aspartyl amide derivative 152 displayed a good GI_{50} value of 21.2 µM with no cytotoxicity to the THP-1 cell line. Furthermore, the dioxime derivative 161 and 28-O-bromoacetylbetulin 138 displayed relatively good GI_{50} values. Unfortunately, betulonic acid 149, while having good antileishmanial activity, also showed cytotoxicity against the THP-1 cell line. The heterocyclic betulin derivatives with small R_1 (Me or Et) substituents at the nitrogen atom of the triazole moiety combined with the sterically least hindered acyl groups at the R_2 positions in the betulin skeleton promoted antileishmanial activity. The most potent derivatives against Leishmania donovani amastigotes were compounds 176, 177, 179 and 182, compound 179 having the best GI_{50} value of 8.9 µM.

Five betulin derivatives, methyl betulonate 150, dihydrobetulonic acid 158, betulin-3,28-dioxime 161, betulin-28-oxime 162 and 3-acetoxybetulinyl-28-nitrile 163, showed high (>70% growth inhibition) antichlamydial activity against Chlamydia pneumoniae. The most potent derivative, betulin-3,28-dioxime 161, displayed 50%
inhibition activity at a nanomolar concentration of 290 nM or 125 nM depending on
the assay method.

We have shown that, by simple chemical modifications, the antibacterial, anti-
protozoal and antiviral activities of the ubiquitous naturally occurring triterpene,
betulin, can be improved considerably. It is possible to derive potent antimicrobial
compounds with low micromolar or even nanomolar inhibition values. In most
cases, a single derivative showed very different activities at different bioassays.
For example, several O-betulanyl acetates were active against SFV, but totally
inactive against *L. donovani* and *C. pneumoniae*. Thus, it is also quite impossible
to predict the general activity of a certain derivative against other microbial or viral
strains. For example, several potent antichlamydial compounds were totally inac-
tive against other bacterial and fungal species such as *Staphylococcus aureus,
Escherichia coli, Pseudomonas aeruginosa, Enterobacter aerogenes, Enterococ-
cus faecalis* and *Candida albicans* (unpublished data, manuscript in preparation).

Further studies are needed to develop more potent betulin derivatives with an-
timicrobial properties, improved water solubility, and zero cytotoxicity to host cell
lines. Moreover, thorough early ADME (absorption, distribution, metabolism and
excretion), biological mechanism and animal studies are needed to evaluate the
potency of betulin-derived compounds *in vivo*. 
References

1 Immonen, K., Nurmi, A. Biopolymeerin lisääine. 2011. FI20115239A.


3 Ekman, R. The suberin monomers and triterpenoids from the outer bark of Betula verrucosa Ehrh. 1985, Holzforschung 1983, 37, 205.

4 Eckerman, C., Ekman, R. Comparison of solvents for extraction and crystallization of betulinol from birch bark waste. Paperi ja puu 1985, 3, 100.


25 Kanamoto, T., Kashiwada, Y., Kanbara, K., Gotoh, K., Yoshimori, M., Goto, T., Sano, K., Nakashima, H. Anti-human immunodeficiency virus activity of


82


69 Burguera, J., Burguera, M., Petit de Pena, Y., Lugo, A., Anez, N. Selective
determination of antimony (III) and antimony (IV) in serum and urine and of
total antimony in skin biopsies of patients with entameous leishmaniasis

70 Cunningham, M., Zvelebil, M., Fairlamb, A. Mechanism of inhibition of trypa-
nothione reductase and glutathione reductase by trivalent organic arsenicals.

71 Sudhandiran, G., Shaha, C. Antimonial-induced increase in intracellular Ca^{2+}
through non-selective cation channels in the host and the parasite is respon-
sible for apoptosis of intracellular Leishmania donovani amastigotes. J. Biol.
Chem. 2003, 278, 25120.

72 Fox, K., Sansom, C., Stevens, M. Footprinting studies on the sequence-
selective binding of pentamidine to DNA. FEBS Lett. 1990, 266, 150.

73 Assan, R., Perronne, C., Assan, D., Chotard, L., Mayaud, C., Matheron, S.,
Zucman, D. Pentamidine-induced derangements of glucose homeostasis.
Determinant roles of renal failure and drug accumulation. A study of 128 pa-
tients. Diabetes Care, 1995, 18, 47.

74 Antoniou, T., Gough, K. Early-onset pentamidine-associated second-degree
heart block and sinus bradycardia: Case report and review of the literature.

75 Bray, P., Barrett, M., Ward, S., de Koning, H. Pentamidine uptake and re-
2003, 19, 232.

76 Saha, A., Mukherjee, T., Bhaduri, A. Mechanism of action of amphotericin B
on Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 1986, 19,
195.

77 Hann, I., Prentice, H. Lipid-based amphotericin B: A review of the last 10

78 Ostrosky-Zeichner, L., Marr, K., Rex, J., Cohen, S. Amphotericin B: Time for

79 Sundar, S., Agrawal, N., Arora, R., Agarwal, D., Rai, M., Chakravarty, J.
Short-course paromomycin treatment of visceral leishmaniasis in India: 14-


102 Al-Abdely, H., Graybill, J., Loebenberg, D., Melby, P. Efficacy of the triazole SCH 56592 against *Leishmania amazonensis* and *Leishmania donovani* in


146 http://en.wikipedia.org/wiki/Chlamydophila_pneumoniae


149 Hammerschlag, M., Chirgwin, K., Roblin, P., Gelling, M., Dumornay, W., Mandel, L., Smith, P., Schachter, J. Persistent infection with Chlamydia


183 Roblin, P., Reznik, T., Kutlin, A., Hammerschlag, M. *In vitro* activities of rifamycin derivatives ABI-1648 (rifalazil, KRM-1648), ABI-1657, and ABI-1131


195 http://www.pherobase.com/


*Publications II and IV of this publication are not included in the PDF version.*
PUBLICATION I

Betulin-derived compounds as inhibitors of alphavirus replication

Betulin-Derived Compounds as Inhibitors of Alphavirus Replication

Leena Pohjala,†,‡ Sami Alakurtti,§ Tero Ahola,† Jari Yli-Kauhaluoma,§ and Päivi Tammela*,†

Centre for Drug Research, Faculty of Pharmacy, P.O. Box 56, FI-00014 University of Helsinki, Finland, Institute of Biotechnology, P.O. Box 56, FI-00014 University of Helsinki, Finland, Division of Pharmaceutical Chemistry, Faculty of Pharmacy, P.O. Box 56, FI-00014 University of Helsinki, Finland, Division of Pharmaceutical Biology, Faculty of Pharmacy, P.O. Box 56, FI-00014 University of Helsinki, Finland, and Technical Research Centre of Finland, VTT, P.O. Box 1000, FI-02044 VTT (Espoo), Finland

Received May 29, 2009

This paper describes inhibition of Semliki Forest virus (SFV) replication by synthetic derivatives of naturally occurring triterpenoid betulin (1). Chemical modifications were made to OH groups at C-3 and C-28 and to the C-20–C-29 double bond. A set of heterocyclic betulin derivatives was also assayed. A free or acetylated OH group at C-3 was identified as an important structural contributor for anti-SFV activity, 3,28-di-O-acetylbetulin (4) being the most potent derivative (IC50 value 9.1 μM). Betulinic acid (13), 28-O-tetrahydropyranylbetulin (17), and a triazolidine derivative (41) were also shown to inhibit Sindbis virus, with IC50 values of 0.5, 1.9, and 6.1 μM, respectively. The latter three compounds also had significant synergistic effects against SFV when combined with 3′-amino-3′-deoxyadenosine. In contrast to previous work on other viruses, the antiviral activity of 13 was mapped to take place in virus replication phase. The efficacy was also shown to be independent of external guanosine supplementation.

The genus Alphavirus consists of enveloped viruses with a single-stranded positive-sense RNA genome of approximately 11.5 kilobases. These widely distributed viruses infect avian and mammalian hosts, spreading in nature by using Aedes sp. mosquitoes as vectors. In vertebrate cells, the infection is acute and cytopathic; most of the amplification occurs in small rodents, whereas humans and other larger mammals are usually dead-end hosts.1 One of the most prominent human epidemics caused by alphaviruses was the recent Chikungunya outbreak, which occurred at different sites surrounding the Indian Ocean in 2006 and involved more than 1.5 million cases.2 In 2007, an outbreak of 205 confirmed cases in northern Italy was also reported, raising awareness of the potential for rapid transmission of tropical arthropod-borne diseases to temperate areas.3,4 Chikungunya and other alphaviruses found on the Eurasian and African continents primarily cause polyarthritis, accompanied by rash-like symptoms and myalgia.5 In contrast, viruses of the same genus found on the American continents, such as Western, Eastern, and Venezuelan equine encephalitis viruses, are primarily associated with small epidemics of encephalitis in both humans and domestic animals.6 Even though alphaviruses are considered a potential cause of both economic loss and human suffering and mortality, currently available pharmacotherapy for alphavirus-borne diseases is limited to relatively inefficient ribavirin and interferon combinations and to symptomatic relief.

Betulin (20S)-29-ene-3β,28-diol, a pentacyclic lupane-type triterpene, is a major constituent of the bark of white birches (Betula sp.) that are found in abundance in northern temperate zones. A more water-soluble compound, betulinic acid, is also present in birch bark in minor quantities (0.3% of dry weight in B. pendula7). However, the distribution of these compounds in nature is not limited to this genus but covers a variety of plant species, including well-known medicinal plants on most continents.8–10 The spectrum of naturally occurring betulin-related compounds also includes betulinic acid, 3-O-sulfates,11 28-O-glycosides, and esters such as nicotinates and caffeates.12,13

Due to the ease of isolation in large quantities and accessibility for chemical modification of the hydroxy groups at positions C-3 and C-28, betulin derivatives have been investigated for a variety of applications. Betulin by itself is quite inactive in pharmaceutical applications; however, it can be oxidized with the Jones’ reagent (CrO3aq, H2SO4) to betulinic acid. Betulinic acid, in turn, can be reduced with NaBH4 selectively to betulinic acid,14 which is an important and pharmaceutically more active precursor for further modifications. The chemistry and therapeutic potential of betulin-derived compounds have been most widely studied for use against certain cancers and human immunodeficiency virus type 1 (HIV-1), and different betulin derivatives are currently undergoing clinical trials for both indications.15 In anti-HIV therapy, two separate mechanisms of action have been proposed, involving both early and late stages in the virus infection cycle. A C-3-substituted betulinic acid derivative, bevirimat [3′-O-(3′,3′-dimethylsucinimidy1)-betulinic acid], has been shown to inhibit HIV-1 maturation by a previously undescribed mechanism, i.e., by blocking the processing of Gag polyprotein between the capsid and p2 spacer sequences and leading to aberrant maturation and decreased infectivity of the virions.16 Phase II clinical trials with bevirimat were positively reported in 2007, indicating favorable pharmacokinetics and preliminary data on efficacy in patients with HIV.17,18 On the other hand, the C-28-substituted aminoalkyl betulin derivatives ICH9564 and A43-D inhibit HIV-1 entry by targeting the V3 loop of HIV gp120.19 Beyond antiretroviral therapy, reports on the antiviral properties of betulin derivatives mainly involve the effects of naturally occurring derivatives on DNA viruses. As such, betulin alone and in combination with aciclovir has been reported to inhibit Herpes simplex viruses types I and II (HSV I and II), showing approximately 10-fold increased sensitivity to HSV-1 when compared to HSV-II.20 Betulinic acid and betulinic acid are also active against HSV, as well as against influenza A and ECHO-6 picornavirus. Betulinic acid was reported to be more potent in the two former cases and betulonic acid in the latter case.21 Furthermore, the naturally occurring 3′-epi-betulinic acid 3′-O-sulfate was recently demonstrated to inhibit HSV, influenza A, and respiratory syncytial virus (RSV).22 A small set of synthetic C-3- and C-28-substituted betulin derivatives has also been assayed against HSV and influenza A, emphasizing the potential role of C-28-substitution in antiviral activity.23

In the present study, antialphaviral properties of 51 betulin derivatives were assayed against Semliki Forest virus (SFV), which is an extensively studied member of the Alphavirus genus. Another
member, Sindbis virus (SIN), was also shown to be sensitive to selected betulin-derived compounds. The anti-SFV activity of betulinic acid was mapped into the replication phase of the virus, and the derivatives of different structural subgroups were shown to exhibit strong synergism in SFV inhibition when combined with 3′-amino-3′-deoxyadenosine.

Results and Discussion

To date, only a limited number of organic small molecules have been found to inhibit alphavirus replication, and most of the existing reports concern nucleoside analogues with often nonoptimal selectivity indices (see ref 24 for review). However, the need for wider structural diversity among the inhibitors of these viruses has been emphasized by the recent epidemic outbreaks. Natural products have often been proven invaluable in the search for novel antimicrobial agents. In the context of alphavirus inhibitors, a seco-pregnane steroid and steroidal glycosides were recently investigated as inhibitors of SFV subgenomic RNA production.25 The current study elucidates the effects of lupane-type triterpenoids on SFV. Even though betulin-derived compounds are known for their various antimicrobial and antineoplastic properties, their effectiveness on RNA viruses remained uncharacterized.

Synthesis of Betulin Derivatives. Compound 2, 28-O-acetylbetulin, was obtained in moderate yield (45%) by treating I with acetic anhydride in the presence of DMAP and pyridine in CH2Cl2 (Scheme 1). Subsequent oxidation of 2 with PCC in CH2Cl2 afforded 28-O-acetyl-3-oxobetulin (3) in 57% yield.26 3,28-Di-O-acetylbetulin (4), in turn, was obtained in excellent (97%) yield by treating 1 with excess acetic anhydride. Treatment of 4 with HBr in toluene caused the migration of the C-20–C-29 double bond of 4 to the C-18–C-19 position, giving 3,28-di-O-acetyllup-18-ene (5) in 42% yield.27 The C-18–C-19 double bond of 5 was epoxidized with mCPBA in CHCl3 to provide the intermediate 6 in excellent 95% yield. Removal of the THP group with PPTS and DHP in CH2Cl2 produced a diastereomeric mixture of the corresponding tetrahydropyranyl ether of 6.

Scheme 1. Synthesis of Compounds 2–6

Scheme 2. Synthesis of Compounds 7–10

Conditions: (a) DEAD, PPh3, 3,3-dimethylglutarimide, THF, 0 °C → rt, 24 h, 31%; (b) Ac2O, DMAP, py, CH2Cl2, rt, 22 h, 81%; (c) H2, 5% Pd/C, THF–MeOH (1:2), rt, 22 h, 99%; (d) H2CrO4, acetone, rt, 20 h, 31%. DEAD = diethyl azodicarboxylate; THF = tetrahydrofuran.
Treatment of 11 with oxalyl chloride in CH₂Cl₂ gave betulonoyl chloride,³¹ which was immediately allowed to react with vanillin in the presence of DMAP in pyridine to produce vanillyl betulonate (12) in 20% yield. Reduction of 11 with NaBH₄ in 2-propanol gave betulinic acid (13) in 82% yield,³² which was subsequently methylated with TMSCHN₂ in PhMe-MeOH to give 14 in 89% yield.³³ Similarly, treatment of 11 with TMSCHN₂ in PhMe-MeOH produced methyl betulonate (15) in 66% yield. Treatment of 11, in turn, with oxalyl chloride in CH₂Cl₂ followed by L-aspartic acid dimethyl ester hydrochloride, TEA, CH₂Cl₂, rt, 19 h, 42%. TMS = trimethylsilyl; TEA = triethylamine.

Betulin (1) was oxidized with PCC (6 equiv) in CH₂Cl₂ to give betulonic aldehyde (21) in 82% yield (Scheme 5).³⁴ When a smaller molar amount of PCC (1.8 equiv) was used, a 3:1 mixture of 21 and betulin aldehyde (22) was produced. Part of the mixture was

---

**Scheme 3. Synthesis of Compounds 12–16**

*Conditions: (a) H₂CrO₄, acetone, 0 °C → rt, 21 h, 44%; (b) (i) (COCl)₂, CH₂Cl₂, rt, 22 h, 85%, (ii) vanillin, DMAP, py, 40 °C, 21 h, 20%; (c) NaBH₄, i-PrOH, rt, 2.5 h, 82%; (d) TMSCHN₂, PhMe-MeOH (3:2), rt, 40 min, 89% 14, 66% 15; (e) L-aspartic acid dimethyl ester hydrochloride, TEA, CH₂Cl₂, rt, 19 h, 42%. TMS = trimethylsilyl; TEA = triethylamine.

**Scheme 4. Synthesis of Compounds 17–20**

*Conditions: (a) DHP, PPTS, CH₂Cl₂, rt, 2 days, 30%; (b) Ac₂O, DMAP, py, CH₂Cl₂, rt, 20 h, 95%; (c) PPTS, EtOH, rt, 14 days, 94%; (d) CH₃SO₂Cl, TEA, CH₂Cl₂, 0 °C, 2 h, 99%. DHP = 3,4-dihydro-2H-pyran; PPTS = pyridinium p-toluenesulfonate.
separated by SiO₂ column chromatography, and 22 was isolated in 18% yield. The rest of the mixture was treated with an excess of hydroxylamine hydrochloride in pyridine- EtOH to produce oximes 23 and 24 in 10% and 33% yields, respectively.39 Separate treatment of 23 and 24 with neat acetic anhydride at 120 °C gave nitriles 25 and 26 in 34% and 46% yields, respectively.

The last series of the synthetic triterpenoids commenced by treating ethyl chrysanthemate with NaOH in THF- MeOH to produce chrysanthenyl chloride (91% yield), which was subsequently allowed to react with oxalyl chloride in CH₂Cl₂ to give chrysanthenyl chloride in 81% yield (Scheme 6). Chrysanthenyl chloride was reacted with 1 to produce a 1:3 mixture of cis- and trans-28-O-chrysanthenylbetulin (27) in 63% yield. Treatment of carvacrol in the presence of chloroacetic acid and NaOH in water gave carvacryloxyacetic acid (45% yield), 38 which was reacted with 1 in PhMe using titanium(IV) isopropoxide as an esterification catalyst to produce betulinyl 28-carboxymethoxyacarvacrolate (28) in 55% yield. A mixture of 1, levulinic acid, and PPTS was reacted in PhMe to produce 3,28-di-O-levulinoxybetulin (29) in 23% yield. Treatment of 1 with nicotinic acid in the presence of DCC and DMAP in CH₂Cl₂ gave 28-O-nicotinoylbetulin (30) in 31% yield. Cinnamic acid was treated with thionyl chloride to produce cinnamoyl chloride, which was treated immediately with 1 to give 28-O-cinnamoylbetulin (31) in 21% yield. N-Acetylanthranilic acid was treated with oxalyl chloride to produce N-acetylanthraniloylbetulin chloride, which was treated immediately with 1 to give 28-O-(N-acetylanthraniloylbetulin (32) in 25% yield. Finally, the mixture 1 was treated with t-BuOK in THF followed by addition of methyl bromoacetate to give 28-O-bromoacetylbetulin (33) in 15% yield.

For the synthesis of heterocyclic betulin derivatives 34-51 (Scheme 7, Table 1), 3,28-di-O-acetyl-18,19-epoxylupane (6) was treated with PPTS in PhMe to give a mixture (4:1) of conjugated dienes, 3,28-di-O-acetyllup-12,18-diene and 3,28-di-O-acetyllup-18,21-diene, in 68% yield.37 Reactions of 4-phenyl- or 4-methyl-1,2,4-triazoline-3,5-dione or reactions of various 4-substituted urazoles38 with a mixture of dienes gave the corresponding heterocycles (34-43) with acetyl R₂ groups in moderate (16% to 62%) yields after the urazoles were oxidized to the corresponding urazones with iodobenzene diacetate in situ.39 For the synthesis of heterocycles (44-51) with different R₂ ester groups, a mixture of 3,28-di-O-acetyllup-12,18-diene and 3,28-di-O-acetyllup-18,21-diene was treated with NaOH in THF- MeOH to remove the acetyl groups. Subsequent acylation with various acyl chlorides yielded a mixture of dienes (44-51) with new R₂ ester groups. Synthesis of betulin heterocycloaldactds will be described in detail elsewhere.

Inhibition of SFV by Betulin Derivatives. The primary screen of 51 betulin-derived compounds against SFV, combined with a counterscreen for Huh-7 cell viability, was run in order to determine the tentative inhibitory potential of each derivative. A relatively high test concentration (50 μM) was selected for the primary screen with the added intention of tracking weakly active derivatives for structure-activity comparisons. The results of the primary screen were expressed as surviving fractions (remaining percentages of viral replication or cell viability) after exposure to each compound. These data were used to divide the derivatives according to their properties into the following four clusters: cluster 1, selective and efficient antiviral activity (compounds yielding <20% remaining viral replication and >80% cell viability); cluster 2a, moderate but selective antiviral activity (remaining viral replication <50% and cell viability >80%); cluster 2b, efficient but moderately selective antiviral activity (remaining viral replication <20% and cell viability between 50% and 80%); cluster 3, antivirally inactive derivatives and compounds with unacceptable cytoxicity (virus replication >50%/cell viability <50%).

Table 2 presents the results of the primary screen, listing the antiviral and cell viability surviving fractions and the corresponding cluster number for each compound. Compounds in cluster 1 represent the best lead candidates and were thus selected for further evaluation by dose-response experiments. The anti-SFV IC₅₀ (50% inhibitory concentration) values for this set of compounds, derived from the fitting of data into a sigmoidal dose-response curve model,
are shown in Table 3. As discussed in more detail in the structure–activity relationship section, the values range from 9.1 µM (compound 4) to 48.5 µM (compound 3). For comparison, a standard SFV inhibitor, ribavirin, has an IC50 value of 95 µM in the assay. In an extended cytotoxicity analysis at 500 µM concentration performed on all cluster 1 compounds, only betulonic aldehyde (21) affected the surviving fraction of Huh-7 cells (cell viability 52% after 24 h exposure). For other cluster 1 compounds, this high concentration, which is close to the solubility limits, was well tolerated (cell viability values >80%).

**Structure–Activity Relationships.** The primary screening data and the results of the potency analysis were used to examine the structural determinants for the anti-alphaviral activity of betulin derivatives and to study the chemical space of antivirally active betulin-derived compounds. Betulin (1) inhibited SFV replication with an IC50 value of 45.5 µM. Removal of the C-20–C-29 double bond yielded compound 9, which failed to show antiviral activity. Both betulinic acid (13) and betulonic acid (11) yielded improved antiviral potency compared to 1 (IC50 values 14.6 and 13.3 µM and p values in Student’s t test <0.05 in both cases). Oxidation of the OH moieties also compensated for the loss of double-bond exclusion activity, even though the potency of the 20–29-saturated dihydrobetulonic acid (10) remained inferior to its unsaturated counterpart 11. Removal or oxidation of the secondary OH group at C-3 disturbed the anti-SFV activity, as demonstrated by the

---

Table 1. Heterocyclic Betulin Derivatives 34–51

<table>
<thead>
<tr>
<th>compound</th>
<th>R1</th>
<th>R2</th>
</tr>
</thead>
<tbody>
<tr>
<td>34</td>
<td>3-MeO-Ph</td>
<td>Ac</td>
</tr>
<tr>
<td>35</td>
<td>1,3-dioxol-5-yl</td>
<td>Ac</td>
</tr>
<tr>
<td>36</td>
<td>indan-5-yl</td>
<td>Ac</td>
</tr>
<tr>
<td>37</td>
<td>4-F-Ph</td>
<td>Ac</td>
</tr>
<tr>
<td>38</td>
<td>3-NO2-Ph</td>
<td>Ac</td>
</tr>
<tr>
<td>39</td>
<td>3-Cl-Ph</td>
<td>Ac</td>
</tr>
<tr>
<td>40</td>
<td>PhCH2</td>
<td>Ac</td>
</tr>
<tr>
<td>41</td>
<td>Ph</td>
<td>Ac</td>
</tr>
<tr>
<td>42</td>
<td>n-Bu</td>
<td>Ac</td>
</tr>
<tr>
<td>43</td>
<td>Et</td>
<td>Ac</td>
</tr>
<tr>
<td>44</td>
<td>Ph</td>
<td>H</td>
</tr>
<tr>
<td>45</td>
<td>Me</td>
<td>COEt</td>
</tr>
<tr>
<td>46</td>
<td>Me</td>
<td>COPr</td>
</tr>
<tr>
<td>47</td>
<td>Me</td>
<td>CO-i-Pr</td>
</tr>
<tr>
<td>48</td>
<td>Me</td>
<td>COcHex</td>
</tr>
<tr>
<td>49</td>
<td>Me</td>
<td>COPh</td>
</tr>
<tr>
<td>50</td>
<td>Ph</td>
<td>COPh</td>
</tr>
<tr>
<td>51</td>
<td>t-Bu</td>
<td>COcHex</td>
</tr>
</tbody>
</table>

---

**Scheme 6. Synthesis of Compounds 27–33**

**Scheme 7. Synthesis of Compounds 34–51**

*a* Synthesis of heterocyclic betulin derivatives 34–51 will be described in detail elsewhere.
inactive 3-deoxy-2,3-didehydro derivatives 7 and 8, as well as the inactivity of oxime derivative 23. Interestingly, betulin aldehyde (21) demonstrated selective antiviral activity in the primary screen, whereas betulin aldehyde (22) had an inverse activity profile. However, in the extended cytotoxicity assay at higher concentration, 22 also had indications of host cell toxicity.

Conversely to the inactive methyl esters of both betulinic acid and betulonic acid (compounds 14 and 15, respectively), 28-O-acetylbetulin (2) was a potent SFV inhibitor (IC50 value 12.1 µM). The inhibitory capacity was retained, yet with loss in potency, in the presence of the individually inactivating 28-O-acetyl-3-oxo-betulin (3). Acetylation of both the C-3 and C-28 hydroxy groups in 1 to yield 4 improved the antiviral activity, yielding an IC50 value of 4.55 ± 0.18 µM.

Table 2. Antiviral (AV) and Cytotoxic Effects (CV) of Betulin-Derived Compounds

<table>
<thead>
<tr>
<th>compound</th>
<th>virus replication (%)</th>
<th>cell viability (%)</th>
<th>cluster</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>7</td>
<td>83</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>87</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>11</td>
<td>83</td>
<td>2a</td>
</tr>
<tr>
<td>4</td>
<td>21</td>
<td>97</td>
<td>2a</td>
</tr>
<tr>
<td>5</td>
<td>15</td>
<td>87</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>16</td>
<td>92</td>
<td>1</td>
</tr>
<tr>
<td>7</td>
<td>121</td>
<td>85</td>
<td>3</td>
</tr>
<tr>
<td>8</td>
<td>98</td>
<td>95</td>
<td>3</td>
</tr>
<tr>
<td>9</td>
<td>95</td>
<td>81</td>
<td>3</td>
</tr>
<tr>
<td>10</td>
<td>14</td>
<td>102</td>
<td>1</td>
</tr>
<tr>
<td>11</td>
<td>13</td>
<td>89</td>
<td>1</td>
</tr>
<tr>
<td>12</td>
<td>43</td>
<td>89</td>
<td>2a</td>
</tr>
<tr>
<td>13</td>
<td>18</td>
<td>123</td>
<td>1</td>
</tr>
<tr>
<td>14</td>
<td>68</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>15</td>
<td>71</td>
<td>83</td>
<td>3</td>
</tr>
<tr>
<td>16</td>
<td>40</td>
<td>30</td>
<td>3</td>
</tr>
<tr>
<td>17</td>
<td>11</td>
<td>92</td>
<td>1</td>
</tr>
<tr>
<td>18</td>
<td>10</td>
<td>91</td>
<td>1</td>
</tr>
<tr>
<td>19</td>
<td>3</td>
<td>86</td>
<td>3</td>
</tr>
<tr>
<td>20</td>
<td>46</td>
<td>99</td>
<td>2a</td>
</tr>
<tr>
<td>21</td>
<td>8</td>
<td>90</td>
<td>1</td>
</tr>
<tr>
<td>22</td>
<td>1</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>23</td>
<td>121</td>
<td>80</td>
<td>3</td>
</tr>
<tr>
<td>24</td>
<td>55</td>
<td>82</td>
<td>3</td>
</tr>
<tr>
<td>25</td>
<td>73</td>
<td>85</td>
<td>3</td>
</tr>
<tr>
<td>26</td>
<td>60</td>
<td>69</td>
<td>3</td>
</tr>
<tr>
<td>27</td>
<td>95</td>
<td>90</td>
<td>3</td>
</tr>
<tr>
<td>28</td>
<td>80</td>
<td>103</td>
<td>3</td>
</tr>
<tr>
<td>29</td>
<td>74</td>
<td>109</td>
<td>3</td>
</tr>
<tr>
<td>30</td>
<td>43</td>
<td>94</td>
<td>2a</td>
</tr>
<tr>
<td>31</td>
<td>111</td>
<td>96</td>
<td>3</td>
</tr>
<tr>
<td>32</td>
<td>82</td>
<td>94</td>
<td>3</td>
</tr>
<tr>
<td>33</td>
<td>125</td>
<td>11</td>
<td>3</td>
</tr>
<tr>
<td>34</td>
<td>121</td>
<td>93</td>
<td>3</td>
</tr>
<tr>
<td>35</td>
<td>97</td>
<td>92</td>
<td>3</td>
</tr>
<tr>
<td>36</td>
<td>81</td>
<td>93</td>
<td>3</td>
</tr>
<tr>
<td>37</td>
<td>64</td>
<td>95</td>
<td>3</td>
</tr>
<tr>
<td>38</td>
<td>3</td>
<td>108</td>
<td>1</td>
</tr>
<tr>
<td>39</td>
<td>1</td>
<td>95</td>
<td>1</td>
</tr>
<tr>
<td>40</td>
<td>1</td>
<td>101</td>
<td>1</td>
</tr>
<tr>
<td>41</td>
<td>13</td>
<td>87</td>
<td>1</td>
</tr>
<tr>
<td>42</td>
<td>19</td>
<td>81</td>
<td>1</td>
</tr>
<tr>
<td>43</td>
<td>24</td>
<td>40</td>
<td>3</td>
</tr>
<tr>
<td>44</td>
<td>73</td>
<td>85</td>
<td>3</td>
</tr>
<tr>
<td>45</td>
<td>21</td>
<td>75</td>
<td>2b</td>
</tr>
<tr>
<td>46</td>
<td>18</td>
<td>93</td>
<td>1</td>
</tr>
<tr>
<td>47</td>
<td>24</td>
<td>106</td>
<td>2a</td>
</tr>
<tr>
<td>48</td>
<td>44</td>
<td>97</td>
<td>2a</td>
</tr>
<tr>
<td>49</td>
<td>22</td>
<td>108</td>
<td>2a</td>
</tr>
<tr>
<td>50</td>
<td>50</td>
<td>88</td>
<td>2a</td>
</tr>
<tr>
<td>51</td>
<td>40</td>
<td>83</td>
<td>2a</td>
</tr>
</tbody>
</table>

The data present results from the primary screen of betulin-derived compounds in anti-SFV and ATP cell viability assays (see the Supporting Information for experimental details). The numbers represent surviving fractions (the remaining percentages of viral replication or cell viability) in each assay. All experiments were made in triplicate using a concentration of 50 µM of each compound.

Table 3. IC50 Values of Betulin-Derived Compounds against Semliki Forest Virus (SFV)*

<table>
<thead>
<tr>
<th>compound</th>
<th>IC50 µM (pIC50)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>45.5 (±4.34)</td>
</tr>
<tr>
<td>2</td>
<td>12.1 (±4.92)</td>
</tr>
<tr>
<td>3</td>
<td>48.5 (±3.52)</td>
</tr>
<tr>
<td>4</td>
<td>9.1 (±4.26)</td>
</tr>
<tr>
<td>5</td>
<td>43.2 (±3.37)</td>
</tr>
<tr>
<td>6</td>
<td>13.3 (±4.94)</td>
</tr>
<tr>
<td>7</td>
<td>30.6 (±5.42)</td>
</tr>
<tr>
<td>8</td>
<td>13.5 (±4.88)</td>
</tr>
<tr>
<td>9</td>
<td>14.6 (±4.84)</td>
</tr>
<tr>
<td>10</td>
<td>17.2 (±4.76)</td>
</tr>
<tr>
<td>11</td>
<td>24.7 (±4.61)</td>
</tr>
<tr>
<td>12</td>
<td>24.2 (±4.62)</td>
</tr>
<tr>
<td>13</td>
<td>38.3 (±4.42)</td>
</tr>
<tr>
<td>14</td>
<td>22.9 (±4.64)</td>
</tr>
<tr>
<td>15</td>
<td>22.1 (±4.65)</td>
</tr>
<tr>
<td>16</td>
<td>35.9 (±4.44)</td>
</tr>
<tr>
<td>17</td>
<td>19.7 (±4.71)</td>
</tr>
<tr>
<td>18</td>
<td>37.9 (±4.42)</td>
</tr>
<tr>
<td>19</td>
<td>30.1 (±5.26)</td>
</tr>
<tr>
<td>20</td>
<td>19.5 (±4.87)</td>
</tr>
</tbody>
</table>

* Dose–response experiments were performed using a luminescent anti-SFV assay (see Supporting Information) using serial dilutions of each derivative and fitting the data into sigmoidal dose–response curves; values are means ± SD (n = 6).
IC₅₀ value 36 µM). Derivatives having an electron-withdrawing group on the aromatic ring, 3-chlorophenyl (39) and 3-nitrophenyl (38), were selective and potent SFV inhibitors, having IC₅₀ values of 22 and 23 µM, respectively (Table 3). However, 4-fluorophenyl-substituted 37 had poor activity. Derivatives having an electron-donating group in the aromatic ring, 3-methoxyphenyl (34), 1,3-dioxol-5-y1 (35), and indan-5-y1 (36), had no activity against SFV.

However, further removal of the acetyl groups from the antivirally active heterocycle 41 resulted in loss of activity (compound 44), but substitution of the acetyl groups by benzoyl at both positions (50) yielded a moderately active compound (cluster 2a; Table 2). In addition, the 4-methyl-1,2,4-triazoline-3,5-dione adducts 47, 48, and 49, combined with either isopropanoyl, cyclohexanoyl, or phenyl 3,28-diesters of betulin, scored into cluster 2a. Indication of cytotoxicity was observed in the case of the corresponding propanoyl 3,28-diester (45). Derivate 51, with bulky substituents (tert-butyl group in N-4, cyclohexanoyl groups in C-3, and hydroxy groups in C-28), scored into cluster 2a. However, the most efficient inhibition of SFV among this subset of heterocycles was achieved with a cyclodecact between 4-methylurazine and 3,28-di-O-butylibetulin-12,18-diene (46). This compound scored into cluster 1 in the primary screen and yielded an IC₅₀ value of 30 µM.

**Inhibition of SIN by Betulin-Derived Compounds.** Sindbis virus (SIN), the causative agent of Pogosta disease (also known as Carelian fever), is another alphavirus that is widely distributed over the European, Asian, and African continents. SIN and SFV represent separate clusters in the alphavirus phylogenetic tree, generated by comparing E1 glycoprotein sequences. SIN and SFV also fall into different serocomplexes according to antibody cross-reactivity. However, the replicase proteins are relatively highly conserved within the genus.¹

Three betulin derivatives from different structural subclasses showing antiviral potency and selectivity, i.e., 13, 17, and 41, were assayed for inhibitory potency against SIN using a radiometric RNA labeling assay. The dose–response curves presented in Figure 1 demonstrate the sensitivity of SIN toward these compounds; the IC₅₀ values extracted from the data were 0.5 µM (pIC₅₀ = −6.34 ± 0.09), 1.9 µM (pIC₅₀ = −5.72 ± 0.10), and 6.1 µM (pIC₅₀ = −5.21 ± 0.16) for 13, 17, and 41, respectively. In all three cases, the studied SIN strain exhibited greater sensitivity toward the derivatives compared to SFV.

**Synergism Studies.** Antiviral therapy is often conducted as a combination of multiple drugs targeting different sites in virus replication.⁴⁰ Parallel administration of inhibitors with different molecular targets is considered beneficial in terms of improved efficacy and/or prevention of resistance. Previously we reported the anti-alphaviral efficacy of several modified nucleosides, including 3′-amino-3′-deoxyadenosine (3′-NH-3′-dAdo) with an IC₅₀ value of 18 µM in the reporter gene assay.³³ The inhibition of the virus life cycle by nucleoside analogues is likely to take place during the replication phase, targeting viral polymerases or components of cellular nucleoside metabolism, whereas betulin-derived compounds have been related to a variety of antiviral mechanisms mainly in the early and late stages of the virus life cycle (see below). Thus, we investigated the possibility of synergistic inhibition of SFV by 3′-NH-3′-dAdo together with derivatives 13, 17, and 41.

The IC₅₀ values for each interaction partner were determined by using varying concentrations of 3′-NH-3′-dAdo and test compound in combination (see Experimental Section and Supporting Information for experimental details). The strong Loewe synergism that was demonstrated in these experiments is visualized by the bending of the isobolograms below the additivity-indicating diagonal line in Figure 2. Calculation of Berembel interaction indices for individual combinations indicated that the most intense Loewe synergism was achieved when 5 µM 3′-NH-3′-dAdo was combined with low or moderate concentrations of each betulin derivative. At this nucleoside concentration, 0.08 µM and 0.4 µM 13 yielded interaction index values of I = 0.28 and 0.25, respectively. For 0.4 µM 28-O-tetrahydropyranylbetulin (17), an I value of 0.24 was obtained, whereas combining 5 µM nucleoside with the heterocycle 41 resulted in the most intense synergism at 2 µM (I = 0.16). Increasing compound 17 and 41 concentrations closer to their IC₅₀ values gave moderate or strong synergism (I values at 10 µM concentration of betulin derivatives with different 3′-NH-3′-dAdo concentration ranged from 0.25 to 0.47), whereas similar conditions with 13 yielded additive rather than synergistic inhibition (I values from 0.52 to 1.26). Complete tables of interaction indices for all three compounds with 3′-NH-3′-dAdo, as well as the equations used to calculate the indices, are provided as part of the Supporting Information.

**Mapping of the Target Site for Anti-SFV Activity.** Since the antiviral effects of betulin derivatives are associated with a range
of target sites, an administration time experiment using a high-multiplicity infection of SFV-Rluc was applied in order to gain preliminary information on the target site of the reported anti-SFV activity. Compounds 13, 17, and 41 were administered into cell cultures at different time points in conditions where the majority of cells were infected at once. The time scale of this experiment represents a single virus replication cycle, as the luciferase reporter gene was expressed by the translation of viral nonstructural proteins, and the readout was thus taken at 4.5 h (see the Supporting Information for experimental details). As illustrated in Figure 3, none of the three betulin derivatives showed antiviral efficacy when present in the cultures only at the time of viral adsorption (0–1 h). The same was also observed for the 3′-amino-3′-deoxyadenosine that was used for comparison. On the other hand, delivery of the compounds just after the removal of the viral inocula (at 1 h) yielded inhibition comparable to the effect obtained when the agent was present throughout the experiment. Furthermore, postponing the administration to 2 h led to attenuated efficacy, yet the response was still detectable in the case of 13.

Even though physicochemical and kinetic features, such as hydrophobicity of the triterpenoids and nucleoside phosphorylation, may affect the interpretation, the entry phase does not appear to be the target of the reported anti-alphaviral activity. In the case of betulinic acid, the activity is associated with the early replication phase, whereas the two other betulin-derived compounds give less obvious results. The end point in the experimental setup is in the translation and processing of viral polyprotein (into which the Rluc gene is inserted; see ref 24). Thus, inhibitors of viral maturation would give seemingly negative results in this particular setup. On the other hand, our previous work indicated that the sensitivity of an in vitro antiviral assay is highly dependent on the infection multiplicity used (L. Pohjala, unpublished results). However, repeating the experiment with a higher concentration (200 µM) yielded similar results, as shown in Figure 3, at 50 µM. Yet the effect of inferior potency cannot be completely ruled out by this means since the target site for the anti-alphaviral activity of 17 and 41 may lie in steps of the virus life cycle occurring after the production of nonstructural polyproteins. Each of the replication phases consists of several substates, which are typically inhibited by different sets of chemical agents.40

As betulin-derived compounds are known to have a wide spectrum of antimicrobial, anti-inflammatory, and antineoplastic effects,41,42 these findings could be reconciled by a general underlying mechanism, such as interference with cellular nucleoside metabolism. Indeed, certain classical inhibitors of RNA virus replication that also share anti-inflammatory properties (e.g., ribavirin and mycophenolic acid) exert their action via depletion of cellular GTP pools.41,42 This mode of action is characterized by the loss of inhibitory effect when the cultures are supplemented with external guanosine to compensate for depletion in cellular guanosine biosynthesis. However, the betulin-derived compounds 13, 17, and 41 maintained their antiviral activity in the presence of 50 µg/mL (177 µM) guanosine supplementation also (data not shown), implying that any contribution of this mechanism to the observed anti-SFV activity is minor at most. The existence of more specific virus-related targets is also supported by the distinct structure–interaction indices (4). The end point in the experimental setup is in the translation and processing of viral polyprotein (into which the Rluc gene is inserted; see ref 24). Thus, inhibitors of viral maturation would give seemingly negative results in this particular setup. On the other hand, our previous work indicated that the sensitivity of an in vitro antiviral assay is highly dependent on the infection multiplicity used (L. Pohjala, unpublished results). However, repeating the experiment with a higher concentration (200 µM) yielded similar results, as shown in Figure 3, at 50 µM. Yet the effect of inferior potency cannot be completely ruled out by this means since the target site for the anti-alphaviral activity of 17 and 41 may lie in steps of the virus life cycle occurring after the production of nonstructural polyproteins. Each of the replication phases consists of several substates, which are typically inhibited by different sets of chemical agents.40

As betulin-derived compounds are known to have a wide spectrum of antimicrobial, anti-inflammatory, and antineoplastic effects,41,42 these findings could be reconciled by a general underlying mechanism, such as interference with cellular nucleoside metabolism. Indeed, certain classical inhibitors of RNA virus replication that also share anti-inflammatory properties (e.g., ribavirin and mycophenolic acid) exert their action via depletion of cellular GTP pools.41,42 This mode of action is characterized by the loss of inhibitory effect when the cultures are supplemented with external guanosine to compensate for depletion in cellular guanosine biosynthesis. However, the betulin-derived compounds 13, 17, and 41 maintained their antiviral activity in the presence of 50 µg/mL (177 µM) guanosine supplementation also (data not shown), implying that any contribution of this mechanism to the observed anti-SFV activity is minor at most. The existence of more specific virus-related targets is also supported by the distinct structure–activity relationships reported for different pharmacological uses.43

The study of antiviral mechanisms of betulin-derived compounds has involved several molecular targets. For relatively simple, naturally occurring compounds such as betulin and betulinic acid, the proposed targets include HIV-1 reverse transcriptase,43 HIV gp41,44 and severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease.45 Recent work on the SARS protease implies that modulation of a single molecular target may not correlate with
in vivo antiviral efficacy: Wen and co-workers\textsuperscript{45} conclude that both betulinic acid and betulonic acid inhibit SARS-CoV replication, but only betulinic acid inhibits 3C\textsubscript{PRR} purified 3C protease. Previous work on the effects of triterpenoid drugs on HSV also supported the hypothesis that the antiviral efficacy of such agents may be a combination of different activities in cell culture, rather than directly associated with any specific phase in the virus life cycle.\textsuperscript{46} Such findings may put into question the usefulness of the compounds from a rational drug design viewpoint, but may reflect nature’s strategy for sustained bioactivity. On the other hand, chemically modified betulin derivatives, such as those in anti-HIV drug discovery, are thought to exert their activity via more limited sets of targets, which is also supported by the generation of resistant HIV strains via point mutations.\textsuperscript{47,48} The results from the current screen elucidate a pattern in which most of the relatively simple derivatives inhibit SFV replication, whereas, among the more complex structures, the antiviral activity is not ubiquitous but shared only by certain structural subclasses. On the other hand, betulinic acid (13) is distinguished from the two derivatives (17 and 41) on the basis of its behavior in the administration time experiments.

Betulin-derived compounds form a family of natural compounds that, along with their synthetic derivatives, have a broad spectrum of antinociceptive and antimicrobial activities. The present results, together with prior reports on SARS-CoV and ECHO-6 picornavi-

**Experimental Section**

**General Experimental Procedures.** Details of the chemical synthesis
to procedures and characterization as well as the biological
tests procedures and characterization as well as the biological
assay with marker virus SFV-Rluc\textsubscript{23} was used to screen for anti-SFV
activity, against Semliki Forest virus and Sindbis virus, together with the
lack of early signs of toxicity, raise hopes about the therapeutic
potential of betulin-derived compounds used against these pathogens
either alone or in combination with other antiviral therapy.

NP9003245
cutaneous leishmaniasis, the mildest form, is usually self-healing.

Destruction and disfiguration of the nasopharynx region; and (3) mucocutaneous leishmaniasis, a chronic form, causes extensive effects internal organs such as the liver, spleen and bone marrow; (2) leishmaniasis, the most severe form, is usually fatal if not treated and parasites are transmitted by female sand flies belonging to the genus Phlebotomus.

Leishmaniases are diseases caused by protozoan parasites that affect millions of people in more than 88 countries worldwide. These are transmitted by female sand flies belonging to the genus Phlebotomus.

**INTRODUCTION**

Keywords: antiprotozoal agents; betulin; betulinic acid; dihydrobetulinic acid; amphotericin B; liposomal amphotericin B; miltefosine; liposomally entrapped amphotericin B; Leishmania donovani; Leishmania braziliensis; Leishmania infantum; Leishmania major; Leishmania tropica; Leishmania amazonensis; Leishmania longipalpis; Lutzomyia in the Old and New World, respectively.

Previously, dihydrobetulinic acid was examined as a new lead molecule. 4 As such, there is an urgent need to develop new treatments for these diseases, particularly in less-developed countries where access to current treatments is limited.

The easily modified positions of the lupane skeleton, the hydroxy groups of C-3 and C-28, as well as the carbon–carbon double bond C-20–C-29 were used as a starting point to prepare betulinic acid and betulonic acid, is described in this study. The easily modified positions of the lupane skeleton, the hydroxy groups of C-3 and C-28, as well as the carbon–carbon double bond C-20–C-29 were used as a starting point to prepare betulinic acid and betulonic acid, is described in this study.

Betulonic acid was the most potent derivative, yielding a GI 50 value of 14.6 μM. In another study, in which leishmanicidal inhibition of amastigotes on a microplate assay at 50 μM was determined. Betulonic acid was the most potent derivative, yielding a GI 50 value of 14.6 μM. In another study, in which leishmanicidal inhibition of amastigotes on a microplate assay at 50 μM was determined. Betulonic acid was the most potent derivative, yielding a GI 50 value of 14.6 μM.

Macrophages was determined. Betulonic acid was the most potent derivative, yielding a GI 50 value of 14.6 μM. In another study, in which leishmanicidal inhibition of amastigotes on a microplate assay at 50 μM was determined. Betulonic acid was the most potent derivative, yielding a GI 50 value of 14.6 μM.

The easily modified positions of the lupane skeleton, the hydroxy groups of C-3 and C-28, as well as the carbon–carbon double bond C-20–C-29 were used as a starting point to prepare betulinic acid and betulonic acid, is described in this study. The easily modified positions of the lupane skeleton, the hydroxy groups of C-3 and C-28, as well as the carbon–carbon double bond C-20–C-29 were used as a starting point to prepare betulinic acid and betulonic acid, is described in this study.

macrophages was determined. Betulonic acid was the most potent derivative, yielding a GI 50 value of 14.6 μM. In another study, in which leishmanicidal inhibition of amastigotes on a microplate assay at 50 μM was determined. Betulonic acid was the most potent derivative, yielding a GI 50 value of 14.6 μM.

The easily modified positions of the lupane skeleton, the hydroxy groups of C-3 and C-28, as well as the carbon–carbon double bond C-20–C-29 were used as a starting point to prepare betulinic acid and betulonic acid, is described in this study. The easily modified positions of the lupane skeleton, the hydroxy groups of C-3 and C-28, as well as the carbon–carbon double bond C-20–C-29 were used as a starting point to prepare betulinic acid and betulonic acid, is described in this study.

This derivative was the most potent, yielding a GI 50 value of 14.6 μM. In another study, in which leishmanicidal inhibition of amastigotes on a microplate assay at 50 μM was determined. Betulonic acid was the most potent derivative, yielding a GI 50 value of 14.6 μM. In another study, in which leishmanicidal inhibition of amastigotes on a microplate assay at 50 μM was determined. Betulonic acid was the most potent derivative, yielding a GI 50 value of 14.6 μM.

The easily modified positions of the lupane skeleton, the hydroxy groups of C-3 and C-28, as well as the carbon–carbon double bond C-20–C-29 were used as a starting point to prepare betulinic acid and betulonic acid, is described in this study. The easily modified positions of the lupane skeleton, the hydroxy groups of C-3 and C-28, as well as the carbon–carbon double bond C-20–C-29 were used as a starting point to prepare betulinic acid and betulonic acid, is described in this study.

Betulinic acid and betulonic acid, is described in this study. The easily modified positions of the lupane skeleton, the hydroxy groups of C-3 and C-28, as well as the carbon–carbon double bond C-20–C-29 were used as a starting point to prepare betulinic acid and betulonic acid, is described in this study. The easily modified positions of the lupane skeleton, the hydroxy groups of C-3 and C-28, as well as the carbon–carbon double bond C-20–C-29 were used as a starting point to prepare betulinic acid and betulonic acid, is described in this study.
Anti-leishmanial activity of betulin derivatives

Sami Alakurtti1,2, Pia Bergström2, Nina Sacerdoti-Sierra3, Charles L Jaffe3 and Jari Yli-Kauhaluoma1

Leishmanicidal activity of 24 derivatives of naturally occurring and abundant triterpenes belonging to the lupane series, betulin, betulinic acid and betulonic acid, is described in this study. The easily modified positions of the lupane skeleton, the hydroxy groups of C-3 and C-28, as well as the carbon–carbon double bond C-20–C-29 were used as a starting point to prepare a library of triterpenoid derivatives for bioactivity studies. The compounds were evaluated against Leishmania donovani axenic amastigotes on a microplate assay at 50 μM. GI50 values of the most effective compounds were evaluated, as well as their cytotoxicity on the human macrophage cell line THP-1, and anti-leishmanial activity against L. donovani-infected THP-1 macrophages was determined. Betulonic acid was the most potent derivative, yielding a GI50 value of 14.6 μM. Promising and distinct structure–activity relationships were observed, and these compounds can be regarded as significant lead molecules for further improvement and optimization.

The Journal of Antibiotics (2010) 63, 123–126; doi:10.1038/ja.2010.2; published online 5 February 2010

Keywords: antiprotozoal agents; betulin; betulinic acid; Leishmania sp.; Terpenoids
58% at 68 μM. At these doses, 4 also showed some toxicity against peritoneal macrophages, with survival indices of 70 and 80%, respectively. Previously, we studied anti-leishmanial activity of heterocyclic betulin derivatives, in which the heterocycloaduct between 3,28-di-O-acetyllupa-12,18-diene and 4-methylurazine 5 was the most effective derivative with a GI50 value of 8.9 μM against L. donovani axenic amastigotes. These results prompted us to investigate more closely the anti-leishmanial activity of 24 betulin derivatives that have been chemically modified in positions C-3, C-28 and C-20–C-29 of the lupane skeleton.

RESULTS AND DISCUSSION

We found that betulin 1 (isolated from Betula sp.) has moderate anti-leishmanial activity against L. donovani axenic amastigotes, showing 35% inhibition at 50 μM in a microplate assay (Table 1). Acetylation, esterification or etherification of the hydroxy groups at C-3 or C-28 in most cases retained anti-leishmanial activity. We observed that 28-O-Cinnamoylbetulin 6 was totally inactive and 28-O-nicotinoylbetulin 7, 28-O-tetrahydropranyl betulin 8, 28-O-chrysanthemoylbetulin 9 and betulinyl-28-O-carboxymethoxycarvacrolate 10 were only slightly active. Only 28-O-(N-acetylanthraniloyl)betulin 11 and 28-O-bromoacetylbetulin 12 showed improved anti-leishmanial activity (59 and 86% inhibition at 50 μM, respectively), compared with 1. In addition, 3-O-acetyl betulin 13 had similar anti-leishmanial inhibition activity compared with the starting material betulin 1, whereas 3,28-di-O-acetylbetulin 14 and 3,28-di-O-levulinoylbetulin 15 were totally inactive.

Oxidation of 1 seems to have a beneficial effect on anti-leishmanial activity. Betulin aldehyde 4 displayed improved anti-leishmanial activity with a 64% inhibition at 50 μM. Betulinic acid 2 possessed moderate anti-leishmanial activity with a 40% inhibition at 50 μM. 28-O-Acetyl-3-oxobetulin 16 and betulonic aldehyde 17 showed moderate anti-leishmanial activity similar to the starting material 1, but betulonic acid 18 had remarkable anti-leishmanial activity with a 98% inhibition at 50 μM. Reduction of the carbon–carbon double bond of betulonic acid 18 to the corresponding dihydrobetulonic acid 19 decreased anti-leishmanial activity to 72% at 50 μM. Furthermore, methylation of betulonic acid 18 to methyl betulonate 20 decreased the inhibition activity at 50 μM to 40%. L-aspartyl amide of betulonic acid 21 showed reduced leishmanicidal activity compared with betulonic acid 18, with a 69% inhibition at 50 μM. Vanillyl betulonate 22 was totally inactive.

Removal of the C-3 hydroxy group of 1 resulted in 3-deoxy-2,3-didehydrobetulin 23, the anti-leishmanial activity of which diminished to 13% at 50 μM. Oxime derivatives 24 and 25 showed good leishmanicial activities at 50 μM, with 69 and 73% inhibition, respectively. Moreover, betulin derivative 26 with a nitrile group at C-28 showed good anti-leishmanial activity with a 63% inhibition at 50 μM.

Derivatives (12, 18, 19, 21 and 25) that showed the best anti-leishmanial activity on microplate assay at 50 μM against L. donovani axenic amastigotes were selected for further investigations: GI50 values, cytotoxicity to the macrophage cell line THP-1 and anti-leishmanial activity against the L. donovani-infected macrophage cell line THP-1 were evaluated. Betulonic acid 18 showed the best GI50 value of 14.6 μM on microplate assay against L. donovani axenic amastigotes, followed by L-aspartyl amide derivative 21 and oxime derivative 25, with GI50 values of 21.2 and 22.8 μM, respectively (Table 1). 28-O-Bromoacetylbetulin 12 and dihydrobetulonic acid 19 had moderate GI50 values of 34.9 and 56.0 μM, respectively. Cytotoxicity of derivatives 12, 18, 19, 21 and 25 was tested against the macrophage cell line THP-1 at concentrations of 50, 25 and 12.5 μM (Table 2). Betulonic acid 18 showed cytotoxicity against the THP-1 cell line at all test concentrations. Dihydrobetulonic acid 19 and oxime derivative 25 showed cytotoxicity against the THP-1 cell line at 50 and 25 μM, but at 12.5 μM concentration, cytotoxicity of 19 and 25 was reduced to 22.0 and 13.6%, respectively. L-aspartyl amide derivative 21 and 28-O-bromoacetylbetulin 12 were nontoxic to macrophage cell line THP-1 at all test concentrations.

Finally, anti-leishmanial activity of compounds 12, 19, 21 and 25 was tested against L. donovani-infected macrophage cell line THP-1, with concentrations that showed <30% cytotoxicity to the THP-1 cell line (Table 3). In all cases, anti-leishmanial activity was reduced when compared with that in the corresponding microplate assay with L. donovani axenic amastigotes. L-aspartyl amide derivative 21 and 28-O-bromoacetylbetulin 12 showed good anti-leishmanial activity at 50 μM, inhibiting 53 and 56% of the intracellular parasites, respectively (compared with 69 and 86% inhibition using axenic amastigotes in the microplate assay, respectively). At 25 μM, 28-O-bromoacetylbetulin 12 still had the best activity of the compounds examined showing 34% inhibition, dihydrobetulonic acid 19 and L-aspartyl amide derivative...
21 were only weakly active at this concentration. Finally, at 12.5 μM concentration, oxime derivative 25 showed the best anti-leishmanial activity with a 52% inhibition, whereas L-aspartyl amide derivative 21 was totally inactive and the rest showed only weak activity.

We have shown that by simple chemical modification, anti-leishmanial activity of ubiquitous naturally occurring triterpene, betulin, can be improved considerably. It is possible to derive relatively potent anti-leishmanial compounds with low micromolar Gl50 values. In

### Table 1 Anti-leishmanial activities at 50 μM on microplate assay and Gl50 values for the most potent synthetic betulin derivatives against Leishmania donovani axenic amastigotes

<table>
<thead>
<tr>
<th>Compound</th>
<th>R1</th>
<th>R2</th>
<th>R3</th>
<th>Inhibition (%) at 50 μM</th>
<th>GI50 (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>OH</td>
<td>CHOH</td>
<td>CH3-C=CH2</td>
<td>35.0</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>OH</td>
<td>CH3-C=CH2</td>
<td>0.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>OH</td>
<td>CH3-C=CH2</td>
<td>8.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>OH</td>
<td>CH3-C=CH2</td>
<td>10.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>OH</td>
<td>CH3-C=CH2</td>
<td>13.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>OH</td>
<td>CH3-C=CH2</td>
<td>16.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>OH</td>
<td>CH3-C=CH2</td>
<td>59.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>OH</td>
<td>CH3-C=CH2</td>
<td>86.0</td>
<td>34.9</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>OAc</td>
<td>OH</td>
<td>CH3-C=CH2</td>
<td>37.4</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>OAc</td>
<td>CH3OAc</td>
<td>CH3-C=CH2</td>
<td>0.0</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>OH</td>
<td>CH3-C=CH2</td>
<td>0.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>OH</td>
<td>CHO</td>
<td>CH3-C=CH2</td>
<td>64.3</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>OH</td>
<td>COH</td>
<td>CH3-C=CH2</td>
<td>39.8</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>O=</td>
<td>CH3OAc</td>
<td>CH3-C=CH2</td>
<td>40.6</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>O=</td>
<td>CHO</td>
<td>CH3-C=CH2</td>
<td>46.2</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>O=</td>
<td>COH</td>
<td>CH3-C=CH2</td>
<td>97.6</td>
<td>14.6</td>
</tr>
<tr>
<td>19</td>
<td>O=</td>
<td>COH</td>
<td>CH3-C=CH2</td>
<td>72.1</td>
<td>56.0</td>
</tr>
<tr>
<td>20</td>
<td>O=</td>
<td>CO3Me</td>
<td>CH3-C=CH2</td>
<td>40.1</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>O=</td>
<td></td>
<td>CH3-C=CH2</td>
<td>69.3</td>
<td>21.2</td>
</tr>
<tr>
<td>22</td>
<td>O=</td>
<td></td>
<td>CH3-C=CH2</td>
<td>0.0</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>-</td>
<td>CH3OH</td>
<td>CH3-C=CH2</td>
<td>13.2</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>OH</td>
<td>CH=NOH</td>
<td>CH3-C=CH2</td>
<td>69.1</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>=NOH</td>
<td>CH=NOH</td>
<td>CH3-C=CH2</td>
<td>72.9</td>
<td>22.8</td>
</tr>
<tr>
<td>26</td>
<td>OAc</td>
<td>CN</td>
<td>CH3-C=CH2</td>
<td>62.7</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviation:** DMSO, dimethyl sulfoxide.

*Amphotericin B (1 μM).

*bCulture medium+DMSO.*
Table 2 Cytotoxicity of the most potent synthetic betulin derivatives on macrophage cell line THP-1

<table>
<thead>
<tr>
<th>Compound</th>
<th>50μM</th>
<th>25μM</th>
<th>12.5μM</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>18</td>
<td>85.3</td>
<td>77.7</td>
<td>38.2</td>
</tr>
<tr>
<td>19</td>
<td>80.2</td>
<td>30.0</td>
<td>22.0</td>
</tr>
<tr>
<td>21</td>
<td>0.0</td>
<td>14.0</td>
<td>3.6</td>
</tr>
<tr>
<td>25</td>
<td>61.4</td>
<td>55.2</td>
<td>13.6</td>
</tr>
</tbody>
</table>

Table 3 Anti-leishmanial activities of the most potent synthetic betulin derivatives against macrophage cell line THP-1 infected with Leishmania donovani

<table>
<thead>
<tr>
<th>Compound</th>
<th>50μM</th>
<th>25μM</th>
<th>12.5μM</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>56.3</td>
<td>34.4</td>
<td>17.8</td>
</tr>
<tr>
<td>19</td>
<td>nt</td>
<td>20.6</td>
<td>14.3</td>
</tr>
<tr>
<td>21</td>
<td>53.3</td>
<td>16.0</td>
<td>0.0</td>
</tr>
<tr>
<td>25</td>
<td>nt</td>
<td>nt</td>
<td>51.5</td>
</tr>
</tbody>
</table>

Abbreviation: nt, not tested because the toxicity to the THP-1 cell line was >30% at that concentration.

EXPERIMENTAL SECTION

Chemical syntheses of betulin derivatives screened in this study for anti-leishmanial activity are described in detail elsewhere. Anti-leishmanial activities of betulin derivatives were screened using a fluorescent viability microplate assay with L. donovani (MHOM/SD/1962/1S-Cl2d) axenic amastigotes and alamarBlue (resazurin, AbD Serotec, Oxford, UK) as described previously. Initial screening was carried out by assessing the inhibition of amastigote growth at 30μM of betulin derivative. All compounds were tested at least twice in triplicate. Complete medium, both with and without dimethyl sulfoxide, was used as negative controls (0% inhibition of amastigote growth). The most potent betulin derivatives from initial screening were selected for further investigation. For these compounds, the GI50 value (concentration for 50% growth inhibition) was also determined, as well as screening for activity on infected macrophages. The latter assay was carried out as previously described using the retinoic acid-treated human macrophage cell line THP-1 infected with L. donovani expressing the luciferase gene (LdpSSU-int/LUC) at a 3:1 parasitemacrophage ratio. Compounds (at 50, 25 and 12.5μM) to be tested were added for 48 h, and luminescence was determined after adding a luciferase substrate and measuring in a microplate reader. Amphoteracin B was included as a positive control on each plate and resulted in >90% inhibition at 1μM. The effect of compounds on THP-1 cells alone was assessed using the alamarBlue viability assay.

ACKNOWLEDGEMENTS

This study was supported by the Finnish Funding Agency for Technology and Innovation (Tekes), the Foundation for Research of Natural Resources in Finland, Marjatta ja Eino Kollin Säätiö and the European Commission (Contract nos LSHB-CT-2004-503467 and EU-KBBE-227239-ForestSpecs). We thank Mrs Anja Salakari and Mr Erkki Metsälä for their excellent technical assistance. Dr Salme Koskimies is thanked for valuable discussions. CLJ holds the Michael and Penny Feiwei Chair in Dermatology and is grateful to the American Friends of Hebrew University for financial support of this project.
<table>
<thead>
<tr>
<th>Title</th>
<th>Synthesis of betulin derivatives against intracellular pathogens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Sami Alakurtti</td>
</tr>
<tr>
<td>Abstract</td>
<td>Birch (Betula spp.) is utilized in huge quantities in the forest industry throughout the Northern Hemisphere, and low-value side-stream birch bark is burnt for energy. Outer birch bark is rich in (up to 30% dry weight) triterpene betulin, which is readily isolable by solvent extraction. Betulin can be used both in its raw form and as a starting material for more valuable products and fine chemicals. The increasing drug resistance of numerous microbes and viruses is an issue of global concern, and new inexpensive therapeutic agents are urgently needed. In this study two sets of betulin derivatives were synthesized and screened as antiviral, antileishmanial and antibacterial agents. The first set includes relatively easily synthesizable betulin derivatives, such as esters and various oxidation products. The second set includes novel heterocyclic betulin derivatives, where the triazole ring is fused by the Diels-Alder reaction to the lupane skeleton of betulin. Alphavirus Semliki Forest virus (SFV) is distributed by mosquitoes and infects avian and mammalian hosts. Some alphaviruses may cause fatal encephalitis in humans, although the number of cases is small. On the other hand, some alphaviruses have caused millions of cases of serious illnesses characterized by fever, rash and painful arthralgia. There is currently no efficient medical treatment against alphaviruses. In the antiviral assay, 18 betulin-derived compounds displayed good activity against SFV with low-micromolar 50% inhibitory concentration values combined with low cytotoxicity. In addition, three assayed potent and representative compounds displayed synergistic effect with modified nucleoside analogue against SFV, and similar good antiviral efficacy against another alphavirus, Sindbis virus. The neglected tropical disease leishmaniasis is caused by protozoan parasites belonging to the genus Leishmania, and is transmitted to mammalian hosts by sandflies. It is estimated that around 12 million people are currently infected, mostly in developing countries. The most severe form, visceral leishmaniasis, is fatal if not treated. There are currently several drugs marketed for the treatment of leishmaniasis. However, none of these are fully effective against Leishmania, and severe side effects, often requiring hospitalization, are common. In addition, parasite resistance to drugs is a serious growing problem. In the present study, the most potent betulin derivatives displayed low-micromolar 50% growth inhibition values against L. donovani amastigotes. Good inhibition activity was well retained against L. donovani amastigotes growing inside macrophages. However, in some cases betulin derivatives also showed cytotoxicity to host macrophage cell line. Chlamydia pneumoniae is a common Gram-negative human pathogen mainly causing mild respiratory infections, which can lead to pneumonia or bronchitis. There is also strong evidence that associates C. pneumoniae with other severe diseases, such as atherosclerotic cardiovascular diseases as well as some neurodegenerative diseases, such as Alzheimer's disease and multiple sclerosis. C. pneumoniae is susceptible to antibiotics that interfere with DNA and protein synthesis. However, its complex life cycle and its chlamydial persistence, which can last for years, as well as, importantly, the lack of specific diagnostic tests for detection of the organism in clinical samples, make the current treatment regimens unsatisfactory. Out of 32 betulin derivatives, five betulin derivatives showed high (&gt;70% growth inhibition) anti-chlamydial activity against C. pneumoniae at 1 µM concentration. The most potent derivative displayed a remarkable 50% inhibition at nanomolar concentration.</td>
</tr>
</tbody>
</table>
ISSN-L 2242-119X  
ISSN 2242-119X (Print)  
ISSN 2242-1203 (Online) |
| Date          | September 2013                                               |
| Language      | English, Finnish abstract                                    |
| Pages         | 99 p. + app 43 p.                                            |
| Keywords      | Betulin, betulinic acid, terpene, organic synthesis, derivative, bioactivity, Semliki Forest virus, Leishmania sp., Chlamydia pneumoniae |
| Publisher     | VTT Technical Research Centre of Finland  
P.O. Box 1000, FI-02044 VTT, Finland, Tel. 020 722 111 |
Betulinijohdannaisten syntetisointi solunsisäisiä patogeenejä vastaan

Betullin, betulinic acid, terpene, organic synthesis, derivative, bioactivity, Semliki Forest virus, Leishmania sp., Chlamydia pneumoniae

ISSN L 2242-119X
ISSN 2242-119X (painettu)
ISSN 2242-1203 (verkkojulkaisu)

Julkaisuaika
Syyskuu 2013

Kieli
Englanti, suomenkielinen tiivistelmä

Sivumäärä
99 s. + liit. 43 s.

Avainsanat
Betulin, betulinic acid, terpene, organic synthesis, derivative, bioactivity, Semliki Forest virus, Leishmania sp., Chlamydia pneumoniae

Julkaisija
VTT
Synthesis of betulin derivatives against intracellular pathogens

White birches (Betula spp.) are utilized in huge quantities in the forest industry in northern latitudes of the world and low-value side-stream birch bark is burnt for energy. Outer birch bark is rich in (up to 30% dry weight) triterpene betulin and it can be easily isolated by solvent extraction. Betulin could be used as such or as starting material for more valuable products, fine chemicals and pharmaceuticals.

In this work two sets of betulin derivatives were synthesized and screened as antiviral, antileishmanial and antibacterial agents. First set includes relatively easily synthesizable betulin derivatives, such as esters and various oxidation products. Second set includes novel heterocyclic betulin derivatives, where triazolo ring is fused by Diels-Alder reaction to the lupane skeleton of betulin.

In the biological assays against human pathogens Semliki Forest virus; L. donovani parasites, which cause tropical disease leishmaniasis; and Gram-negative bacteria Chlamydia pneumoniae, several betulin derivatives displayed low-micromolar 50% growth inhibition values in vitro. In addition, most of the derivatives showed low cytotoxicity against the host cell lines.